NZ561145A - Pyrazolylaminopyridine derivatives useful as kinase inhibitors - Google Patents
Pyrazolylaminopyridine derivatives useful as kinase inhibitorsInfo
- Publication number
- NZ561145A NZ561145A NZ561145A NZ56114506A NZ561145A NZ 561145 A NZ561145 A NZ 561145A NZ 561145 A NZ561145 A NZ 561145A NZ 56114506 A NZ56114506 A NZ 56114506A NZ 561145 A NZ561145 A NZ 561145A
- Authority
- NZ
- New Zealand
- Prior art keywords
- amino
- mmol
- formula
- compound
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Disclosed is a compound of formula (I) wherein one of X1, X2, X3 and X4 is =N-, the other three are independently selected from =CR8, =CR9- and =CR10-, A is a direct bond or optionally substituted C1-2alkylene, Ring C is carbocyclyl or heterocyclyl, and wherein the rest of the substituents are disclosed within the specification. Also disclosed is a process for preparing a compound of formula (I). Also disclosed is the use of a compound of formula (I) in the manufacture of a medicament for use in the inhibition of Trk activity, for the treatment or prophylaxis of cancer or for use in the production of an anti-proliferative effect.
Description
New Zealand Paient Spedficaiion for Paient Number 561145
101749
PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS
Field of the invention
The present invention relates to novel pyrazole derivatives, their pharmaceutical 5 compositions and methods of use. In addition, the present invention relates to therapeutic methods for the treatment and prevention of cancers and to the use of these pyrazole derivatives in the manufacture of medicaments for use in the treatment and prevention of cancers.
Background of the invention
Receptor tyrosine kinases (RTK's) are a sub-family of protein kinases that play a critical role in cell signalling and are involved in a variety of cancer related processes including cell proliferation, survival, angiogenesis and metastasis. Currently up to 100 different RTK's including tropomyosin-related kinases (Trk's) have been identified.
Trk's are the high affinity receptors activated by a group of soluble growth factors 15 called neurotrophins (NT). The Trk receptor family has three members - Trie A, TrkB and TrkC. Among the NTs there are (i) nerve growth factor (NGF) which activates TrkA, (ii) brain-derived growth factor (BDNF) and NT-4/5 which activate TrkB and (iii) NT3 which activates TrkC. Each Trk receptor contains an extra-cellular domain (ligand binding), a trans-membrane region and an intra-cellular domain (including kinase domain). Upon binding 20 of the ligand, the kinase catalyzes auto-phosphorylation and triggers downstream signal transduction pathways.
Trk's are widely expressed in neuronal tissue during its development where Trk's are critical for the maintenance and survival of these cells. A post-embryonic role for the Trk/neurotrophin axis (or pathway), however, remains in question. There are reports showing 25 that Trk's play important role in both development and function of the nervous system (Patapoutian, A. et al Current Opinion in Neurobiology, 2001, 11, 272-280).
In the past decade, a considerable number of literature documentations linking Trk signalling with cancer have published. For example, while Trk's are expressed at low levels outside the nervous system in the adult, Trk expression is increased in late stage prostate 30 cancers. Both normal prostate tissue and androgen- dependent prostate tumours express low levels of Trk A and undetectable levels of Trk B and C. However, all isoforms of Trk receptors as well as their cognate ligands are up-regulated in late stage, androgen-independent prostate cancer. There is additional evidence that these late stage prostate cancer
101749
cells become dependent on the Trk/neurotrophin axis for their survival. Therefore, Trk inhibitors may yield a class of apoptosis-inducing agents specific for androgen- independent prostate cancer (Weeraratna, A. T. et al The Prostate, 2000, 45,140-148).
Furthermore, very recent literature also shows that over-expression, activation, amplification and/or mutation of Trk's are associated with secretory breast carcinoma (Cancer Cell, 2002, 2, 367-376), colorectal cancer (Bardelli et al Science, 2003, 300, 949-949) and ovarian cancer (Davidson, B. et al Clinical Cancer Research, 2003, 9, 2248-2259).
There are a few reports of selective Trk tyrosine kinase inhibitors. Cephalon described CEP-751, CEP-701 (George, D. et al Cancer Research, 1999, 59, 2395-2341) and other indolocarbazole analogues (WOOl 14380) as Trk inhibitors. It was shown that CEP-701 and/or CEP751, when combined with surgically or chemically induced androgen ablation, offered better efficacy compared with mono-therapy alone. GlaxoSmithKline disclosed certain oxindole compounds as Trk A inhibitors in W00220479 and W00220513. Recently, Japan Tobacco reported pyrazolyl condensed cyclic compounds as Trk inhibitors (JP2003231687A).
In addition to the above, Vertex Pharmaceuticals have described pyrazole compounds as inhibitors of GSK3, Aurora, etc. in W00250065, W00262789,W003027111 and W0200437814; and AstraZeneca have reported pyrazole compounds as inhibitors against IGF-1 receptor kinase (W00348133).
Summary of the invention
In accordance with the present invention, the applicants have hereby discovered novel pyrazole compounds, or pharmaceutically acceptable salts thereof, which possess Trk kinase inhibitory activity and are accordingly useful for their anti-proliferation and/or proapoptotic (such as anti-cancer) activity and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said pyrazole compounds, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-proliferation and/or proapoptotic effect in warm-blooded animals such as man.
Also described herein are methods of using such pyrazole compounds, or pharmaceutically acceptable salts thereof, in the treatment of cancer.
The properties of the compounds claimed in this invention are expected to be of value in the treatment of disease states associated with cell proliferation such as cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid
101749
arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation-bone diseases and ocular diseases with retinal vessel proliferation.
Furthermore, the compounds, or pharmaceutically acceptable salts thereof, of the 5 invention are expected to be of value in the treatment or prophylaxis of cancers selected from congenital fibrosarcoma, mesoblastic nephroma, mesothelioma, acute myeloblasts leukemia, acute lymphocytic leukemia, multiple myeloma, melanoma, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer including secretory breast cancer, colorectal cancer, prostate 10 cancer including hormone refractory prostate cancer, bladder cancer, melanoma, lung cancer -non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, thyroid cancer including papillary thyroid cancer, mesothelioma and leukaemia; particularly ovarian cancer, breast cancer, colorectal cancer, prostate cancer and lung cancer - NSCLC and SCLC; more particularly prostate cancer; and 15 more particularly hormone refractory prostate cancer.
Detailed description of the invention
Accordingly, the present invention provides a compound of formula (I):
(I)
wherein:
R1 and R2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Chalky!, C-:_6alkenyl, C2-6alkynyl, Ci^alkoxy, Ci-salkanoyl, Ci-ealkanoyloxy, A^-(Ci.6alkyl)amino, Af.A^Ci.fialkyOiamino, C).6alkanoylamino, AL(Ci^alkyl)carbamoyl, 25 A^7V-(Ci-6alkyl)2carbamoyl, C|_6alkylS(0)a wherein a is 0 to 2, Cj^alkoxycarbonyl,
iV-(Ci_6alkyl)sulphamoyl, N,N-(Ci-<-,alkyl)2Sulphamoyl, Ci^alkylsulphonylamino, carbocyclyl
101749
1 2
or heterocyclyl; wherein R and R independently of each other may be optionally substituted on carbon by one or more R6; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R7;
one of X1, X2, X3 and X4 is —N-, the other three are independently selected from 5 =CR8-, =CR9- and =CR10-;
R is hydrogen or optionally substituted Ci_6alkyl; wherein said optional substituents are selected from one or more R11;
R4 and R34 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^alkyl, C2-ealkenyl, 10 C2-6alkynyl, Ci_6alkoxy, Ci.galkanoyl, Cj-galkanoyloxy, iV-(C|.6alkyl)amino, A^A^-(Ci.6alkyl)2amino, Ci-galkanoylamino, jV-(Ci_6alkyl)carbamoyl, A/,Ar-(Ci-6alkyl)2carbamoyI, C[.6alkylS(0)a wherein a is 0 to 2, Ci^alkoxycarbonyl, 7V-(Ci.6alkyl)sulphamoyl, A', A'-(C i^alkylbsulphamoyl, Ci_(,alkyl sulphonyl amino, carbocyclyl or heterocyclyl; wherein R4 and R34 may be independently optionally substituted on carbon by 15 one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13;
A is a direct bond or C]-2alkylene; wherein said C|-2alkylene may be optionally substituted by one or more R14;
Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH-20 moiety that nitrogen may be optionally substituted by a group selected from R13;
R3 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C]_6alkyl, C2-6alkenyl, C2-6alkynyI, Ci_6alkoxy, C]-6alkanoyl, C[.6alkanoyloxy, A^Ci^alky^amino, A^Ar-(C|.6alkyl)2amino,
Ci-ealkanoylamino, A^-(C]-6alkyl)carbamoyl; A^-(Ci.6aIkyl)2carbamoyl, Ci_6alkylS(0)a 25 wherein a is 0 to 2, Cj-ealkoxycarbonyl, A^-(C|.6alkyl)sulphamoyl,
Af,Af-(Ci-6alkyl)2Sulphamoyl, Ci-ealkylsulphonylamino, carbocyclyl-R37- or heterocyclyl-Rj8-; wherein R5 may be optionally substituted on carbon by one or more R15; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17;
n is 0, 1, 2 or 3; wherein the values of R21 may be the same or different;
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C].6alkyl, C2-6alkenyl, C2-6alkynyl, C|-6alkoxy, Cj^alkanoyl, Ci.ealkanoyloxy, ^-(Ci^alkyOamino,
101749
A^7V-(C[.6alkyl)2amino, Ci-6alkanoylamino, ^-(Ci-ealkyOcarbamoyl, A/,Af-(C1.6alkyl)2carbamoyl, Ci.6alkylS(0)a wherein a is 0 to 2, Cj^alkoxycarbonyl,
A-(C i _,,al kyl) su i pham oy 1, ;V, N- (C t -/,al k y 1)? s u 1 phamoy 1, C (_()alkylsulp ho n y 1 ami n o, carbocyclyl-R2i- or heterocyclyl-R26-; wherein R8, R9 and R10 independently of each other 5 may be optionally substituted on carbon by one or more R18; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19;
R6, R11, R12, R14, R16 and R]8 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci_6alkyl, 10 C2_6alkenyl, C2-6alkynyl, Q.^alkoxy, Cj.salkanoyl, C^alkanoyloxy, //-(Ci-salkyOamino, 7V,//-(Ci_6alkyl)2amino, C]-6alkanoylamino, A^Ci-ealkyOcarbamoyl,
A,r,A-(C [_6alkyI )2car barnoy I, CL_6alkylS(0)a wherein a is 0 to 2, Ci^alkoxycarbonyl, AT-(Ci-salkyI)su 1 phamoyl, A', A'-( C ]-,<alkyl)2 s ulphamoyl, Ci.6alkylsulphonylamino, carbocyclyl-R27- or heterocyclyl-R28-; wherein R6, Rn, R12, R14, R16 and R18 independently of 15 each other may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
R7, R13, R15, R17, R19 and R21 are independently selected from Ci-6alkyl, C^alkanoyl, Cs.6alkylsuIphonyI, Ci-salkoxycarbonyl, carbamoyl, A^-(C].6alkyl)carbamoyl, 20 A^A'-fCi.ealkyOcarbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenyl sulphonyl; wherein R7, R13, R'\ R17, R19 and R2! independently of each other may be optionally substituted on carbon by one or more R~ ;
R20 and R2: ! are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C^alkyl, C2-6alkenyl, 25 C2_6alkynyl, Ci-galkoxy, C^alkanoyl, Cj.ealkanoyloxy, W-(Ci-6alkyl)amino,
N,N-(Ci _6alkyl)2 ami no, C j kano y 1 amino, N-(C i -ealky l)carb amoy 1, A^,A^-(C1.6alkyl)2carbamoyI, Ci.6alkylS(0)a wherein a is 0 to 2, Ci^alkoxycarbonyl, A^-(Ci.6alkyl)sulphamoyl, A^A^Ci-calkyf^sulphamoyl, C^alkylsulphonylamino, Cj-6alkyIsulphonyl-A^-(Ci.6alkyl)amino, carbocyclyl-R33- or heterocyclyl-R36-; wherein R20
22
and R independently of each other may be optionally substituted on carbon by one or more R ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R24;
101749
R23, R26, R27, R28, R3\ R36, R37 and R38 are independently selected from a direct bond, -0-, -N(R29)-, -C(O)-, -N(R30)C(O)-, -C(0)N(R31)-, -S(0)s-, -NH=CH-, -S02N(R32)- or -N(R33)S02-; wherein R29, R30, R", R32 and R33 are independently selected from hydrogen or Ci^alkyl and s is 0-2;
23
R is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, /V-mothy 1 -;V-ethy 1 amino. acetylamino, jV-methylcarbamoyl, A'-ethylcarbamoyl. A. ;V-dimethyIcarhamoy 1, N, TV-diethylcarbarnoyl, A'-methyl-A'-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, 7V-methylsulphamoyl, JV-ethylsulphamoyl, /V, A-d j methyl sul phamoyl, A;,/V-diethylsulphamoyl, /V-methy1-A'r-elhylsulphamoyl or phenyl; and
R2 1 is selected from Q-galkyl, Ct-galkanoyl, C^alkylsulphonyl, Ci^alkoxycarbonyl, carbamoyl, JV-(Ci^alkyl)carbamoyl, Af JV-(C]-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
or a pharmaceutically acceptable salt thereof.
According to a further feature of the present invention there is provided a compound of formula (I) which is a compound of formula (la):
i H
A
(la)
wherein:
R1 and R2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C^alkyl, C2-6alkenyl, C2-6alkynyl, C].6alkoxy, Ci-ealkanoyl, C]-6alkanoyloxy, A/-(Cs-6alkyl)amino, A^A^Ci^alkyl^amino, Ci^alkanoylamino, A/-(Ci.6aIkyl)carbamoyl, A,A^-(Ci-6alkyl)2carbamoyl, C]-<salkylS(0)a wherein a is 0 to 2, C].6alkoxycarbonyl,
101749
jV-(Ci_6alkyl)sulphamoyl, 7V,./V-(C!_6alkyl)2Sulphamoyl, Ci^alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R1 and R2 independently of each other may be optionally substituted on carbon by one or more R6; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R7;
one of X1, Xz, XJ and X4 is =N-, the other three are independently selected from CR
R3 is hydrogen or optionally substituted Cj^alkyl; wherein said optional substituents
CR8-, =CR9- and =CR10
are selected from one or more Rn;
R4 is selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, 10 carboxy, carbamoyl, mercapto, sulphamoyl, Cj^alkyl, C2-6alkenyl, C2-6alkynyl, C^alkoxy, Cj-ealkanoyl, C[.6alkanoyloxy, JV-(Ci^alkyl)amino, iV,_/V-(Ci.6alkyl)2amino, Ci-ealkanoylamino, jV-(Cj.6alkyl)carbamoyl, iY,jV-(Ci.6alkyl)2carbamoyl, Ci_6alkylS(0)a wherein a is 0 to 2, Cj.ealkoxycarbonyl, 7V-(Cj_6alkyl)sulphamoyl,
A?,A?-(C|.6alkyl)2Sulphamoyl, C|_6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein 15 R4 may be optionally substituted on carbon by one or more Ri2; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13;
A is a direct bond or Ci_2alkylene; wherein said Ci.2alkylene may be optionally substituted by one or more R14;
Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH-
moiety that nitrogen may be optionally substituted by a group selected from Rls;
R3 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-ealkyl, C2-6alkenyl, C2-6alkynyl, C|_6alkoxy, . C[_f,alkanoyL C].6alkanoyloxy, Af-fCi-talky^amino, 7V,A^-(Cj.6alkyl)2amino, 25 Ci.6alkanoylamino, JV-(Ci-6alkyl)carbamoyl, A^A^-(C].6alkyl)2carbamoyl, Ci-6alkylS(0)a wherein a is 0 to 2, Ci-ealkoxycarbonyl, 7V-(C].6alkyl)sulphamoyl,
A^A^-(C;-6alkyl)2sulphamoy], Ci^alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R5 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group 30 selected from R17;
n is 0, 1, 2 or 3; wherein the values of R3 may be the same or different;
R8, R9 and Rl(l are independently selected from hydrogen, halo, nitro, cyano, hydrox; trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Chalky!, C2-6aIkenyl,
101749
C2-6alkynyl, Ci^alkoxy, C].6alkanoyl, C[.6aIkanoyloxy, A'-(C[.6alkyl)amino5 N, N-(C i _6alkyl)2amino, C i .6alkanoylamino. N-(C (.6alkyl)carbamoyl, 7Vr,iV-(Ci.6alkyl)2carbamoyl, Ci_6alkylS(0)a wherein a is 0 to 2, Ci^alkoxycarbonyl, iV-(C]_6alkyl)sulphamoyl, A^A^Ci-ealkyl^sulphamoyl, C;-6alkylsulphonylamino, 5 carbocyclyl-R25- or heterocyclyl-R26-; wherein R8, R9 and R10 independently of each other
18
may be optionally substituted on carbon by one or more R ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19;
R6, Rn,R12,R14, R16 and R,s are independently selected from halo, nitro, cyano, 10 hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^alkyl, C2-6alkenyl, C2-6alkynyl, Ci^alkoxy, Ci^alkanoyl, C^alkanoyloxy, A^-(Ci.6alkyl)amino, A?,jV-(Ci.6alkyl)2amino, Ci-6alkanoylamino, 7V-(C]-6alkyl)carbamoyl,
JV-(Ci_6alkyl)2carbamoyl, Ci-6aIkylS(0)a wherein a is 0 to 2, Ci^alkoxycarbonyl, 7\f-(C].6alkyl)suIphamoyl, Ar)JV-(C].6alkyI)2SulphamoyIJ Ci^alkylsulphonylamino, 15 carbocyclyl-R27- or heterocyclyl-R28-; wherein R6, R* 1, R12, R14, R16 and RIS independently of each other may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R2';
R7, R13, Rla, R17, R19 and R21 are independently selected from Ci^alkyl, Ci^alkanoyl, 20 Ci-6alkylsulphonyl, Ci-ealkoxycarbonyl, carbamoyl, A/-(C|_6alkyl)carbamoyl,
iV,A^-(Ci.6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenyl sulphonyl; wherein
*7 1 ^ 1 ^ 17 1Q Ti ,
R , R , R , R , R and R independently of each other may be optionally substituted on
22
carbon by one or more R ;
R20 and R22 are independently selected from halo, nitro, cyano, hydroxy,
trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^alkyl, C2-6alkenyl,
C2-6aIkynyl, C^alkoxy, Ci-galkanoyl, C|.6alkanoyloxy, JV-(Ci_6aIky])amino,
Ar,A^-(Ci.6alkyl)2amino, C]_6alkanoylamino, JV-(Ci.(5alkyl)carbamoyL
j^AHCi-ealkyl^carbamoyl, Ci-6alkylS(0)a wherein a is 0 to 2, C^alkoxycarbonyl,
7V-(Ci_6alkyl)sulphamoyl, iV„/V-(C|.6alkyl)2Sulphamoyl, Cj^alkylsulphonylamino, carbocyclyl
or heterocyclyl; wherein R20 and R22 independently of each other may be optionally substituted on carbon by one or more R23; and wherein if said heterocyclyl contains an -NH-moiety that nitrogen may be optionally substituted by a group selected from R24;
101749
R23, R26, R27 and R28 are independently selected from a direct bond, -0-, -N(R29)-, -C(O)-, -N(R30)C(O)-, -C(0)N(R31K -S(0)s-, -S02N(R32)- or -N(R33)S02-; wherein R29, R30,
31 32 33
R , R and RJJ are independently selected from hydrogen or Ci_6alkyl and s is 0-2;
23
R is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, 5 amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, A-methyi-A<;-cthy[amino, acetylamino, AZ-methylcarbamoyl, Af-ethylcarbamoyl, A/.Af-dimethylcarbamoyl, Af Af-diethylcarbamoyl, A,T-methyl-A-ethylcarbanioyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, 10 N-methylsulphamoyl, A;-cthy 1 sulphainoyl, N, A/-dimethylsulphamoyl, N, A/-diethylsuiphamoyl orA/-methyI-A/-ethylsulphamoyl; and
R24 is selected from Ci^alkyl, Ci-galkanoyl, Ci-6alkylsulphonyl, C^alkoxycarbonyl, carbamoyl, A^-(Ci_6aIkyl)carbamoyl, A^7V-(C].6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
or a pharmaceutically acceptable salt thereof.
Accordingly to a further feature of the present invention there is provided a compound of formula (I) wherein:
i
R and R are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-galkyl, C2_6alkenyi, 20 C2-6alkynyl, Ci^alkoxy, Ci-ealkanoyl, C^galkanoyloxy, jV-(Ci.6alkyl)amino, //,A/-(Ci.6alkyl)2amino, Cj_6alkanoylamino, jV-(C].6aIkyl)carbamoyl, Af,Af-(Ci.6alkyl)2carbamoyl, C]_6alkylS(0)a wherein a is 0 to 2, Ci^alkoxycarbonyl, iV-(Cnsalkyl)sulphamo.yl, A^A^Ci-ealkyl^sulphamoyl, C|.6alkylsulphonylamino, carbocyclyl
1 2
or heterocyclyl; wherein R and R independently of each other may be optionally substituted 25 on carbon by one or more R6; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R ;
one of X1, X2, X3 and X4 is =N-, the other three are independently selected from CR8-, =CR9- and =CR10-;
R3 is hydrogen or optionally substituted Ci^alkyl; wherein said optional substituents 30 are selected from one or more Rn;
R4 and R34 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^alkyl, C2.6alkenyl, C2-6alkynyl, Cj^alkoxy, Ci_6alkanoyl, Cj-ealkanoyloxy, A/-(Ci-6alkyl)amino,
101749
A^AKCi-ealkyl^amino, Cj-salkanoylamino, ^-(Ci^alky^carbamoyl, jV,iV-(C]_6alkyl)2carbamoyl, Ci_6alkylS(0)a wherein a is 0 to 2, Ci^alkoxycarbonyl, Af-tCi.ealky^sulphamoyl, A^Ar-(Ci.6alkyl)2sulphamoyl, Ci^alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R4 and R34 may be independently optionally substituted on carbon by
one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may
] ^
be optionally substituted by a group selected from R J;
A is a direct bond or C^alkylene; wherein said C|_2alkylene may be optionally substituted by one or more R14;
Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH-10 moiety that nitrogen may be optionally substituted by a group selected from R15;
R5 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci_6alkyl, C2.6alkenyl, C2^alkynyl, CVealkoxy, C^alkanoyl, C^alkanoyloxy, iV-(Ci..6alkyl)amino, N-(C|_6alkyI)2amino,
Ci-6alkanoylamino, ^-(Ci-galky^carbanioyl, TV,/^-(C^alky ^carbamoyl, C]-6alkylS(0)a 15 wherein a is 0 to 2, Ci-galkoxycarbonyl, TV-tC^alky^sulphamoyl,
A/,A^-(Ci„6alkyl)2Sulphamoyl, C].6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R5 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17;
n is 0, 1, 2 or 3; wherein the values of R3 may be the same or different;
R8, R9 and Ri0 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C^alkyl, C2-6alkenyl, C2-6alkynyl, Ci^alkoxy, Ci-ealkanoyl, C^alkanoyloxy, ^-(Ci-salkyOamino, iV,yV-(Ci-6alkyl)2amino, Ci-ealkanoylamino, Ar-(Cl.r,alkyl)carbamoyl,
A^A^Ci^alky [^carbamoyl, Ci_6alkylS(0)a wherein a is 0 to 2, Ci_6alkoxycarbonyl, iV-(C i_(5alkyI)sulphamoyl, /'/-(Ci.salkyl^sulphamoyl, C|.6alkylsulphonylamino, carbocyclyl-R25- or heterocyclyl-R26-; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more RiS; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from 30 R19;
R6, R13, R12, R14, R16 and R18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Chalky!, C^alkenyl, C2-6aIkynyl, Ci^alkoxy, Ci^alkanoyl, Cj^alkanoyloxy. A^(Ci-6alkyl)amino,
101749
N,N-(Ci _6alkyl)2amino, C i_6alkanoyl amino, N-(Ci .6alkyl)carbamoyl, A^A^Ci^alkyi^carbamoyl, C|_6alkylS(0)a wherein a is 0 to 2, Ci-galkoxycarbonyl, jV-fCi.6alkyl)sulphamoyl, Ar)A^-(C|.6alkyI)2sulphamoyl, Cj^alkylsnlphonylamino, carbocyclyl-R27- or heterocyclyl-R28-; wherein R6, R11, R12, R14, R16 and R18 independently of 5 each other may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group
21
selected from R ;
R7, R13, Rlft, R17, R19 and R21 are independently selected from C^aHcyl, Ci^alkanoyl, C]_6alkylsulphonyI, Ci-6alkoxycarbonyl, carbamoyl, ./V"-(C]-6alkyl)carbamoyl, 10 ^//-(Ci^alkyljcarbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenyl sulphonyl; wherein R7, R13, R13, Ri7, R19 and R21 independently of each other may be optionally substituted on
22
carbon by one or more R ;
R20 and R22 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^alkyl, C2-6alkenyl, 15 C2.6alkynyl, C]-6alkoxy, Cj^alkanoyl, C].6alkanoyloxy, ^/-(Ct.ealkyOamino, A',iV-(C].6alkyl)2amino, Ci^alkanoylamino, ^-(Ci-fialky^carbamoyl, A^7V-(Ci-6aIkyl)2carbamoyl, C|.6alkylS(0)a wherein a is 0 to 2, C]_6alkoxycarbonyl, ^-(Ci-^alky^sulphamoyl, MA^-(Ci.6alkyl)2Sulphamoyl, Cj-salkylsulphonylamino, carbocyclyl
90 99
or heterocyclyl; wherein R and R independently of each other may be optionally 20 substituted on carbon by one or more R ; and wherein if said heterocyclyl contains an -NH-moiety that nitrogen may be optionally substituted by a group selected from R24;
r23, j^27 ancj j^28 arg independently selected from a direct bond, -0-, -N(R29)-, -C<0)-, -N(R30)C(O)-, -C(0)N(R31)-, -S(0)s-, -S02N(R32> or -N(R33)S02-; wherein R29, R30, R31,R32 and R33 are independently selected from hydrogen or Ci-ealkyl and s is 0-2; 25 R23 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl,
amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, ALmethyl-A/-ethylarnino, acetylamino, ALmethylcarbamoyI, A^-ethylcarbamoyl, ACN-dimethylcarbamoyl, A^-diethylcarbamoyl, /V-methyl-A'-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, 30 ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl,
A^-methylsulphamoyl, jV-ethylsuIphamoyl, A^ A^dimethylsulphamoyl, A^A^-diethylsulphamoyl or A'-methyl-A'-ethylsuIphamoyl; and
101749
R24 is selected from Cj^alkyl, C]_6alkanoyl, Ci-galkylsulphonyl, Ci^alkoxycarbonyl, carbamoyl, //-(Cj-salkyOcarbamoyl, /^//-(Ci^alkyljcarbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
or a pharmaceutically acceptable salt thereof.
According to a further feature of the invention there is provided a compound of formula (I) wherein:
R1 and R2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Chalky!, C2-6alkenyl, C2-6alkynyl, C].6alkoxy, Ci-ealkanoyl, Ci.galkanoyloxy, jV-(Ci.6alkyl)amino, 10 jV,jV-(Ci_6alkyl)2amino, Ci^alkanoylamino, JV-(C].6alkyl)carbamoyl,
iV,jy-(Ci-6alkyl^carbamoyl, C]_6alkylS(0)a wherein a is 0 to 2, C^alkoxycarbonyl, ^-(Cj-galkyOsulphamoyl, jV-(Ci-6alkyl)2Sulphamoyl, C]-6alkylsulphonylamino, carbocyclyl
1 2
or heterocyclyl; wherein R and R independently of each other may be optionally substituted on carbon by one or more R6; and wherein if said heterocyclyl contains an -NH- moiety that 15 nitrogen may be optionally substituted by a group selected from R7;
one of X1, X2, X3 and X4 is =N-, the other three are independently selected from =CR8-, =CR9- and =CR10-;
R3 is hydrogen or optionally substituted C|_6alkyl; wherein said optional substituents are selected from one or more R1';
R4 and R34 are independently selected from hydrogen, halo, nitro, cyano, hydroxy,
trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C^alkyl, C2-6alkenyl, C2-6alkynyl, Ci^alkoxy, Ci.6alkanoyl, Ci^alkanoyloxy, A^-(Ci.6alkyl)amino, AfjV-(Ci_(5alkyl)2amino, Ci.salkanoylamino, iV-(C]-6alkyl)carbamoyl, A/J#-(Ci-6alkyl)2carbamoyl, C[.f,alkylS(0)a wherein a is 0 to 2, Ci.galkoxycarbonyl, 25 jV-(C[_6alkyl)sulphamoyls iV,iV-(Ci-6alkyl)2Sulphamoyl, Ci^alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13;
A is a direct bond or C].2alkylene; wherein said C].2alkylene may be optionally 30 substituted by one or more R14;
Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH-moiety that nitrogen may be optionally substituted by a group selected from Ri3;
101749
R3 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^alkyl, C2-6alkenyl, C^alkynyl, Ci^alkoxy, Ci.f,alkanoyl, Ci-salkanoyloxy, 7V-(Ci-6aIkyl)amino, jV.jV^i-galkyl^amino,
C]-6alkanoylamino, JV-(C].6alkyl)carbamoyl, AfA^Ci.ealkyl^carbamoyl, Ci^alkylS(0)a 5 wherein a is 0 to 2, C(-6alkoxycarbonyl, Af-(Ci_6alkyl)sulphamoyl,
jV,7V-(C].6alkyl)2sulphamoyl, C^alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R3 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R!7;
n is 0, 1, 2 or 3; wherein the values of R5 may be the same or different;
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci_6alkyl, C2-6alkenyl, C2-6alkynyl, C].6aIkoxy, C|_(lalkanoyL Ci^alkanoyloxy, AL (Ci_salky 1)amino, A^Af-(C].6alkyl)2amino, Ci-6alkanoylamino, A'-(Ci^alkyl)carbamoyl, 15 TV,A^-(Ci.6alkyl)2carbamoyI, Ci_5aIkylS(0)a wherein a is 0 to 2, Cj^alkoxycarbonyl, A^-(Ci_6alkyI)sulphamoyl, iVJA/-(Ci.6alkyl)2sulphamoyl, Ci-galkylsulphonylamino, carbocyclyl-R25- or heterocyclyl-R26-; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from 20 R19;
R6,R",R12, R14, R16 and R18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-f,alkyl, C2-6alkenyl, Ca-galkynyl. Ci.6alkoxy, Ci^alkanoyl, C.i^alkanoyloxy, //-(Ci-galky^amino, ArJN-(Ci-6alkyl)2amino, C]_6alkanoylamino, A/-(Ci_&alkyl)carbamoyl, 25 ^/,Af-(Ci.6alkyl)2carbamoyl, Ci^alkylS(0)a wherein a is 0 to 2, Ci^alkoxycarbonyl, Ar-(C|^alkyl)suIphamoyl, A^iV-(Ci.6alkyl)2sulphamoyl, Cj_6alkylsulphonylamino, carbocyclyl-R27- or heterocyclyl-R28-; wherein R6, R11, R12, R14, R16 and R18 independently of each other may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group 30 selected from R21;
R7, R13, Rla, R17, R19 and R21 are independently selected from Ci.galkyl, C]-(,alkanoyl, Ci^alkylsulphonyl, C]-6alkoxycarbonyl, carbamoyl, iV-(C]-6alkyI)carbamoyl, A'r)j¥-(C].6alkyl)carbamoyI, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein
101749
R7, R13, R!\ R17, R19 and R21 independently of each other may be optionally substituted on
22
carbon by on or more R ;
R20 and R22 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C]_galkyls C2-6alkenyl, 5 C2-6alkynyl, Ci^alkoxy, Ci.6alkanoyl, C]_6alkanoyloxy, AL(Cj„6alkyl)amino, Ar,A^-(Ci.6alkyl)2amino, Ci^alkanoylamino, A/-(C]_6alkyl)carbamoyl, A7,Ar-(Ci.6alkyl)2carbamoyl, C[_6alkylS(0)a wherein a is 0 to 2, Cj.6alkoxycarbonyl, JV-(Ci-6alkyl)sulphamoyl, N, AHCi-ealkyi^sulphamoyl, C|_6alkylsulphonylamino, Cj^alkylsulphonyl-JV-(Ci-6alkyl)amino, carbocyclyl-R35- or heterocyclyl-R36-; wherein R20
22
and R independently of each other may be optionally substituted on carbon by one or more R ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R24;
R25, R26, R27, R28, R35 and R36 are independently selected from a direct bond, -0-, -N(R29)-, -C(O)-, -N(R30)C(O)-, -C(0)N(R31)-, -S(0)s-, -NH=CH-, -S02N(R32)- or 15 -N(R33)SC>2-; wherein R29, R30, R31, R32 and R33 are independently selected from hydrogen or Ci-galkyl and s is 0-2;
R23 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, Af-methyl-iV-ethylamino, 20 acetylamino, AT-methylcarbamoyl, iV-ethylcarbamoyl, iV,jV-dimethylcarbamoyl,
A^Af-diethylcarbamoyl, TV-methyl-A^-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, A/-methylsulphamoyl, iV-ethylsuIphamoyl, A', Af-dimethylsulphamoyl, A/^A/'-di ethyl sulphamoyl, A-meihyl-A-elhylsulphamoyl or phenyl; and 25 R24 is selected from Ci-6alkyl, C^alkanoyl, C]_6alkyIsulphonyl, Cugalkoxycarbonyl,
carbamoyl, Af-(Ci_6alkyl)carbamoyl, AfAf-fCi-ealky^carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
or a pharmaceutically acceptable salt thereof.
Particular values of the variable groups contained in formula (I) are as follows. Such 30 values may be used, where appropriate, with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
R1 is Ci^alkoxy or carbocyclyl.
R1 is Ci^alkyl, Ci_f,alkoxy and cyclopropyl.
101749
R is isopropoxy or cyclopropyl.
R1 is Ci-ealkoxy.
R1 is cyclopropyl.
R1 is isopropoxy.
R1 is methyl, /-butyl, isopropoxy or cyclopropyl.
2
R is hydrogen.
I 2
R and R are independently selected from hydrogen, C^alkoxy and carbocyclyl. R1 and R2 are independently selected from hydrogen, Ci^alkyl, C]-6alkoxy and carbocyclyl.
I 2 *
R and R are independently selected from hydrogen, Ci^alkoxy and cyclopropyl.
1 2
R and R are independently selected from hydrogen, Chalky!, C;_6aIkoxy and cyclopropyl.
R1 and R2 are independently selected from hydrogen, isopropoxy and cyclopropyl.
I 2
R and R are independently selected from hydrogen, methyl, /-butyl, isopropoxy and cyclopropyl.
R' R1 R1 R1 R1 R1 R1 R1 R' X1 X2 X3 X4
2
s C^alkoxy or carbocyclyl and R is hydrogen.
•j s Ci-ealkyl, Ci-6alkoxy or carbocyclyl and R is hydrogen, s Ci-6alkoxy and cyclopropyl and R2 is hydrogen.
s Ci^alkyl, C^alkoxy and cyclopropyl and R2 is hydrogen, s C]-6alkoxy and R2 is hydrogen.
* 2 »
s isopropoxy and R is hydrogen.
s cyclopropyl and R2 is hydrogen.
s isopropoxy or cyclopropyl and R2 is hydrogen.
s methyl, /-butyl, isopropoxy or cyclopropyl and R is hydrogen, s =N-, X2 is =CR8-, X3 is =CR9- and X4 is =CR10-.
s =N-, X1 is =CR8-, X3 is =CR9- and X4 is =CR10-.
s =N-, X2 is =CR8-, X1 is =CR9- and X4 is =CR!0-.
s =N-, X2 is =CR8-, X3 is =CR9- and X1 is =CR10-.
X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from
=CR8-, =CR9- and =CR' °-.
R" is hydrogen.
R3 is optionally substituted Ci-6alkyl; wherein said optional substituents are selected from one or more R
11
101749
R4 is not hydrogen.
R4 is selected from hydrogen or Cj^alkyl; wherein R4 may be optionally substituted on
12 12
carbon by one or more R ; wherein R is selected from hydroxy.
R4 is selected from hydrogen or Ci^alkyl; wherein R4 may be optionally substituted on carbon by one or more R!2; wherein R12 is selected from hydroxy and R34 is hydrogen.
R4 and R34 are independently selected from hydrogen or Ci^alkyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy.
R4 is selected from hydrogen or methyl; wherein R4 may be optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy.
R4 is selected from hydrogen or methyl; wherein R4 may be optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy and R34 is hydrogen.
R4 and R34 are independently selected from hydrogen or methyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy.
R4 is selected from hydrogen, methyl or hydroxymethyl.
R4 is selected from hydrogen, methyl or hydroxymethyl and R34 is hydrogen.
R4 and R34 are independently selected from hydrogen, methyl or hydroxymethyl.
R34 is selected from hydrogen.
R34 is selected from hydrogen or hydroxymethyl.
R4 is selected from methyl or hydroxymethyl.
R4 is selected from methyl or hydroxymethyl and R34 is hydrogen.
R4 is selected from methyl and R34 is hydrogen.
R4 is selected from hydroxymethyl and R34 is hydrogen.
A is a direct bond.
A is C|_2alkylene; wherein said C]_2alkylene may be optionally substituted by one or more R14.
Ring C is carbocyclyl.
Ring C is or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R15;
Ring C is carbocyclyl or heterocyclyl.
Ring C is phenyl, pyridyl or pyrimidinyl.
Ring C is phenyl, pyrid-2-yl, pyrid-3-yl or pyrimidin-2-yl.
101749
Ring C is phenyl.
Ring C is pyridyl.
Ring C is pyrid-2-yl.
R3 is selected from halo, Ci.galkanoylamino, Ci^alkylsulphonylamino or carbocyclyl-R37-; wherein
R37 is -C(0)N(R31)-; wherein R31 is hydrogen.
R3 is halo.
R5 is selected from fluoro, acetylamino, mesylamino or cyclopropyl-R37-; wherein R37 is -C(0)N(Rjl)-; wherein R31 is hydrogen.
R3 is fluoro.
R5 is selected from fluoro, acetylamino, mesylamino or cyclopropylcarbonylamino. n is 0.
n is 1.
n is 1 or 2; wherein the values of R5 may be the same or different.
n is 2; wherein the values of R5 may be the same or different.
n is 3; wherein the values of R5 may be the same or different.
Ring C and (R5)n together form 4-fluorophenyl; wherein the fluoro group is para to the A group of formula (I).
Ring C and (R3)n together form 4-fluorophenyl, 5-fluoropyrid-2-yI, 3,5-difluoropyrid-2-yl, 5-fluoropyrimidin-2-yl, 4-fluoro-3-mesylaminophenyl, 6-fluoropyrid-3-yl, 4-fluoro-3-acetylaminophenyl and 4-fluoro-3-cyclopropyIcabonylamino.
Ring C and (R5)n together form 5-fluoropyrid-2-yl; wherein the fluoro group is para to the A group of formula (I).
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, amino, carboxy, carbamoyl, C]-6alkyl, Ct.6alkanoyl, iV-(C]_6alkyl)amino or carbocyclyl-R23-; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18;
1R
R is selected from hydroxy, amino, ^-(Ci^alky^amino, C|_6aIkanoylamino,
9 7 ~)R 1Q
Ci.galkylsulphonylamino, carbocyclyl-R - or heterocyclyl-R -; wherein R may be
optionally substituted on carbon by one or more R ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
101749
9fi
R is selected from halo, amino, Ci-salkyl, Ar,Af-(C].6alkyl)2ammo, C]-6alkylsulphonyl-A^-(Ci-6alkyl)amino, carbocyclyl-R35- or heterocyclyl-R36-; wherein R20 may be optionally substituted on carbon by one or more R23;
9 1
R is selected from Cuealkylsulphonyl;
23
R is dimethylamino or phenyl; and
R27, R28, Rj5 and R36 are independently selected from a direct bond, -C(0)N(R3i)-, -NII^CII- or -S02N(RJ )-; wherein R and R are independently selected from hydrogen or Ci-ealkyl.
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, amino, 10 carbamoyl and Ci_6alkyl; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more RiS; wherein
1R
R is selected from amino, C]-6alkanoylamino, Ci^alkyl sulphonyl amino or
28 18 20
heterocyclyl-R -; wherein R may be optionally substituted on carbon by one or more R ;
90
R is amino; and 15 R28 is -C(0)N(R3')-; wherein R31 is hydrogen.
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, iodo, nitro, cyano, amino, carboxy, carbamoyl, methyl, isopropyl, formyl, methylamino, isopropylamino or cyclopropyl-R25-; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more RIS;
R18 is selected from hydroxy, amino, methylamino, acetylamino, propionylamino,
3-methylbutanoylamino, mesylamino, cyclopropyl-R27-, phenyl-R27-, tetrahydrofuran-2-yI-R28-. furan-2-yl-R28-, pyrrol-2-y!-R28-, isoxaxol-5-yl-R28-, isoxaxol-4-yl-R28-, piperidin-4-yl-R28-, thien-2-yl-R28-, pyrid-3-yl-R2S-, pyrid-4-yl-R28-,
* 28 28 28
tetrahydro-2i/-thiopyran-4-yl-R morpholino-R - or 2-oxopyiTolidin-5-yl-R -; wherein 25 R18 may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
R20 is selected from fluoro, amino, methyl, dimethylamino, Af-(isopropyI)-Af-(mesyl)amino, A^ethy^-A^mesyOamino, phenyl-R35-, thien-2-yl-R36-, 30 thien-3-yl-R36-, pyrid-3-yl-R36- or morphoIino-Rj6-; wherein R20 may be optionally substituted on carbon by one or more R23;
91
R is selected from mesyl;
R is dimethylamino or phenyl; and
101749
R27, R28, R"° and R36 are independently selected from a direct bond, -C(0)N(R31)-,
^2 21 32
-NH=CH- or -S02N(R" )-; wherein R and R are independently selected from hydrogen or methyl.
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, 5 amino, carboxy, carbamoyl, methyl, isopropyl, formyl, methylamino, isopropylamino or cyclopropyl-R23-; wherein R8, R9 and Ri0 independently of each other may be optionally
I 8
substituted on carbon by one or more R ;
18
R is selected from hydroxy, amino, methylamino, acetylamino, propionylamino, 3-methylbutanoylamino, mesylamino, cyclopropyl-R27-, phenyl-R27-, 10 tetrahydrofuran-2-yl-R28-, furan-2-yl-R28-, pyrrol-2-yl-R28-, isoxaxol-5-yl-R28-,
isoxaxol-4-yl-R28-, piperidin-4-yl-R28-, thien-2-yl-R28-, pyrid-3-yl-R28-, pyrid-4-yl-R28-,
28 1 * 28 ug tetrahydro-2//-thiopyran-4-yl-R -, morpholino-R - or 2-oxopyrrolidin-5-yl-R~ wherein R18 may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group
21
selected from R ;
* *
R is selected from fluoro, amino, methyl, dimethylamino, Ar-(isopropyl)-Al'-(mesyl)amino, 7vr-(ethyl)-7v|r-(mesyl)amino, phenyl-Rj:i-, thien-2-yI-R36-,
-I / If r\S -S A
thien-3-yl-RJ -, pyrid-3-yl-R - or morpholino-R wherein R may be optionally
*y\
substituted on cai'bon by one or more R ;
R21 is selected from mesyl;
R is dimethylamino or phenyl; and
R27, R28, R35 and R36 are independently selected from a direct bond, -C(0)N(R31)-,
"12 ■ 3 J 32
-NH=CH- or -SCbNfR )-; wherein R and R are independently selected from hydrogen or methyl.
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano,
amino, carbamoyl and methyl; wherein R8, R9 and R10 independently of each other may be
1 R
optionally substituted on carbon by one or more R ; wherein
Ri8 is selected from amino, acetylamino, mesylamino or 2-oxopyrrolidin-5-yl-R28-; wherein R18 may be optionally substituted on carbon by one or more R20;
R20 is amino; and
R28 is -C(0)N(R31)-; wherein R31 is hydrogen.
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, iodo, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl,
101749
acetylaminomethyl, (2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyl,
(R)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,
(S)-2-oxopyrrolidin-5-yl-carbonyIaminomethyl,
(R,S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, isoxaxol-5-yl-carbonylaminomethyl, 5 mesylaminomethyl, morpholinomethyl, benzoylaminomethyl,
pyrid-3-yl-carbonylaminomethyl, 6-dimethylaminopyrid-3-yl-carbonylaminomethyl, 6-morpholinopyrid-3-yl-carbonylaminomethyl, pyrid-4-yl-carbonylaminomethyl, 5-methylisoxaxoI-4-yl-carbonylaminomethyI, thien-2-yl-carbonylaminomethyl,
4- dimethyl amino benzy Ic arbonyl aminom ethyl, 10 2-(JV-(isopropyl)-A'-(mesyl)amino)acetylaminomethyl, 2-(iV-(phenethyl)-A^-(mesyl)amino)acetylaminomethyl,
1 -mesylpiperidin-1 -ylcarbonylaminomethyl, 2-(pyrid-3-yl)acetylaminomethyl, tetrahydro-2//-thiopyran-4-yl-carbonyIaminomethyl,
2-(thien-2-yl)acetylcarbonylaminomethyl, 2-(thien-3-yl)acetylcarbonylaminomethyl, 15 3-phenylpropiony 1 aminomei.hy 1, 2-(ALbenzoyl-Af-methylamino)acetylaminomethyl,
4- dimethylaminobenzoy 1 ami nom ethyl, phenyl sulphony laminomethy 1, 2-amino-3-methylbutanoylaminomethyl, c y c lopro py 1 carbon y 1 am i nom ethyl, pyrrol-2-yI-carbonylaminomethyl, tetrahydrofuran-2-yl-carbonylaminomethyl, furan-2-yl-carbonylaminomethyl, cyclopropylsulphonylaminomethyl,
(cyclopropylimino)methyl, methylaminomethyl, trifluoromesylaminomethyl, isopropyl, isopropylamino or methylamino.
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, -hydroxymethyl, acetylaminomethyl, (2-aminoacetyl)aminomethyl, (2-morpholmoacetyl)aminomethyl,
2 5 (R)-2 -oxopy rroli din- 5 -yl -carbony 1 am inomethy 1, (S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,
(R,S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, isoxaxol-5-yl-carbonylaminomethyl, mesylaminomethyl, morpholinomethyl, benzoylaminomethyl, pyrid-3-yl-carbonylaminomethyl, 6-dimethylaminopyrid-3-yl-carbonylaminomethyl, 30 6-morpholinopyrid-3-yl-carbonylaminomethyl, pyrid-4-yl-carbonylaminomethyl,
-methylisoxaxol-4-yl-carbonylaminomethyl: thien-2-yl-carbonylaminomethyl, 4-dimethylaminobenzylcarbonylaminomethyl, 2-(iV-(isopropyl)-Ar-(mesyl)amino)acetylaminomethyl,
101749
2-(Af-(phenethyl)-AL(mesyl)amino)acetylaminomethyl,
1-mesylpiperidin-l-ylcarbonylaminomethyl, 2-(pyrid-3-yl)acetylaminomethyl, tetrahydro-2//-thiopyran-4-yI-carbonylaminomethyl,
2-(thien-2-yl)acetylcarbonylaminomethyl, 2-(thien-3-yl)acetylcarbonylaminomethyl, 5 3-phenylpropionylaminomethyl, 2-(JV-benzoyl-Ar-methylamino)acetylaminomethyl,
4-dimethylaminobenzoylaminomethyl, phenylsulphonylaminomethyl,
2-amino-3 -methylbutanoylaminomethy 1, cyclopropylcarbony 1 aminomethyl, pyrroI-2-yl-carbonylaminomethyl, tetrahydrofuran-2-yl-carbonylaminomethyl,
furan-2 - y 1 -carbonylaminomethy 1, cyclopropylsulphonylaminomethy 1, 10 (cyclopropylimino)methyl, methylaminomethyl, trifluoromesylaminomethyl, isopropyl, isopropylamino or methylamino.
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carbamoyl, aminomethyl, acetylaminomethyl, mesylaminomethyl, 2-oxopyrroIidin-5-ylcarbonylaminomethyl and (2-aminoacetyl)aminomethyl. 15 R8, R9 and R10 are independently selected from hydrogen, fluoro and cyano.
Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:
R1 and R2 are independently selected from hydrogen, Ci^alkoxy and carbocyclyl; X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from 20 =CR8-, =CR9- and =CR10-;
R3 is hydrogen;
R4 is selected from hydrogen or Cj^alkyl; wherein R4 may be optionally substituted on
12
carbon by one.or more R ;
R34 is hydrogen;
A is a direct bond;
Ring C is carbocyclyl;
R3 is halo;
n is 1;
Rs, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, amino, 30 carbamoyl and Ci^alkyl; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18;
I 9
R is selected from hydroxy;
101749
18
R is selected from amino, Cj^alkanoylamino, Ci-salkylsulphonylamino or
■^8 IP
heterocyclyl-R" -; wherein R may be optionally substituted on carbon by one or more R" ;
R is amino; and
R28 is -C(0)N(R31)-; wherein Rjl is hydrogen;
or a pharmaceutically acceptable salt thereof.
Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:
R1 and R2 are independently selected from hydrogen, C^alkyl, Ci^alkoxy and carbocyclyl;
X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from =CR8-, =CR9- and CR10-;
R3 is hydrogen;
R4 and R34 are independently selected from hydrogen or C^alkyl; wherein R4 and R34
1 0
may be independently optionally substituted on carbon by one or more R ;
A is a direct bond;
Ring C is carbocyclyl;
R5 is halo;
n is 1;
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, amino, carbamoyl and Ci-^alkyl; wherein Rs, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18;
1 9
R is selected from hydroxy;
I Q
R is selected from amino, C|_6aIkanoylamino, Ci^alkylsulphonylamino or
28 18 20
heterocyclyl-R -; wherein R may be optionally substituted on carbon by one or more R ;
R is amino; and
R28 is -C(0)N(Rjl)-; wherein Rjl is hydrogen;
or a pharmaceutically acceptable salt thereof.
Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:
R1 is Ci-ealkyl, C].&alkoxy or carbocyclyl;
2 ,
R is hydrogen;
X3 or X4 is =N-, X! and X2 and the other of XJ and X4are independently selected from =CR8-, =CR9- and =CR10-;
101749
R3 is hydrogen;
R4 and R34 are independently selected from hydrogen or Chalky!; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy;
A is a direct bond;
Ring C is carbocyclyl;
RD is halo;
n is 1;
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, amino, 10 carboxy, carbamoyl, Ci^alkyl, Ci-ealkanoyl, iV-(Ci-6alkyl)amino or carbocyclyl-R23-; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18;
R18 is selected from hydroxy, amino, ^-(Ci^alky^amino, Ci-6alkanoylamino,
"2.1 28 18
Ci-galkylsulphonylamino, carbocyclyl-R - or heterocyclyl-R -; wherein R maybe
9f)
optionally substituted on carbon by one or more R ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
R20 is selected from halo, amino, C^alkyl, JVrJAr-(Ci.6alkyl)2amino, C|.6alkylsulphonyl-yV-(Ci_6alkyl)amino, carbocyclyl-R35- or heterocyclyl-R36-; wherein R20 may be optionally substituted on carbon by one or more R23;
R21 is selected from C]-6aIkylsulphonyl;
9 ^
R is dimethylamino or phenyl; and
R27, R2S, R'53 and Rj6 are independently selected from a direct bond, -C(0)N(R31)-,
T 9 ^41 19
-NH=CH-or-S02N(R )-; wherein R and R are independently selected from hydrogen or Ci.6alkyl;
or a pharmaceutically acceptable salt thereof
Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:
R1 is Ci-galkyl, Ci_6alkoxy or carbocyclyl;
R2 is hydrogen;
X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from
=CR8-, -CR9-and =CR10-;
RJ is hydrogen;
101749
R4 and R34 are independently selected from hydrogen or Ci^alkyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy;
A is a direct bond;
Ring C is carbocyclyl or heterocyclyl;
R3 is selected from fluoro, acetylamino, mesylamino or cyclopropyl-R37-; wherein Rj7 is -C(0)N(R31)-; wherein R31 is hydrogen;
n is 1 or 2; wherein the values of R3 may be the same or different;
R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, amino,
carboxy, carbamoyl, C|_6alkyl, Ci^alkanoyl, 7V-(Ci_6alkyl)amino or carbocyclyl-R -; wherein R8, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R18;
i 8
R is selected from hydroxy, amino, iV-(Ci-6alkyl)amino, Ci^alkanoylamino, Ci-6aIkylsulphonylamino, carbocyclyl-R27- or heterocyclyl-R28-; wherein R18 may be
2.0
optionally substituted on carbon by one or more R ; and wherein if said heterocyclyl contains
^ |
an -NH- moiety that nitrogen may be optionally substituted by a group selected from R ;
R20 is selected from halo, amino, Chalky], 7V,jV-(Ci.6alkyl)2amino, Ci-6alkylsulphony]-Af-(C|-6alkyl)amino, carbocyclyl-R35- or heterocyclyl-R36-; wherein R20 may be optionally substituted on carbon by one or more R23;
21
R is selected from Cj_6alkylsulphonyl;
23 '
R is dimethylamino or phenyl; and r27, ^ jn(jepen(jently selected from a direct bond, -C(0)N(R31)-,
-NH=CH- or -S02N(Rj2)-; wherein R31 and Rj2 are independently selected from hydrogen or C].6alkyl;
or a pharmaceutically acceptable salt thereof.
Therefore in a further aspect of the invention there is provided a compound of formula
(I) (as depicted herein above) wherein:
R1 is isopropoxy or cyclopropyl;
R is hydrogen;
X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from
=CR8-, =CR9- and =CR10-;
R3 is hydrogen;
R4 is selected from hydrogen, methyl or hydroxymethyl;
101749
■^A
RJ is hydrogen;
A is a direct bond;
Ring C is phenyl;
R5 is fluoro;
n is 1; and
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carbamoyl, aminomethyl, acetylaminomethyl, mesylaminomethyl, 2-oxopyrrolidin-5-ylcarbonylaminomethyl and (2-aminoacetyl)aminomethyl; or a pharmaceutically acceptable salt thereof.
Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:
R1 is methyl, /-butyl, isopropoxy or cyclopropyl;
R2 is hydrogen;
X3 or X4 is =N-, X! and X2 and the other of X3 and X4are independently selected from =CRS-, =CR9- and =CR10-;
R is hydrogen;
R4 is selected from hydrogen, methyl or hydroxymethyl;
R34 is selected from hydrogen or hydroxymethyl;
A is a direct bond;
Ring C is phenyl;
R5 is fluoro;
nisi; and
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carbamoyl, aminomethyl, acetylaminomethyl, mesylaminomethyl, 2-oxopyrrolidin-5-ylcarbonylaminomethyl and (2-aminoacetyl)aminomethyl; or a pharmaceutically acceptable salt thereof.
Therefore in a further aspect of the invention there is provided a compound of formula (1) (as depicted herein above) wherein:
R1 is methyl, /-butyl, isopropoxy or cyclopropyl;
R2 is hydrogen;
X3 or X4 is -N-, X1 and X2 and the other of X3 and X4are independently selected from =CR8-, =CR9- and CR10-;
RJ is hydrogen;
101749
R4 and Rj4 are independently selected from hydrogen, methyl or hydroxymethyl;
A is a direct bond;
Ring C is phenyl;
R5 is fluoro;
n is 1;
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl, acetylaminomethyl, (2-aminoacetyl)aminomethy 1, (2-morpholinoacetyI)aminomethyl,
(R)-2-oxopyrro lidin-5-y 1-cai'bony laminomethy 1, (S)-2-oxopyrrolidin-5-yI-carbonylaminomethyl,
(R,S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, isoxaxol-5-yl-carbonylaminomethyl, mesylaminomethyl, morpholinomethyl, benzoylaminomethyl, pyrid-3-yl-carbonylaminomethyI, 6-dimethylaminopyrid-3-yl-carbonylaminomethyl, 6-morpholinopyrid-3-yI-carbonylaminomethyl, pyrid-4-yl-carbonylaminomethyl, 5-methylisoxaxol-4-yl-carbonylaminomethyl, thien-2-yl-carbonyIaminomethyl, 4-dimethylaminobenzylcarbonylaminomethyl, 2-(A/'-(isopropyI)-jV-(mesyl)amino)acetylaminomethyl, 2-(Af-(phenethyl)-AL(mesyI)amino)acetylaminomethyl,
1 -mesylpiperidin-1 -ylcarbonylaminomethyl, 2-(pyrid-3 -yl)acetylaminomethyl, tetrahydn>2Z/-thiopyran-4-yl-carbonylaminomethyl,
2-(thien-2-yi)acetylcarbonylaminomethyl, 2-(thien-3-yl)acetylcarbonyIaminomethyl,
3-phenylpropionylaminomethyl, 2-(iV-benzoyl-ALmethylamino)acetylaminomethyl,
4-dimethylaminobenzoylaminomethyI, phenylsulphonylaminomethyl,
2-amino-3-methylbutanoy lam inomethyl, cyclopropylcarbonylaminomethyl, pyrrol-2-yl-carbonylaminomethyl, tetrahydrofuran-2-yl-carbonylaminomethyl, furan-2-yl-carbonylaminomethyl, cyclopropylsulphonylaminomethyl, (cyclopropylimino)methyl, methyiaminomethyl, trifluoromesylaminomethyl, isopropyl, isopropylamino or methylamino;
or a pharmaceutically acceptable salt thereof
Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:
R1 is methyl, /-butyl, isopropoxy or cyclopropyl;
R2 is hydrogen;
101749
XJ or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from =CR8-, =CR9- and -CR10-;
R3 is hydrogen;
R4 and Rj4 are independently selected from hydrogen, methyl or hydroxymethyl; A is a direct bond;
Ring C is phenyl, pyrid-2-yl, pyrid-3-yl or pyrimidin-2-yl;
R3 is selected from fluoro, acetylamino, mesylamino or cyclopropylcarbonylamino; n is 1 or 2; wherein the values of R5 may be the same or different;
R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, iodo, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl,
acetylaminomethyl, (2-aminoacetyl)aminomethyl, (2-morpholinoacetyI)aminomethyl, (R)-2-oxopyrrolidin-5-yl-carbonyIaminomethyl, (S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,
(R,S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, isoxaxol-5-yI-carbonylaminomethyl,
mesylaminomethyl, morpholinomethyl, benzoylaminomethyl,
pyrid-3 -yl-carbonylaminomethyl, 6-dimethylaminopyrid-3-yl-carbonylaminomethyl,
6-morpholinopyrid-3-yl-carbonylaminomethyl, pyrid-4-yl-carbonylaminomethyl,
-methylisoxaxol-4-yl-carbonylaminomethyl, thien-2-yl-carbonylaminomethyl,
4-dimethylaminobenzylcarbonylaminomethyl,
2-(iV-(isopropyl)-AL(mesyl)amino)acetylaminomethyl,
2-(iV-(phenethyl)-/V-(mesyl)amino)acetylaminomethyl,
1 -mesylpiperidin-l-ylcarbonylaminomethyl, 2-(pyrid-3-yl)acetylaminomethyl,
tetrahydi'0-2//-thiopyran-4-yl-carbonylaminonicthyl.
2-(thien-2-yI)acetylcarbonylaminomethyl. 2-(thien-3-yl)acetylcarbonylaminomethyl,
3-phenyIpropionylaminomethyl, 2-(A/-benzoyl-iV-methylamino)acetylaminomethyl,
4-dimethylaminobenzoylaminomethyl, phenylsulphonylaminomethyl, 2-amino-3-methylbutanoylaminomethyl, cyclopropylcarbonylaminomethyl, pyrrol-2-yl-carbonylaminomethyl, tetrahydrofuran-2-yl-carbonylaminomethyl, furan-2-yl-carbonylaminomethyl, cyclopropylsulphonylaminomethyl, (cyclopropylimino)methyl, methylaminomethyl, trifluoromesylaminomethyl, isopropyl, isopropylamino or methylamino;
or a pharmaceutically acceptable salt thereof.
In a further aspect of the invention there is provided a compound of formula (la):
101749
NH
(la)
wherein Ra is nitro or amino; and other variable groups are as defined herein above.
In a further aspect of the invention there is provided a compound of formula (lb):
NH
(lb)
wherein Rb is nitro or amino; and other variable groups are as defined herein above.
In another aspect of the invention, preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt thereof.
In another aspect of the invention, preferred compounds of the invention are any one ofExamples 1,6, 11, 16,64, 110, 112, 113, 119and 120 or a pharmaceutically acceptable salt thereof.
In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use as a medicament.
In an additional embodiment the present invention provides a compound of formula
(I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the inhibition of Trk activity.
101749
In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.
In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment of cancer in a warm-blooded animal such as man.
In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man.
In an additional embodiment the present invention provides a compound of formula (1), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the production of an anti-proliferative effect.
Also described herein is a method of inhibiting Trk activity comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
Also described herein is a method for the treatment of cancer comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
Also described herein is a method for the treatment or prophylaxis of cancer comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Also described herein is a method for the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof
101749
Also described herein is a method of producing an antiproliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient.
In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the inhibition of Trk activity.
In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment of cancer.
In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancer.
In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.
In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the production of an anti-proiiferative effect in a warm-blooded animal such as man.
In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the inhibition of Trk activity.
101749
In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancer.
In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a warm-blooded animal such as man.
In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancers (solid tumours and leukaemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimrnune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man.
In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the production of an antiproliferative effect.
In one embodiment where the inhibition of Trk activity is referred to particularly this refers to the inhibition of Trk A activity.
In another embodiment where the inhibition of Trk activity is referred to particularly this refers to the inhibition of Trk B activity.
Where the treatment (or prophylaxis) of cancer is referred to, particularly it refers to the treatment (or prophylaxis) of mesobiastic nephroma, mesothelioma, acute myeloblastic leukemia, acute lymphocytic leukemia, multiple myeloma, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer including secretory breast cancer, colorectal cancer, prostate cancer including hormone refractory prostate cancer, bladder cancer, melanoma, lung cancer -non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma thyroid cancer including papillary thyroid cancer, mesothelioma, leukaemia, tumours of the central and peripheral nervous system, melanoma, fibrosarcoma including congenital fibrosarcoma and osteosarcoma. More particularly it refers to prostate cancer. In addition, more particularly it refers to SCLC, NSCLC, colorectal cancer, ovarian cancer and / or breast cancer. In a further aspect it refers to hormone refractory prostate cancer.
101749
In a further aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of:
Process a) reaction of a compound of formula (II):
(II)
wherein Pg is a nitrogen protecting group; with a compound of formula (III):
L R4
T^t>34
(III)
wherein L is a displaceable group;
Process b) for compounds of formula (I) wherein R4 is hydroxymethyl and R34 is hydrogen; reaction of a compound of formula (II) with an epoxide of formula (IV):
(IV)
Process c) reacting a compound of formula (V):
101749
33-
R
i H
2.X. .N
X'
IU I 4
X' ^X4 s o
R
3 ,Nv ,R
R Yr«
A
C +-(R5)n
(V)
with hydrazine;
Process d) reacting a compound of formula (VI):
NH
(VI)
wherein L is a displaceable group; with an amine of formula (VII):
hi
3^NL ^R
R
R
34
A
(R')„
(VII)
Process e) reacting a compound of formula (VIII):
101749
2,X. X
X'
X3 ^x4
3 ,NV
R
34
A
R
c j-mn
(VIII)
wherein L is a displaceable group; with an amine of formula (IX):
H2N N
^ SNH
(IX)
Process f) reacting an amine of formula (X):
2.X. .NH
X"
X3 ^X4
3 ,N . .R
R
with a compound of formula (XI):
c -HR5)n
NI-I
(XI)
wherein L is a displaceable group;
and thereafter if necessary:
i) converting a compound of the formula (I) into another compound of the formula (I);
101749
ii) removing any protecting groups;
iii) forming a pharmaceutically acceptable salt.
L is a displaceable group, suitable values for L are for example, a halo or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or 5 toluene-4-sulphonyloxy group.
Pg is a nitrogen protecting group. Suitable values for Pg are described herein below. Specific reaction conditions for the above reactions are as follows.
Process a) Compounds of formula (II) and (III) may be reacted together under standard nucleophilic addition reactions for example in the presence of a suitable base such as 10 potassium carbonate and a suitable solvent such as DMF and at a temperature in the range from 25 to 100°C.
Compounds of the formula (II) may be prepared according to Scheme 1:
-m 2 \,_—p0 1. Pd catalyst, ligand
Y 3 -w-4 _|_ , »- (II)
^ ^ ^ ' 2. Reduction
3. R3-L
N02 *
(Ila) (lib)
Scheme 1
1 ^ in ii D rr -i i-i n «-i t+'/s rrA« O nifr* Vt 1 /-« i jfilii Ar> Pni1 D ri ri ■*-- a /-I r* -Pi «-* n w-]
i j vvii^i^iu i £ io a piuLiAsimg giirnp. ounauit vaiuw lut i g ait utiintu uciuw, anu wherein L is a displaceable group as defined above.
Compounds of formula (III), (Ha) and (Ilb)are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.
Process b) Compounds of formula (II) and (IV) may be reacted together under epoxide ring opening reaction conditions for example in the presence of a suitable catalyst such as LiC104, NaC104, Mg(C104)2 and a suitable solvent such as CH3CN and at a temperature in the range from 25 to 80°C.
Compounds of formula (IV)are commercially available compounds, or they are known 25 in the literature, or they are prepared by standard processes known in the art.
Process c) The s reaction may be carried out in a suitable solvent, for example, an alcohol such as ethanol or butanol at a temperature in the range from 50-120°C, in particular in the range from 70-100°C.
Compounds of the formula (V) may be prepared according to Scheme 2\
101749
-36
i 2 X' N
X ^ ^ base if H ^ »* !4 » 00
" 1 S X^^x4
X3 ^x4
(III) Base, A
3 ,N. .R4
3,NH r X
R K T^r*
(Va)
(Vb)
Scheme 2
Compounds of the formula (Va) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.
Process d) Compounds of formula (VI) and (VII) may be reacted together under the conditions listed in Process a).
Compounds of formula (VI) may be prepared according to Scheme 3:
2 X' I
x DIEA>A
Xi /.X4 + (,Ib) <VI>
L (Via)
Scheme 3
wherein L is a displaceable group as defined herein above.
Compounds of the formula (Via) and (VII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. Process e) Compounds of fonnuia (VIII) and (IX) may be reacted together under the conditions listed in Process a).
Compounds of formula (VIII) may be prepared according to Scheme 4:
DIEA, A
(Via) + (VII) ^ (VIII)
Scheme 4
Compounds of the formula (IX) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.
101749
Process f) Compounds of formula (X) and (XI) may be reacted together under the conditions listed in Process a).
Compounds of formula (X) may be prepared according to Scheme 5:
2.X' .NH,
X" 2 a) DIEA, A
xl ^X4 + (VII) (X)
or
L b) Pd mediated coupling
(Xa)
Scheme 5
wherein L is a displaceable group as defined herein above.
Compounds of the formula (Xa) and (XI) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.
It will be appreciated that certain of the various ring substituents in the compounds of 10 the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation 15 of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group 20 using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl. 25 It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley
101749
and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.
A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a 5 m ethoxy carbonyl, ethoxycarbonyl or r-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali 10 metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a /-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with 15 a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an 20 arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by 25 hydrogenation over a catalyst such as palladium-on-carbon.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a r-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic 30 acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
101749
Definitions
In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "Chalky!" and "C].4alkyl" include methyl, ethyl, propyl, 5 isopropyl and ^-butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight-chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched-chain version only. A similar convention applies to other radicals. The term "halo" refers to fluoro, chloro, bromo and iodo.
Where optional substituents are chosen from "one or more" groups it is to be 10 understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.
A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2-15 group can optionally be replaced by a -C(O)-, and a ring sulphur atom may be optionally oxidised to form the S-oxides. Examples and suitable values of the term "heterocyclyl" are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyI, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, 20 pyrazinyl, pyridazinyl, isoxazolyl, AZ-methylpyrrolyl, 4-pyridone, 1-isoquinolone,
2-pyrrolidone, 4-thiazolidone, pyridine-/V-oxide and quinoline-/V-oxide. Further examples and suitable values of the term "heterocyclyl" are morpholino, piperazinyl and pyrrolidinyl. In one . aspect of the invention a "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, 25 sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH2-group can optionally be replaced by a -C(0)-and a ring sulphur atom may be optionally oxidised to form the S-oxides. Further examples and suitable values of the term "heterocyclyl" are tetrahydrofuranyl, furanyl, pyrrolyl, isoxaxolyl, piperidinyl, thienyl,
pyridyl, tetrahydro-2//-thiopyranyl, morpholino and 2-oxopyrrolidinyl. 30 A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH2- group can optionally be replaced by a -C(O)-. Particularly "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl,
101749
cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 3-oxoindanyl.
Where "one of X1, X2, XJ and X4 is =N-, the other three are independently selected from =CR8-, =CR9- and =CR!0-" it is to be understood that this means one of X1, X2, X3 and 5 X4 is =N-. one of the other three is =CR8-, one of the remaining two is =CR9- and the last is =CR10-. For example the scenario wherein X1 is =N-, X2 is =CR8-, X3 is =CR9- and X4 is =CR10- is embraced by this definition as is X3 is =N-, X1 is =CR8-, X2 is =CR9- and X4 is =CR10-. The ring containing X1, X2, X3 and X4 is thus a pyridine ring.
The term "Cm_n" or "Cm.n group" used alone or as a prefix, refers to any group having 10 m to n carbon atoms.
The term "optionally substituted" refers to either groups, structures, or molecules that are substituted and those that are not substituted.
An example of "C]-6alkanoyloxy" is acetoxy. Examples of "C|_6alkoxycarbonyl" include C]^alkoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, n- and /-butoxycarbonyl. 15 Examples of "C|.6alkoxy" include Ci_4alkoxy, Cj^alkoxy, methoxy, ethoxy and propoxy. Examples of "Ci.ealkoxyimino" include Cj^alkoxyimino, Ci^alkoxyimino, methoxyimino, ethoxyimino and propoxyimino. Examples of "Ci-ealkanoylamino" include formamido, acetamido and propionylamino. Examples of "Ci-6alkylS(0)a wherein a is 0 to 2" include C[_4alkyIsulphonyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and 20 ethylsulphonyl. Examples of "Ci-galkylthio" include methylthio and ethylthio. Examples of "Ci-6alkylsulphonylamino" include methylsulphonylamino and ethylsulphsulphonylamino. Examples of "Ci^alkanoyl" include C|.4alkanoyl, formyl, propionyl and acetyl. Examples of "iV-(C]-6aiky])amino'' include methylamino and ethylamino. Examples.of 'W,7V-(Ci.^alkyl)2amino" include di-A^-methylamino, di-(iV-ethyl)amino and 25 A'-ethyl-N-methylamino. Examples of "C2-6alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C2-6alkynyl" are ethynyl, 1-propynyl and 2-propynyI. Examples of 'W-(Ci-6alkyl)sulphamoyl" are /V-(methyl)sulphamoyl and 7V-(ethyl)sulphamoyl. Examples of cW-(C|-6alkyl)2Sulphamoyl" are AfyV-(dimethyl)suIphamoyl and #-(methyl)-Ar-(ethyi)sulphamoyl. Examples of'W-(Ci.6alkyl)carbamoyl" are 30 A^-(C]-4alkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl. Examples of
"A£Af-(Ci-6alkyI)2carbamoyP' are A^Af-(C].4alkyl)2carbamoyl, dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of "Ci^alkylsulphonyl-AL(Ci-6alkyl)amino" include ALmesy]-jV-methylamino and jV-mesyl-iV-isopropylamino.
101749
"RT" or Mrt" means room temperature.
A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
It should be noted that the pyrazoles claimed in this invention are capable to exist in different resonance structures and thus the pyrazoles claimed herein include all possible resonance structures, for example optical isomers, diastereoisomers and geometric isomers and all tautomeric forms of the compounds of the formula (I).
It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms.
Formulations
Compounds of the present invention may be administered orally, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingually, intramuscularly, subcutaneously, topically, intranasally, intraperitoneaily, intrathoracially, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.
The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient.
An effective amount of a compound of the present invention for use in therapy of cancer is an amount sufficient to symptomatically relieve in a warm-blooded animal, particularly a human the symptoms of cancer, to slow the progression of cancer, or to reduce in patients with symptoms of cancer the risk of getting worse.
For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form
101749
preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
A solid carrier can be one or more substance, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
Suitable carriers include magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
Some of the compounds of the present invention are capable of forming salts with various inorganic and organic acids and bases and such salts are also within the scope of this invention. Examples of such acid addition salts include acetate, adipate, ascorbate, benzoate, benzenesulfonate, bicarbonate, bisulfate, butyrate, camphorate, camphorsulfonate, choline, citrate, cyclohexyl sulfamate, diethylenediamine, ethanesulfonate, fumarate, glutamate, glycolate, hemisulfate, 2-hydroxyethylsulfonate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxymaleate, lactate, malate, maleate,.methanesulfonate,. meglumine, 2-naphthalenesulfonate, nitrate, oxalate, pamoate, persulfate, phenylacetate, phosphate, diphosphate, picrate, pivalate, propionate, quinate, salicylate, stearate, succinate, sulfamate, sulfanilate, sulfate, tartrate, tosylate (p-toluenesulfonate), trifluoroacetate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as aluminum, calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, ornithine, and so forth. Also, basic nitrogen-containing groups may be quaternized with such agents as: lower alkyl halides, such as methyl, ethyl, propyl, and butyl halides; dialkyl sulfates like dimethyl, diethyl, dibutyl; diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl halides; aralkyl
101749
halides like benzyl bromide and others. Non-toxic physiologically-acceptable salts are preferred, although other salts are also useful, such as in isolating or purifying the product.
The salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water, which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion-exchange resin.
In order to use a compound of the formula (I) or a pharmaceutically acceptable salt thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
In addition to the compounds of the present invention, the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to herein.
The term composition is intended to include the formulation of the active component or a pharmaceutically acceptable salt with a pharmaceutically acceptable carrier. For example this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.
Liquid form compositions include solutions, suspensions, and emulsions. Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
101749
The pharmaceutical compositions can be in unit dosage form. In such form, the composition is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in 5 vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
Combinations
The anti-cancer treatment defined herein may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or 10 chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents:
(i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for
example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and 20 taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);
(ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene,
raloxifene, droloxifene and iodoxyfene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone
acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5a-reductase such as finasteride;
(iii) agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors 30 like marimastat and inhibitors of urokinase plasminogen activator receptor function);
(iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erbb2 antibody trastuzumab [Herceptin™] and the anti-erbbl antibody cetuximab [C225]), farnesyl
101749
transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine 5 (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and
6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morphoImopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family;
(v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [Avastin™], compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin 15 «vp3 function and angiostatin);
(vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213;
(vii) antisense therapies, for example those which are directed to the targets listed above, 20 such as ISIS 2503, an anti-ras antisense;
(viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCAl or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or
radiotherapy such as multi-drug resistance gene therapy; and
(ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as
cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.
(x) other treatment regimes including: dexamethasone, proteasome inhibitors (including bortezomib), isotretinoin (13-cis retinoic acid), thalidomide, revemid, Rituxamab, ALIMTA,
101749
Cephalon's kinase inhibitors CEP-701 and CEP-2563, anti-Trk or anti-NGF monoclonal antibodies, targeted radiation therapy with 1311-metaiodobenzylguanidine (131I-MIBG), anti-G(D2) monoclonal antibody therapy with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) following chemotherapy.
Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention, or pharmaceutically acceptable salts thereof, within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.
Synthesis
The compounds, or pharmaceutically acceptable salts thereof, of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds, or pharmaceutically acceptable salts thereof, of the present invention can be synthesized using the methods described below, together with synthetic methods known in the 15 art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Such methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety by reference.
The novel compounds, or pharmaceutically acceptable salts thereof, of this invention may be prepared using the reactions and techniques described herein. The reactions are 20 performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily 25 recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents, which are compatible with the reaction conditions, will be readily apparent to one skilled in the art and alternate methods must then be used.
Examples
The invention will now be further described with reference to the following illustrative examples in which, unless stated otherwise:
101749
(i) temperatures are given in degrees Celsius (°C); operations are carried out at room temperature or ambient temperature, that is. in a range of 18-25 °C;
(ii) organic solutions were dried over anhydrous magnesium sulfate; evaporation of organic solvent was carried out using a rotary evaporator under reduced pressure
(4.5-30 mmHg) with a bath temperature of up to 60 °C;
(iii) chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was earned out on silica gel plates;
(iv) in general, the course of reactions was followed by TLC or liquid chromatography/mass spectroscopy (LC/MS) and reaction times are given for
illustration only;
(v) final products have satisfactory proton nuclear magnetic resonance (NMR) spectra and/or mass spectra data;
(vi) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more
material was required;
(vii) when given, NMR data is in the form of delta values for major diagnostic protons, given in part per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz in DMSO-dg unless otherwise stated;
(viii) chemical symbols have their usual meanings;
(ix) solvent ratio was given in volume:volume (v/v) terms.
(x) the following abbreviations have been used:
EtOAc ethyl acetate;
ether diethyl ether;
EtOH
ethanol;
THF
tetrahydrofuran;
TFP
tetrafluorophenyl;
DIEA
diisopropylethylamine;
DMAP
4-dimethylaminopyridine;
NMP
N-methylpyridinone;
MTBE
methyl tert-butyl ether;
DMF
A^iV-dimethylformamide;
HBTU
2-( 1 H-benzotriazole-1 -yl)-1,1,3,3-tetramethyIuronium
hexafluorophosphate;
101749
DCM
DCE
TFP resin
MeOH
dichloroethane; tetrafluorophenol resin; methanol; and dichloromethane.
Example 1
(■Sy6-(5-Cyclopropvl-l//-p\Tazol-3-vlamino)-5-fluoro-2-d-f4-fluorophcnyl)ethylamino') nicotinonitrile
A portion of 2-chloro-6-(5-cyclopropyl-l//-pyrazol-3-ylamino)-5-fluoronicotinonitrile 10 (Method 1; 0.8g, 2.8 mmol) and (5)-l-(4-fluorophenyl)ethanamine (0.8g, 5.6 mmol) were added to a solution of r-BuOH (4 ml) and DIEA (0.5g, 3.7 mmol) in a sealed tube. The reaction was heated to 140 °C for 48 hrs, then cooled to 25 °C and concentrated. The resulting residue was purified by column chromatography (DCM - MeOH = 50 : 1) to give the title compound (0.55g, 50%). !H NMR (400 MHz, CDC13) 5 8.44 (br s, 1H), 7.37-7.33 (m, 2H), 15 7.27 (d, J= 9.6 Hz, 1H), 7.07-7.03 (m,2H), 6.11 (s, 1H), 5.24-5.20 (m, 2H), 1.87-1.83 (m, 1H), 1.60 (d, J = 6.2 Hz, 3H), 1.01-0.98 (m, 2H), 0.79-0.65 (m, 2H). MS: Calcd.: 380; Found: [M+FI]+ 381.
(>S')-6-(5-Cyclopropvl-l//-pyrazol-3-vlamino)-5-fluoro-2-(l-('4-fluorophenyl)ethvlamino) nicotinamide
To a solution of (5)-6-(5-cyclopropyl-l/7-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluorophenyl)ethyIamino)nieotinonitrile (Example 1; 0.5g, 1.3 mmol) in MeOH (50 ml), was added a 25% aqueous solution (2 ml) of KOH (400 mg) at 25 °C, followed by the addition of 25 0.1 ml of 30% H2O2. The resulting dark red solution was heated to 65 °C for I h, cooled to 25 °C, and concentrated. The resulting residue was dissolved in EtOAc (50 ml), washed with water (30 ml), dried, filtered and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 30 : 1) to give the title compound (0.30g, 60%). 'H NMR (400 MHz, CDCI3) 5 9.06 (d, ./ = 7.0 Hz, 1H), 7.90 (br s, 1H), 7.35-7.32 (m, 2H), 7.25 (d, J = 30 7.2 Hz, 1H), 7.00-6.95 (m,2H), 6.00 (brs, 1H), 5.66 (br s, 2H), 5.21-5.17 (m, 1H), 1.86-1.82 (m, 1H), 1.54 (d, 6.8 Hz, 3H), 0.96-0.92 (m, 2H), 0.69-0.67 (m, 2FI). MS: Calcd.: 398; Found: [M+H]+399.
Examole 2
101749
Example 3
(5>3-(AminomethvO-A^-("5-cvclopropyi-l./7-pvrazol-3-vl)-5-fluoro-A'r2-n-(4-fluorophenyl) ethyl)pvridine-2.6-diamine
To a MeOH solution (5 ml) was added (S)-6-(5-cyclopropyl-l//-pyrazol-3-ylammo)-5 5-fluoro-2-(l-(4-fluorophenyl)ethylamino)nicotinonitrile (Example 1; 0.15g, 0.4 mmol), conc. HC1 (0.1 ml), and Pd (10 wt. %, dry basis, on activated carbon, 0.12g). The mixture was then flushed with N2, evacuated, and then placed under 40 psi of H2 for 6 hrs. The reaction was then evacuated, flushed with N2, filtered, washed with MeOH (3x30 ml), and concentrated. The resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml), and a 10 saturated aqueous solution of Na2C03 (100 ml) was added, and the mixture was shaken vigorously for 30 min. The layers were then allowed to separate, and the aqueous layer was extracted with DCM (3 x 100 ml). The combined organic layers were dried, filtered and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 9: 1) to give the title compound (0.09g, 58%). *H NMR (400 MHz, CD3OD) S 7.42-7.38 (m, 15 2H),7.15 (d, J= 11. Hz, 1H), 7.02-6.97 (m, 2H), 5.15-5.08 (m, 1H), 3.74 (s, 2H), 1.88-1.81 (m, 1H), 1.54 (d,J= 7.0 Hz, 3H), 0.93-0.92 (m, 2I-I), 0.67-0.63 (m, 2H). MS: Calcd.: 384; Found: [M+H]+ 385.
Example 4
fiSVA^f6-(5-Cyclopropvl-///-pvrazol-3-vlamino)-5-fluoro-2-(l-(4-fluorophenyI)ethylamino) pyridin-3-yl)methyl)acetamide
A round bottom flask was charged with (LS)-3-(aminomethyl)-//6-(5-cyclopropyl-l//-pyrazol-3-yl)-5-fluoro-jV2-(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.08g, 0.2 mmol) and acetic acid loaded TFP resin (1.4 mmol/g loading, 0.2 mmol) in mixture of 25 THF - DCM (1:1,3 ml) at 0 °C. The resulting solution was shaken vigorously at 0 °C for 45 min and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title compound (0.045g, 50%). 'H NMR (400 MHz, CD3OD) 5 7.34-30 7.33 (m, 2H), 7.11 (d, J= 10.7 Hz, IH), 7.01-6.97 (m, 2H), 5.14-5,04 (m, 1H), 4,30-4.17 (m, 2H), 1.99 (s, 3H), 1.88-1.81 (m, 1H), 1.50 (d,J= 6.8 Hz, 3H), 0.94-0.92 (m, 2H), 0.67-0.63 (m, 2FI). MS: Calcd.: 426; Found: [M+Hf 427.
101749
Example 5
(5r)-A^-((6-('5-Cvclopropvl-l/f-pvrazol-3-vlamino)-5-fluoro-2-fl-(4-fluorophenvl')ethvlamino) pyridin-3-vDmethyl)methanesulfonamide
A round bottom flask was charged with (5)-3-(aminomethyl)-iV6-(5-cyclopropyl-l//-5 pyrazoh3-y])-5-fluoro-A''2-(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.025g, 0.065 mmol), methanesulfonic acid loaded TFP resin (0.9 mmol/g loading, 0.065 mmol), DIEA (0.017g, 0.13 mmol), DMAP (0.09g, 0.072 mmol), and THF (5 ml). The resulting solution was shaken vigorously at 60 °C for 8 hrs. The reaction was filtered and the resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting 10 organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H2O over 400 nil) to give the title compound (0.016g, 53%). ]H NMR (400 MHz, CD3OD) 8 7.42-7.39 (m, 2H), 7.14 (d, J = 10.7 Hz, 1H), 7.01-6.97 (m, 2H), 5.16-5.09 (m, 1H), 4.15-4.06 (m, 2H), 2.99 (s, 3H), 1.88-1.83 (m, 1H), 1.52 (d, J = 6.8 Hz, 3H), 0.95-0.93 (m, 2H), 0.66-0.64 (m, 2H). MS: Calcd.: 15 462; Found: [M+H]+463.
Example 6
fjO-6-(5-Cvclopropvl-l//-pvrazol-3-ylamino)-5-fluoro-2-n-(4-fluorophenvl)-2-hvdroxyethvlamino)nicotinonitrile 20 2-Chloro-6-(5-cyclopropyl-l//-pyrazol-3-ylamino)-5-fluoronicotinonitrile (Method 1;
0.5g, 1.8 mmol) and (i?)-2-amino-2-(4-fluorophenyI)ethanol (0.6g, 3.6 mmol) were added to a solution of h-BuOH (4 ml) and DIEA (0.3g, 2.3 mmol) in a sealed tube. The reaction was heated to 140 °C for 48 hrs, then cooled to 25 °C and concentrated. The resulting residue was purified by column chromatography (DCM - MeOH = 80 : 1) to give the title compound 25 (0.3g, 40%). 'H NMR (400 MHz, CD3OD) 5 7.37-7.35 (m, 3H), 7.05-7.00 (m, 2H), 5.99 (s, 1H), 5.20-5.11 (m, 1FI), 3.90-3.77 (m, 2H), 1.90-1.86 (m, 1FI), 1.05-0.96 (m, 2H), 0.73-0.66 (m, 2H). MS: Calcd.: 396; Found: [M+H]+ 397.
Example 7
(j?)-6-(5-Cyclopropyl-l/j,-pvrazol-3-vlamino)-5-fluoro-2-(l-(4-fluorophenyl)-2-hvdroxvethylamino)nicotinamide
(/?)-6-(5-Cyclopropyl-l/7-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluorophenyl)-2-hydroxyethylamino)nicotinonitrile (Example 6; 0.07g, 0.2 mmol), was placed in MeOH (5
101749
ml) at 25 °C. A 25% aqueous solution (0.2 ml) of KOH (50 mg) was then added, followed by the addition of 0.05 ml of 30% H2O2. The resulting dark red solution was heated to 65 °C for 1 h, cooled to 25 °C, and concentrated. The resulting residue was dissolved in EtOAc (50 ml), washed with water (30 ml), dried, filtered, and concentrated. The resulting solid was purified 5 by column chromatography (DCM - MeOH = 30 : 1) to give the title compound (0.065g,
90%). 'H NMR (400 MHz, CD3OD) 5 7.69 (d, ./= 12.1 Hz, 1H), 7.39-7.36 (m, 2H), 7.04-7.00 (m, 2H), 5.94 (s, 1H), 5.22-5.16 (m, IH), 3.87-3.75 (m, 2H), 1.91-1.84 (m, 1H), 0.98-0.96 (m, 2H), 0.74-0.69 (m, 2H). MS: Calcd.: 414; Found: [M+H]+ 415.
Example 8
(i?)-2-(3-(AminomethvD-6-(5-cyclopropyl-l//-pyrazol-3-vlamino)-5-fluoropvridm-2-ylamino)-2-f4-fluorophenyl)ethanol
The mixture of (i?)-6-(5-cyclopropyl-li/-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluorophenyl)-2-hydroxyethylamino)nicotinonitrile (Example 6; 0.13g, 0.33 mmol), conc. 15 HC1 (0.1 ml), and Pd (10 wt. %, dry basis, on activated carbon, 0.12g) in MeOH (5 ml) was flushed with N2, evacuated, and then placed under H2 (40 psi) for 6 hrs. The reaction was then evacuated, flushed with N2, filtered, washed with MeOH (3 x 30 ml), and concentrated. The resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml), and a saturated o m l no o/"\111+1 r\n "NT a -. ( 1 OO m 1 Tirac aAr\ HTIt *=» m 1 -v+nfo uroc cl"1! ol/on t n rrrwm id ^ r frit' 1 O
UJ VI _ ^ 3 ^ 1 U W J vy U-VHJ-1 11V llilAlUlk' VVttJ J11U1\.V11 iv/1 -J \J
min and allowed to separate. The aqueous layer was extracted with DCM (3 x 100 ml). The combined organic layer was dried, filtered and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H20 over 400 ml) to give the title compound (0.074, 57%). 'H NMR (400 MHz, CD3OD) 8 7.45-7.42 (m, 2H), 7.17 (d, J = 11.1 Hz, 1H), 7.04-7.00 (m, 2H), 5.72 (br s, 1H), 5.18-5.08 (m, 1H), 3.89-3.72 (m, 4H), 1.87-25 1.83 (m, 1H), 0.94-0.92 (m, 2H), 0.69-0.65 (m, 2H). MS: Calcd.: 400; Found: [M+H]+ 401.
Example 9
(R)-N-((6-(5-Cyclopropyl-l//-pyrazol-3-vlamino)-5-fluoro-2-( l-f 4-fluorophenyl)-2-hvdroxyethylamino)pyridin-3-yl)methvl)acetamide 30 (i?)-2-(3-(Aminomethyl)-6-(5-cyclopropyl-1 //-pyrazol-3-ylamino)-5-fluoropyridin-2-
ylamino)-2-(4-fluorophenyl)ethanol (Example 8; 0.034g, 0.085 mmol) and acetic acid loaded TFP resin (1.4 mmol/g loading, 0.085 mmol) were placed in a THF - DCM solution (1 : 1,3 ml) at 0 °C. The resulting suspension was shaken vigorously at 0 °C for 45 min. The reaction
101749
was filtered and the resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title compound (0.018g, 48%). 'H NMR (400 MHz, CD3OD) S 7.42-5 7.36 (m, 2H), 7.12 (d, 7= 9.6 Hz, 1H), 7.04-6.99 (m, 2H), 6.09 (br s, 1H), 5.19-5.02 (m, 1H), 4.36-4.17 (m, 2H), 3.83-3.71 (m, 2H), 1.99 (s, 3H), 1.88-1.83 (m, 1H), 0.98-0.87 (m, 2H), 0.72-0.66 (m, 2H). MS: Calcd.: 442; Found: [M+H]+ 443.
Example 10
(70-Af-f(6-(5-Cyclopropyl-li/-pvrazol-3-vlamino)-5-fIuoro-2-(l-('4-fluoi-ophenyl)-2-hydroxvethylamino)pvridin-3-yl)methyl)methanesulfonamide
A round bottom flask was charged with (i?)-2-(3-(aminomethyl)-6-(5-cyclopropyl-l//-pyrazol-3-yIamino)-5-fluoropyridin-2-ylamino)-2-(4-fluorophenyl)ethanol (Example 8; 0.20g, 0.50 mmol), methanesulfonic acid loaded TFP resin (0.9 mmol/g loading, 0.50 mmol), DIEA 15 (0.13g, 1.00 mmol), DMAP (0.067g, 0.067 mmol), and THF (10 ml). The resulting solution was shaken vigorously at 60 °C for 8 hrs. The reaction was filtered and the resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title compound 20 (0.075g, 31%). !H NMR (400 MHz, CD3OD) 5 7.50-7.41 (m, 2H), 7.15 (d, 9.1 Hz, 1H), 7.04-7.00 (m, 2H), 6.09 (br s, 1H), 5.22-5.03 (m, 1H), 4.20-4.07 (m, 2H), 3.86-3.74 (m, 2H), 2.98 (s, 3H), 1.89-1.85 (m, 1H), 1.04-0.92 (m, 2H), 0.78-0.66 (m, 2H). MS: Calcd.: 478; Found: [M+H]+479.
Example 11
(j?)-5-Fluoro-2-(l-(4-fluorophenvl)-2-hvdroxvethvlamino)-6-(5-isopropoxy-l//-pyrazol-3-ylamino)nicotinonitrile
2-Chloro-5-fluoro-6-(5-isopropoxy-li/-pyrazol-3-ylamino)nicotinonitrile (Method 2; 1.6g, 5.0 mmol) and (i?)-2-ammo-2-(4-fluorophenyl)ethanol (2.0g, 11.0 mmol) were added to 30 a solution of rc-BuOH (8 ml) and DIEA (0.8g, 6.0 mmol) in a sealed tube. The reaction was heated to 135 °C for 72 hrs, cooled to 25 °C, and concentrated. The resulting residue was purified by column chromatography (DCM - MeOH = 50 : 1) to give the title compound (0.7g, 31%). 'HNMR (400 MHz, CD3OD) 8 7.49 (d, J= 9.5 FIz, 1H), 7.41-7.38 (m, 2H),
101749
7.07-7.02 (m, 2H), 5.40 (s, 1H), 5.10-5.01 (m, 1H), 4.62-4.55 (m, 1H), 3.91-3.79 (m, 2H), 1.33-1.31 (m, 6H). MS: Calcd.: 414: Found: [M+H]+ 415.
Example 12
(iO-5-Fhioro-2-(l-(4-fluorophenyl)-2-hvdroxvethvfammo)-6-('5-isopropoxy-l//-pvrazol-3-vlamino)nicotinamide
(J?)-5-FIuoro-2-(l-(4-fluorophenyl)-2-hydroxyethylamino)-6-(5-isopropoxy-l//-pyrazoI-3-ylamino)nicotinonitrile (Example 11; 0.06g, 0.1 mmol) was placed in MeOH (5 ml) at 25 °C. A 25% aqueous solution (0.2 ml) of KOH (0.05 g, 0.7 mmol) was then added, 10 followed by the addition of 0.05 ml of 30% H2O2. The resulting dark red solution was heated to 65 °C for 1 h, cooled to 25 °C, and concentrated. The resulting residue was dissolved in EtOAc (50 ml), washed with water (30 ml), dried, filtered, and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 30 : 1) to give the title compound (0.037g, 60%). *H NMR (400 MHz, CD3OD) 8 7.75 (d, J= 11.9 Hz, 1H), 7.43-15 7.39 (m, 2H), 7.06-7.02 (m, 2H), 5.37 (br s, 1H), 5.10-5.02 (m, 1H), 4.60-4.54 (m, 1H), 3.90-3.86 (m, 1H), 3.79-3.74 (m, 1H), 1.32 (d, J= 6.0 Hz, 6H). MS: Calcd.: 432; Found: [M+H]+ 433.
(-/0-2-(3-(AminomethyD-5-fhioro-6-(5-isopropoxv-l//-pyrazol-3-ylamino)pyridin-2-yIamino)-2-(4-fluorophenyl)ethanol
A solution of (J?)-5-fluoro-2-(l-(4-fluorophenyl)-2-hydroxyethyIamino)-6-(5-isopropoxy-l//-pyrazol-3-ylamino)nicotinonitrile (Example 11; 0.60g, 1.44 mmol), conc. I-IC1 (0.3 ml), and Pd (10 wt. %, dry basis, on activated carbon, 0.3g) in MeOH (8 ml) was flushed 25 with N2j evacuated, and then placed under of H2 (40 psi) for 6 hrs. The reaction was then evacuated, flushed with N2, filtered, washed with MeOH (3 x 30 ml), and concentrated. The resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml) and treated with a saturated aqueous Na2C03 solution (100 ml). The resulting mixture was shaken vigorously for 30 min and allowed to separate. The aqueous layer was extracted with DCM (3 30 x 100 ml), The combined organic layers were dried, filtered and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title compound (0.40g, 66%). 'H NMR (400 MHz, CD3OD) 6 7.47-7.44 (m, 2H), 7.37 (d,J= 10.7 Hz, 1FI), 7.06-7.02 (m, 2H), 5.10-5.06 (m, 1H), 4.57-4.51 (m, 1H), 4.28
101749
(d,J= 14.2 Hz, 1H), 4.07 (d,J= 14.2 Hz, 1H), 3.92-3.80 (m, 2H), 1.32 (d,J=3.7Hz, 6H). MS: Calcd.: 418; Found: [M+H]+ 419.
Example 14
(7?)-ALf(3-Fluoro-2-(l-(4-f1uorophenvl')-2-hydroxyethylamino)-6-('5-isopropoxv-lZ/-pvrazol-3-vlamino)pvridin-3-vl)methvl)acetamide
(i?)-2-(3-(Aminomethyl)-5-fluoro-6-(5-isopropoxy-l//-pyrazol-3-ylamino)pyridin-2-ylamino)-2-(4-fluorophenyl)ethanol (Example 13; 0.175g, 0.42 mmol) and acetic acid loaded TFP resin (1.4 mmol/g loading, 0.42 mmol) were placed in a THF - DCM solution (1 : 1, 5 10 ml) at 0 °C. The resulting solution was shaken vigorously at 0 °C for 45 min and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H20 over 400 ml) to give the title compound (0.075g, 39%). 'HNMR (400 MHz, CD3OD) 8 7.42-7.39 (m, 2H), 7.17 (d, J = 15 10.7 Hz, 1H), 7.05-7.01 (m, 2H), 5.26 (s, 1H), 5.02-4.95 (m, 1H), 4.55-4.53 (m, 1H), 4.36 (d, J= 15.0 Hz, 1H), 4.22 (d,J= 15.0 Hz, 1H), 3.84-3.72 (m, 2H),2.01 (s, 3H), 1.31 (d,J = 6.0Hz, 6FI). MS: Calcd.: 460; Found: [M+H]+ 461.
Example 15
(./?)-iV-((5-Fluoro-2-n -(4-fluorophenyD-2-hydro)iLyethylamino)-6-f 5-isopropoxy-1H- pyrazol-3-ylamino)pyridin-3-vl)methyl)methanesulfonamide
A round bottom flask was charged with (i?)-2-(3-(aminomethyl)-5-fluoro-6-(5-isopropoxy-1 /7-pyrazol-3-ylamino)pyridin-2-ylamino)-2-(4-fliiorophenyI)ethanol (Example 13; 0.1 Og, 0.24 mmol), methanesulfonic acid loaded TFP resin (0.9 mmol/g loading, 0.24 25 mmol). DIEA (0.062g, 0.48 mmol), DMAP (0.032g, 0.26 mmol), and THF (5 ml). The resulting suspension was shaken vigorously at 60 °C for 8 hrs and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H20 over 400 ml) to give the title 30 coompound (0.075g, 63%). "H NMR (400 MHz, CD3OD) 5 7.48-7.45 (m, 2H), 7.20 (d, J = 10.9 Hz, 1H), 7.05-7.01 (m, 2H), 5.30 (s, 1H), 5.04-5.01 (m, 1H), 4.56-4.53 (m, lH),4.20(d, J= 14.4 Hz, 1H). 4.12 (d, J= 14.4 Hz, 1H), 3.86-3.73 (m, 2H),3.01 (s, 3H), 1.32 (d,J= 6.0 Hz, 3H). MS: Calcd.: 496; Found: [M+H]+ 497.
101749
Example 16
(lS)-5-Fiuoro-2-f 1 -f4-fluorophenvl)ethylamino')-6-('5-isQpropoxv-1 //- pyrazol-3-ylamino)nicotmonitrile
2-Ch]oro-5-fluoro-6-(5-isopropoxy-l //-pyrazol-3-yIamino)nicotinonitrile (Method 2; 5 1.4g, 5.0 mmol) and (S)-l-(4-fluorophenyl)ethanamine (l.Og, 9.0 mmol) were added to a solution of «-BuOH (8 ml) and DIEA (0.8g, 6.0 mmol) in a sealed tube. The reaction was heated to 135 °C for 48 hrs, cooled to 25 °C, and concentrated. The resulting residue was purified by column chromatography (DCM - MeOH = 80 : 1) to give the title compound (0.90g, 48%). !H NMR (400 MHz, CD3OD) 8 7.43 (d, 7= 10.5 Hz, 1H), 7.39-7.35 (m, 2H), 10 7.04-6.99 (m, 2H), 5.47 (s, 1H), 5.12-5.11 (m, 1H), 4.60-4.51 (m, 1H), 1.56 (d, J= 7.0 Hz, 3H), 1.33-1.30 (m, 6H). MS: Calcd.: 398; Found: [M+H]+ 399.
Example 17
(ff)-5-Fluoro-2-(T-f4-fluorophenyl)ethvlamino)-6-(5-isopropoxy-l//-pvrazol-3-15 ylamino)nicotinami de
(iS)-5-Fluoro-2-(l-(4-fluorophenyl)ethylamino)-6-(5-isopropoxy-l.ff-pyrazol-3-ylamino)nicotinonitrile (Example 16; 0.15g, 0.38 mmol), was placed in MeOH (7 ml) at 25 °C. A 25% aqueous solution (0.4 ml) of KOH (0.11 g, 1.9 mmol) was then added,
■firi 11 Vnr tVi ^ aHHifinrt n"f* 0 1 m I r\-p o ivsonl+irirr rl A c aIi iti umn
AVAIWy VV4 U J HIV- UWVfUlVAl KSX \S. t J.J.JIJ. yi \J f U S.±2x^rZm 1 J.V 1 VU OWlULlVJll VV CIO ll^U-LV-'U LU
65 °C for lh, cooled to 25 °C, and concentrated. The resulting residue was dissolved in
EtOAc (50 ml), washed with water (30 ml), dried, filtered, and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 25 : 1) to give the title ' compound (0.044g, 28%). 'H NMR (400 MHz, CD3OD) 8 7.75 (d, ./= 11.7 Hz, 1H), 7.39-7.36 (m, 2H), 7.04-7.00 (m, 2H), 5.37 (s, 1H), 5.11-5.00 (m, 1H), 4.61-4.52 (m, 1H), 1.53 (d, 25 J= 7.0 Hz, 3H), 1.31 (m, 6H). MS: Calcd.: 416; Found: [M+H]+ 417.
Example IS
(iSV3-fAminomethyl)-5-fluoro-iV2-f l-f4-fluorophenyOethvO-jV6-(5-isopropoxv-li/-pvrazol-3-yQpyridine-2.6-diamine
The mixture of (S)-5-fluoro-2-(l-(4-fluorophenyl)ethylamino)-6-(5-isopropoxy-l H-
pyrazoI-3-ylamino)nicotinonitrile (Example 16; 0.90g, 2.26 mmol), conc. HC1 (0.3 ml), and Pd (10 wt. %, dry basis, on activated carbon, 0.55g) in MeOH (20 ml) was flushed with N2, evacuated, and then placed under H? (40 psi) for 6 hrs. The reaction was then evacuated,
101749
flushed with N2, filtered, washed with MeOH (3x30 ml), and concentrated. The resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml) and treated with a saturated aqueous Na2C03 solution (100 ml). The mixture was shaken vigorously for 30 min and allowed to separate. The aqueous layer was extracted with DCM (3 x 100 ml). The 5 combined organic layers were dried, filtered and concentrated. The resulting solid was purified by reverse- phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give the title compound (0.7g, 77%). lH NMR (400 MHz, CD3OD) 6 7.45-7.41 (m, 2H), 7.35 (d,./ = 10.9 Hz, IH), 7.03-6.99 (m, 2H), 5.35 (s, 1H), 5.09-5.04 (m, IH), 4.55-4.49 (m, 1H), 4.18 (d, J= 14.2 Hz, IH), 4.08 (d, J= 14.2 Hz, IH), 1.59 (d, J= 6.8 Hz, 3H), 1.31 (d, J= 8.3 10 Hz, 6H). MS: Calcd.: 402; Found: [M+H]+ 403.
Example 19
f5r)-AL(('5-Fluoro-2-(l-('4-fluorophenyl)ethvlamino)-6-f5-isopropoxv-l//-pvrazol-3-ylamino)pyridin-3-yl)methyQacetamide 15 (S)-3-(Aminomethyl)-5-fluoro-/V2-(l-(4-fluorophenyl)ethyl)-iV6-(5-isopropoxy-l./7-
pyrazol-3-yl)pyridine-2,6-diamine (Example 18; 0.20g, 0.49 mmol) and acetic acid loaded TFP resin (1.4 mmol/g loading, 0.49 mmol) were placed in a THF - DCM solution (1:1,6 ml) at 0 °C. The resulting solution was shaken vigorously at 0 °C for 45 min and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1,3x5 ml for 30 min. each). The 20 resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H20 over 400 ml) to give the title compound (0.01 Og, 49%). ]HNMR (400 MHz, CD3OD) S 7.37-7.34 (m, 2H), 7.14 (d,./ = 10.9 Hz, IH), 7.02-6.98 (m, 2H), 5.25 (s, IH), 4.96-4.95 (m, IH), 4.55-4.52 (m, IH), 4.30 (d, J= 14.8 Hz, IH), 4.21 (d,J= 14.8 Hz, IH), 2.01 (s, 3H), 1.51 (d,.7=6.8 Hz, 3H), 1.31 (d,J = 25 6.0 Hz, 6H). MS: Calcd.: 444; Found: [M+Hf 445.
Example 20
(y)-J/V-(f5-Fluoro-2-(T-f4-fluorophenyl)ethvlamino)-6-(5-isopropoxy-l//-pyrazol-3-ylamino)pyridin-3-yl)methyl)methanesulfonamide 30 A round bottom flask was charged with (S)-3-(aminomethyl)-5-fluoro-./V2-(1 -(4-
f]uorophenyl)ethyl)-jV6-(5-isopropoxy-l//-pyrazol-3-yl)pyridine-2,6-diamine (Example 18; 0.1 Og, 0.25 mmol), methanesulfonic acid loaded TFP resin (0.9 mmol/g loading, 0.25 mmol), DIEA (0.064g, 0.50 mmol), DMAP (0.033g, 0.27 mmol), and THF (5 ml). The resulting
101749
suspension was shaken vigorously at 60 °C for 8 hrs and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H2O over 400 ml) to give (0.82g, 67%). lH NMR 5 (400 MHz, CD3OD) 5 7.44-7.41 (m, 2H), 7.17 (d,J= 10.7 Hz, IH), 7.02-6.97 (m, 2H), 5.26 (s, IH), 5.01-4.99 (m, IH), 4.56-4.53 (m, IH), 4.16-4.08 (m, IH), 3.01 (s, 3H), 1.52 (d,J = 7.0 Hz, 3H), 1.31 (d,J= 6.0 Hz, 6H). MS: Calcd.: 480; Found: [M+H]+ 481.
Example 21
(iSV 3,5-Dichloro-iV2-(5-cyclopropyl-1 //-pyrazol-S-yD-A^-f 1 -f4-fIuorophenyl)ethyl)pyridine-2,6-diamine
3,5,6-Trichloro-AL(5-cyclopropyl-l/7-pyrazol-3-yI)pyridin-2-amine (Method 3; 0.05g, 0.2 mmol) and (£)-l-(4-fluorophenyl)ethanamine (0.05g, 0.4 mmol) were dissolved in NMP (2 ml) with DIEA (0.03g, 0.22 mmol). The reaction was heated in a microwave at 200 °C for 15 30 min. The reaction was cooled to 25 °C, quenched with water (10 ml), and extracted with MTBE (4 x 30 ml). The combined organic fractions were then dried, filtered, and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in PEO over 400 ml) to give the title compound (0.008g, 11%). SH NMR (400
H /it Tr, £-7/11 (~ 1 t t \ n nn n ir\ ott\ n f\^ £ no /„„ ottn /r m /„ tin r 1 n r „ t _
iviiiz,, ^i_^3u / .h-i iiij, / .j j- / ju z.nj, / z,n)7 u.uj (s, jnj, 1 / j —
6.8 Hz, IH), 2.02-1.98 (m, IH), 1.59 (d, J= 6.8 Hz, 3H), 1.21-1.65 (m, 2H), 0.86-0.82 (m, 2H). MS: Calcd.: 406; Found: [M+H]+ 407.
Example 22
Ar-(5-Cyclopropyl-l//-pyrazol-3-yl)-A"-[nyt-l-f4-fluorophenyl)ethvl]pvridine-2.6-diamine 25 rerf-Butyl 5-cyclopropyl-3-[(6-{[(3^-1 -(4-fluorophenyl)ethyl]amino}pyridin-2-
yl)amino]-1 //-pyrazole- 1-carboxylate (Method 21; 146mg) was dissolved in a solution of hydrogen chloride in ether (2.0 M, 2 ml, 4 mmol) and the reaction mixture was stirred at room temperature for 4 hours. The solvent was removed and semi-prep HPLC (Gilson) purification gave the title compound (37 mg, 25%). 'H NMR (CDC13) 5 0.55 (m, 2H), 0.70 (m, 2H), 1.35 30 (m, 3H), 1.65 (m, IH), 4.53 (m, 2H), 4.91 (brs, IH), 6.10 (br s, IH), 6.70 (m, IH), 7.00 (m, 2H), 7.25 (m, 3H).
101749
Examplc 23
f5y2-Amino-A^-ff6-f5-cvclopropyl-l//-pvrazol-3-ylamino)-5-fluoro-2-fl-(4-fluorophenvDethy1amino)pvridin-3-yl)methyl)acetamide
To a solution of tert-buty\ (2-{[(6-[(5-cyclopropy]-l//-pyrazol-3-yl)amino]-5-fluoro-5 2-{[(15)-1 -(4-fluorophenyl)ethyl]amino}pyridin-3-yl)methyl]amino} -2-oxoethyl)carbamate (Method 22; 0.035g, 0.065 mmol) in dioxane (4 ml), was added an HCI/dioxane solution (4.0 M, 30eq.). The resulting solution was stirred at 25 °C for 3 hrs. The reaction was then concentrated, re-dissolved in MeOH (0.5 ml), and quickly treated with ether (50 ml). The resulting solid was collected to give the HCI salt of the title compound (0.025g, 87%). 'H 10 NMR (400 MHz, CD3OD) 5 7.60 (d, J = 10.7 Hz, 1H), 7.47-7.44 (m, 2H), 7.07-7.03 (m, 2H), 5.78 (s, IH), 5.04 (q, J= 6.6 Hz, IH), 4.43-4.40 (m, 2H), 3.79 (s, 2H), 2.01-1.96 (m, IH), 1.66 (d, 6.6 Hz, 3H), 1.17-1.13 (m, 2H), 0.82-0.81 (m, 2H). MS: Calcd.: 441; Found: [M+H]+ 442.
Example 24
N-((6-( 5 -Cyclopropyl- li7-pyrazol-3 -vlamino')-5-fluoro-2-((.Sy1 -(4-fluorophenvl)ethylamino)pvridin-3-yl)methyO-5-oxopvrrolidine-2-carboxamide
A round bottom flask was charged with (5)-3-(aminomethyl)-7V6-(5-cyclopropyl-l//-pyrazol-3-yl)-5-fluoro-A^-(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.08g, 20 0.2 mmol), 5-oxopyrrolidine-2-carboxylic acid loaded TFP resin (1.4 mmol/g loading, 0.2 mmol), and a THF - DCM solution (3 ml) at 0 °C. The resulting solution was shaken vigorously at 0 °C for 45 min and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-25 50% CH3CN in H2O over 400 ml) to give the title compound (0.013g, 10%). 'H NMR (400 MHz, CD3OD) 8 7.41-7.32 (m, 2H), 7.21-7.13 (m, IH), 7.05-6.97 (m, 2H), 6.05 (s, IH), 5.21-5.02 (m, IH), 4.34-4.19 (m, 3H), 2.44-2.28 (m, 3H), 2.11-1.98 (m, IH), 1.88-1.81 (m, IH), 1.51 (d, J= 5.2 Hz, 3H), 0.99-0.86 (m, 2H), 0.69-0.61 (m, 2H). MS: Calcd.: 495 Found: [M+H]+ 496.
101749
Example 25
jV4-f5-Cyclopropvl-l//-pyrazol-3-yl)-A^-r('S)-l-f4-fluoro-phenvi)-ethvn-pvridine-2,4-diamine
A mixture of (2-chloro-pyridin-4-yl)-(5-cyclopropyl-l/f-pyrazole-3-yl)-amine (Method 4; 0.116 g, 0.49 mmol). DIEA (0.20 ml, 1.18 mmol), and (iS)-l-(4-fluoro-phenyl)-5 ethylamine (1.0 ml, 7.4 mmol) was heated to 160 °C in a sealed tube for 2 days. The reaction mixture was concentrated under reduced pressure and purified by reverse-phase prep HPLC (column: mC-PACK- ODS-AQ, 250 x 20 nm, 3.0 x 50 mm; 5-95 % gradient MeCN (0.05% TFA) in water (0.1% TFA); flow rate: 10.0 ml/min). 'H NMR (400 MHz) 8 0.696 (m, 2H), 0.958 (m, 2H), 1.49 (m, 4H), 4.75 (q, IH), 5.60 (s, IH), 7.19 (t, 2H), 7.29 (t, IH), 7.42 (t, 3H), 10 7.6 (s, IH), 9.89 (s, IH). MS: Calcd.: 337; Found: [M+H]+ 338.
Example 26
(1SViV6-(5-CyclopropvI-lZ/-pyrazol-3-vlVAf2-(T-('4-fluorophenvDethvr)-3 -nitrop vridine -2.6-diamine
A mixture of (S)-6-chloro-jV-( 1 -(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine
(Method 5; 1.74 g, 5.88 mmol), 5-cyclopropyl-li/-pyrazoI-3-amine (0.91 g, 7.36 mmol), and DIEA (1.28 ml, 7.36 mmol) in ti-BuOH (10 ml) was heated in a sealed tube at 160 °C for 60 hrs. The solvent was removed under reduced pressure and the residue was purified by chromatography (hexane - EtOAc = 1 : 1) to give the title compound as a yellow solid (1.35 g, 20 60%). 'HNMR (400 MHz) 5 12.15 (s, IH), 10.43 (br, IH), 9.19 (br, IH), 8.12 (d, 9.2 Hz, IH), 7.45 (m, 2H), 7.17 (m, 2H), 6.25 (br, IH), 6.14 (br, IH), 5.45 (m, IH), 1.87 (m, IH), 1.60 (d, J= 6.8 Hz, 3H), 0.95 (m, 2H), 0.65 (m, 2H). MS: Calcd.: 382; Found: [M+H]+ 383.
Examples 27-30
Following a similar procedure to Example 26, the following compounds were synthesized from a chloronitropyridine by reacting it with an amine.
101749
Ex
Product
NMR/MS
Amine
SM
27
Nb-(5-
(400 MHz.) 12.10 (br s, IH), 10.40
-
Method
Cyclopropyl-
(br s, IH), 9.43 (br, IH), 8.09 (d, J
cyclopropyl-
6
lH-pyrazol-3-
= 6.8 Hz, IH), 7.37(m, 2H), 7.15
lH-pyrazol-3-
yl)-N2-(4-
(m, 2H), 6.24 (br s, IH), 6.04 (br s,
amine
fluorobenzyl)-
IH), 4.80 (d, J = 5.6 Hz, 2H),
3-nitropyridine-
1.772 (m, IH), 0.85 (m, 2H), 0.46
2,6-diamine
(m, 2H). MS: Calcd.: 368; Found: [M+H]+ 369
28
(2R)-2-({6-[(5-
(400 MHz) 12.10 (s, IH), 10.39
-
Method
Cyclopropyl-
(br s, IH), 9.57 (br s, IH), 8.11 (d,
cyclopropyl-
7
lH-pyrazol-3-
J = 9.2 Hz, IH), 7.28 (m, 2H), 7.15
lH-pyrazol-3-
yl)amino]-3-
(m, 2H), 6.23 (br s, IH), 5.76 (s,
amine
nitropyridin-2-
IH), 5,35 (br s, IH), 5.19 (t, J =
yl}amino)-2-(4-
4.8 Hz, IH), 3.86 (m, 1H), 3.75
fluorophenyl)et
(m, IH), 1.87 (m, IH), 0.95 (m,
hanol
2H), 0.64 (m, 2H). MS: Calcd.: 398; Found: [M+H]+ 399
29
2-({6-[(5-
(400 MHz) 11.94 (s, 1H), 10.15
-
Method
Cyclopropyl-
(br s, IH), 9.85 (s, IH), 8.12 (d, J
cyclopropyl-
8
lH-pyrazol-3-
= 9.2 Hz, IH), 7.40 (m, 2H), 7.13
lH-pyrazol-3-
yl)amino]-3-
(m, 2H), 6.19 (br s, IH), 2.86 (br s,
amine
nitropyridin-2-
2H), 4.44 (m, 4H), 1.65 (m, IH),
yl}amino)-2-(4-
0.87 (m, 2H), 0.47 (m, 2H). MS:
fluorophenyl)pr
Calcd.: 428; Found: [M+Hf 429.
opane-l,3-diol
101749
Ex
Product
NMR/MS
Amine
SM
N6-(5-
MS: Calcd.: 382; Found: [M+H]+
-
Method
Cyclopropyl-
383.
cyclopropyl-
9
lH-pyrazol-3-
lH-pyrazol-3-
yl)-N2-[(lR)-l-
amine
(4-
fluorophenyl)
ethyl]-3-
nitropyridine-
2,6-diamine
Example 31
(,S)-./V<?-f5-Cyclopropvl-l//-pvrazol-3-yl)--/V2-n-(4-fluorophenvOethvl)pvridine-2.3.6-triamine
To a suspension of (5)-A^-(5-cyclopropyl-l//-pyrazol-3-yl)-A^-(l-(4-fluorophenyl)ethyl)-3-nitropyridine-2,6-diamine (Example 26; 0.40 g, 1.05 mmol) and zinc dust (0.342 g, 5.23 mmol) in MeOH - THF (1 : 1, 16 ml) was slowly added a saturated aqueous ammonium chloride solution (2.5 ml). The mixture was stirred at 25 °C for 1 hr, then treated with saturated ammonium acetate solution (4 ml). The resulting mixture was stirred for another 30 min. The Zn dust was removed by filtration and the cake was washed with EtOAc (20 ml). The organic layer was separated, washed with brine (10 ml), and dried over Na2S04. Removal of the solvent gave the title compound at quantitative yield. 'H NMR (400 MHz) 8 11.5 (br, IH), 7.98 (br, IH), 7.43 (m, 2H), 7.07 (m, 2H), 6.67 (d, J= 8 Hz, IH), 6.09 (s, IH), 5.63-5.70 (m, 2H),5.19(m, IH),4.04(br, 2H), 1.77 (m, IH), 1.46 (d, J=6.8Hz, 3H), 0.85 (m, 2H), 0.59 (m, 2H). MS: Calcd.: 352; Found: [M+H]+ 353.
Examples 32-35
Following a similar procedure to Example 31, the following compounds were synthesized from a nitropyridine by reacting it with zinc dust.
Ex
Product
MS SM
32
N6-(5-Cyclopropyl-1 H-pyrazol-3-yl)-N2-(4-fluorobenzyl)pyridine-2,3,6-triamine
Calcd.: 338; Found: Example [M+H]+ 339 27
101749
Ex
Product
MS
SM
33
(2R)-2-({3-Amino-6-[(5-cyclopropyl-lH-pyrazol-3-yI)amino]pyridin-2-yl} amino)-2-(4-fluorophenyl)ethanoI
Calcd.: 368; Found: [M+FI]+ 369
Example 28
34
2-({3-Amino-6-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]pyridin-2-yl} amino)-2-(4-fluorophenyl)propane-1,3-diol
Calcd.: 398; Found: [M+H]+ 399
Example 29
N6-(5-Cyclopropyl-l H-pyrazoI-3-yl)-N2-[( 1R)-1 -(4-fluoropheny 1) ethyl] pyridine -2,3,6 -triamine
Calcd.: 352; Found: [M+H]+ 353
Example 30
Example 36
(SyS-Chloro-iV2-f5-cvclopropyI-l//-pyrazol-3-viyiV6-n-(4-fluorophenvI')ethvO-5-
nitrop yridin-2.6-di amine 5 A mixture of (iS)-5,6-chloro-JV-(l -(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine
(Method 13; 0.61 g, 79% pure, 1.46 mmol), 5-cyclopropyl-l//-pyrazol-3-amine (0.27 g, 2.19 mmol), and DIEA (0.38 ml, 2.19 mmol) in h-BuOH (5 ml) was heated in a sealed tube at 100 °C for 48 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane : EtOAc = 2 : 1) to give the title compound as a 10 vellow solid (0.57 p. 94%Y NMR f400 MHz! 17 34 1T-H 9 34 fs im 8 93 (c\ ./= 7 ft H7
J \ _ ■ c - "• ' ^ ~ • -A ~ • V"? -■ ■ ~ — r - _ V --5 w J ■ w ■*■*—'5
IH), 8.26 (s, IH), 7.32 (m, 2H), 7.12 (m, 2H), 6.01 (s, IH), 5.29 (m, IH), 1.91 (m, IH), 1.56 (d, J - 7.2 Hz, 3H), 0.96 (m, 2H), 0.65 (m, 2H). MS: Calcd.: 416; Found: [M+H]+ 417.
Examples 37-40
Following a similar procedure to Example 36, the following compounds were synthesized from a chloronitropyridine by reacting it with an amine.
101749
Ex
Product
NMR/MS
Amine
SM
37
(2R)-2-({5-Chioro-6-
[(5-cyclopropyl-lH-
pyrazol-3-yl)amino]-
3-nitropyridin-2-
yl}amino)-2-(4-
fluorophenyl)ethanol
(400 MHz) 12.28 (s, IH), 9.33 (d, J = 7.6 Hz, IH), 9.28 (s, IH), 8.27 (s, IH), 7.30 (m, 2H), 7.13 (m, IH), 5.94 (s, IH), 5.22 (br s, 2H), 3.84-3.73 (m, 2H), 1.90 (m, IH), 0.97 (m, 2H), 0.68 (m, 2H). MS: Calcd.: 432; Found: [M+H]+ 433
-
cyclopropyl -1H-
pyrazol-3-amine
Method 14
38
(2R)-2-({5-Chloro-6-
[(5-methyl-lH-
pyrazol-3-yl)amino]-
3-nitropyridin-2-
yl}amino)-2-(4-
fluorophenyJ)ethanol
(400 MHz) 12.23 (s, IH), 9.35 (d, J = 7.2 Hz, IH), 9.30 (s, IH), 8.27 (s, IH), 7.32 (m 2H), 7.14 (m, 2H), 5.86 (s, IH), 5.23 (t, J = 4.8 Hz, IH), 5.18 (m, IH), 3.81 (m, IH), 3.74 (m, IH), 2.23 (s, 3H). MS: Calcd.: 406; Found: [M+H]+ 407
-methyl-lH-pyrazol-3-amine
Method 14
39
(2R)-2-({6-[(5-tert-
Butyl-1 H-pyrazol-3-
yl)amino]-5-chloro-3-
nitropyridin-2-
yl}amino)-2-(4-
fluorophenyl)ethanol
(400 MHz) 12.36 (s, IH), 9.30 (s, IH), 9.29 (d, J = 7,6 Hz, IH), 8.27 (s, IH), 7.26 (m 2H), 7.08 (m, 2H), 6.18 (s, IH), 5.29 (m, IH), 5.21 (t, J - 4.8 Hz, IH), 3.81 (m, 2H)„ 1.28 (s, 9H). MS: Calcd.: 448; Found: [M+H]+ 449
-tert-butyl-lH-pyrazol-3-amine
Method 14
40
3-Chloro-Ni-(5-
cyclopropyl-lH-
pyrazol-3 -y l)-N6-(4-
fluorobenzyl)-5-
nitropyridine-2,6-
diamine
(400 MHz) 12.33 (s, IH), 9.32 (br s, IH), 8.26 (s, IH), 8.20 (brs, IH), 7.53 (m, 2H), 7.11 (m, 11-I), 5.96 (s, IH), 4.69 (d, J = 6.0 Hz, 2H), 1.79 (m, IH), 0.87 (m, 2H), 0.47 (m, 2H). sMS: Calcd.: 402; Found: [M+H]+ 403
(4-
fluoropheny l)methanami ne
Method 15
Example 41
(5y5-ChIoro-A^-(5-cyclopropyl-l//-pvrazol-3-yQ-jV2-fl-(4-fliiorophenyl)ethyl)pvridme-2J,6-triamine
To a suspension of (£)-3-chIoro-iV2-(5-cyclopropyl-l/-/'-pyrazol-3-yl)-jV6-(l-(4-
fluorophenyl)ethyl)-5-nitropyridin-2,6-diamine (Example 36; 0.57 g, 1.37 mmol) and zinc
101749
dust (0.447 g, 6.84 mmol) in MeOH : THF (1 : 1, 24 ml) was slowly added saturated ammonium chloride solution (3.5 ml). The reaction mixture was stirred at 25 °C for 2 hours, followed by addition of saturated ammonium acetate solution (5 ml). The resulting mixture was stirred for another 30 minutes. Zn dust was removed by filtration and washed with EtOAc 5 (20 ml). The organic layer was separated, washed with brine (10 ml), dried over Na2S04and the solvent removed to give the title compound. MS: Calcd.: 386; Found: [M+H]+ 387.
Examples 42-45
Following a similar procedure to Example 41, the following compounds were 10 synthesized from a nitropyridine by reacting it with zinc dust.
Ex
Product
NMR/MS
SM
42
(2R)-2-({3-Amino-5-chloro-6-[(5-cyclopropyl-lH-
pyrazol-3-yl)amino]pyridin-2-yl}amino)-2-(4-
fluorophenyl)ethanol
MS: Calcd.: 402; Found: [M+H]+ 403
Example 37
43
(2R)-2-({3-Amino-5-chloro-6-[(5-methyl-lH-pyrazol-3-yl)amino]pyridin-2-yl}amino)-2-(4-fluorophenyl)ethanol
MS: Calcd.: 376; Found: [M+H]+ 377
Example 38
44
(2R)-2-( {3 - Amino-6-[(5-tert-butyI-1 H-pyrazol-3 -
yl)amino]-5-chloropyridin-2-yl}amino)-2-(4-
fluorophenyl)ethanol
MS: Calcd.: 418; Found: [M+H]+ 419
Example 39
45
-Chloro-N6-(5-cyclopropyl-l H-pyrazol-3-yl)-N'i-(4-fluorobenzyl)pyridine-2,3,6-triamine
MS: Calcd.: 372; Found: [M+H]+ 373
Example 40
Example 46
(1$r)-6-('5-Cvclopropvl-l/f-pvrazol-3-vlamino)-5-fluoro-2-(l-(4-fluorophenvl)ethvIammo^ nicotinic acid
(iS)-6-(5-CycIopropyl-l//-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-
fluorophenyl)ethylamino)nicotinamide (Example 2; l.Og, 2.5 mmol) was dissolved in a 10% aqueous EtOH solution (10 ml) at 25 °C, followed by addition of solid KOH (2.8g, 50.0 mmol). The reaction solution was heated to 95 °C for 4 days, cooled to 25 °C, and extracted with DCM (2 x 50 ml). The aqueous layer was then acidified to pH 3. The resulting solid
101749
(0.55 g), was collected by filtration and dried under vacuum to give the title compound. MS: Calcd.: 399; Found: [M+H]+ 400.
Example 47
5-Cyclopropyl-1 //-pyrazol-3-yl)-A^-(1 -f4-fluorophenvl)ethvl)-3-nitropyridine-2.6-
diamine
A mixture of 6-chloro-Af-(5-cyclopropyl-lf/-pyrazol-3-yl)-3-nitropyridin-2-amine (Method 16; 0.30 g, 1.07 mmol), (5)-l-(4-fIuoro-phenyI)-ethylamine (0.23 g, 1.61 mmol), and DIEA (0.23 ml, 1.34 mmol) in ;?-BuOH (5 ml) was heated in a sealed tube at 165 °C for 18 10 hrs. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane - EtOAc = 1 : 1) to give the title compound as a yellow solid (0.41 g, 99%). 'H NMR (400 MFIz) 6 12.22 (s, IH), 10.98 (s, IH), 8.70 (d, J =7.2 Hz, IH), 8.10 (d, J = 9.2 Hz, IH), 7.39 (m, 2FI), 7.18 (m, 2H), 6.22 (d, 9.2 Hz, IH), 6.17 (s, IH), 5.27 (m, IH), 1.89 (m, IH), 1.52 (d, J- 6.4 Hz, 3H), 0.95 (m, 2H), 0.64 (m 2H). MS: Calcd.: 382; 15 Found: [M+H]+ 383.
Examples 48-50
Following a similar procedure to Example 47, the following compounds were synthesized from 6-chloro-A/-(5-cyclopropyl- l//-pyrazol-3-yl)-3-nitropyridin-2-amine 20 (Method 16) and the appropriate amine.
Ex.
Product
NMR/MS
Amine
48
N6-(4-Fluorobenzyl)~ N2-(5-cyclopropyl-1H-pyrazol-3-yl)-3-nitropyridine-2,6-diamine
(400 MHz) 12.24 (s, IH), 10.98 (s, IH), 8.29 (brs, IH), 8.11 (d, J = 9.2'Hz, IH), 7.36 (m, 2H), 7.18 (m, 2H), 6.20 (d, J = 9.6 Hz, IH), 6.19 (s, IH), 4.66 (d, J = 5.2 Hz, 2H), 1.79 (m, IH), 0.86 (m, 2H), 0.45 (m, 2H). MS: Calcd.: 368; Found: [M+H]+ 369
(4-
fluorobenzyl) amine
101749
Ex.
Product
NMR/MS
Amine
49
(R)-2-[6-(5-
Cyclopropyl-IH-
pyrazol-3-ylamino)-5-
nitropyridin-2-
ylamino]-2-(4-
fluorophenyl)ethanol
(400 MHz) 12.21 (s, IH), 10.97 (s, IH), 8.74 (d, J = 7.6 Hz, IH), 8.09 (d, J = 9.6 Hz, IH), 7.38 (m, 2H), 7.18 (m, 2H), 6.31 (d, J = 9.2 Hz, IH), 6.20 (s, IH), 5.21 (d, J = 5.6 Hz, IH), 5.09 (t, J = 5.2 Hz, IH), 3.64-3.75 (m, 2FI), 1.91 (m, IH), 0.98 (m, 2H), 0.66 (m, 2H). MS: Calcd.: 398; Found: [M+FI]+ 399.
(R)-2-amino-2-(4-
fluorophenyl) ethanol
50
2- [6-(5-Cyclopropyl-
lH-pyrazol-3-
ylamino)-5-
nitropyridin-2-
ylamino]-2-(4-
fluorophenyl)propane-
1,3-diol
(400 MHz) 12.02 (s, 1FI), 10.95 (s, IH), 8.07 (d, J = 9.2 Hz, IH), 7.93 (s, IH), 7.35 (m, 2H), 7.14 (m, 2H), 6.48 (d, J = 9.2 Hz, IH), 5.04 (s, IH), 4.81 (s, 2H), 4.04 (m, 2H), 3.90 (m, 2H), 1.68 (m, IH), 0.90 (m, 2H), 0.51 (m, 2H). MS: Calcd.: 428; Found: [M+H]+ 429.
2-amino-2-(4-fluorophenyl) propane-1,3-diol
Example 51
CSy3-Chloro-A^-(5-cvclopropvi-lZ/-pyrazol-3-vlVAf2-n-(4-fluorophenyl)ethvri-5-nitropyridin-2,6-diamine 5 A mixture of 5,6-chloro-Ar-(5-cycIopropyl- ] //-pyrazol-3-yl)-3-nitropyridine-2-amine
(Method 17; 0.26 g, 0.83 mmol), (5)-l-(4-fIuoro-phenyl)ethylamine (0.17 g, 1.25 mmol), and DIEA (0.22 ml, 1.25 mmol) in «-BuOH (5 ml) was heated in a sealed tube at 165 °C for 3 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane : EtOAc =1 : 1) to give the title compound as a yellow solid 10 (0.34 g, 99%). NMR (400 MHz) 12.29 (s, IH), 10.68 (s, lH),8.27(s, IH), 8.24 (d, J= 8.0 Hz, IH), 7.39 (m, 2H), 7.16 (m, 2H), 6.11 (s, IH), 5.42 (m, IH), 1.89 (m, IH), 1.60 (d,.7=7.2 Hz, 3H), 0.95 (m, 2H), 0.61 (m, 2H). MS: Calcd.: 416; Found: [M+H]+ 417.
Examples 52-54
Following a similar procedure to Example 51, the following compounds were synthesized from the appropriate starting material and amine.
101749
Ex.
Product
NMR/MS
SM
Amine 2
52
N2-(4-Fluorobenzyl)-
3-cbloro-N6-(5-
cyclopropyl-lH-
pyrazol-3-yl)-5-
nitropyridin-2,6-
di amine
(400 MHz) 12.29 (s, IH), 10.73 (s, IH), 8.70 (t, J = 6.0 Hz, IH), 8.12 (b, IH), 7.30 (m, 2H),7.16 (m, 2H), 6.02 (s, IH), 4.71 (d, J = 6.0 Hz, 2H), 1.77 (m, 1H),0.86 (m, 2FI), 0.41 (m, 2H). MS: Calcd.: 402; Found: [M+H]+ 403.
Method 17
(4-fluoro-
phenyl)metha namine
53
(R)-2-[3-Chloro-6-(5-cyclopropyl-lH-pyrazol -3 -ylamino)-5-nitropyridin-2-ylamino]-2-(4-fluorophenyl) ethanol
(400 MHz) 12.27 (s, IH), 10.70 (s, IH), 8.29 (d, J = 1.6 Hz, IH), 8.03 (d, J = 7.6 Hz, IH), 7.39 (m, 2H), 7.14 (m, 2H), 6.15 (s, IH), 5.31 (m, IH), 5.13 (t, J = 4.8 Hz, IH), 3.32-3.86 (m, 2H), 1.92 (m, IH), 0.98 (m, 2H), 0.68 (m, 2H). MS: Calcd.: 432; Found: [M+H]+ 433.
Method 18
-
cyclopropyl-
lH-pyrazol-3-
amine
54
(2i?)-2-({3-Chloro-6-
[(5-methvl-l H-
pyrazol-3-yl)amino]~
-nitropyridin-2-
yl}amino)-2-(4-
fluorophenyl)ethanol
(400 MHz) 12.23 (s, IH), 10.69 (a. 1HY 8.30 fs. 1HY 8.00 (d_./ =
s/ /J \ - J J S - ■ ■ \ ■ J -
7.6 Hz, IH), 7.41 (m 2H),7.17 (m, 2H), 6.12-5.26 (m, IH), 5.13 (t, J= 5.2 Hz, IH), 3.73-3.86 (m, 2H), 2.25 (s, 3H). MS: Calcd.: 406; Found: [M+H]+ 407
Method 18
-methyl-1H-r>vrazo1-3-
r j
amine
Example 55
(\S)-Af2-f5-Cyclopropvl-l//-pyra2ol-3-vl)-A^-ri-(4-fhiorophenyl)ethvllpyridine-2,3.6-triamine To a suspension of (5)-A?2-(5-cyclopropyl-lJf/-pyrazol-3-yl)-A^-[l-(4-5 fluorophenyl)ethyl]-3-nitropyridine-2,6-diamine (Example 47; 0.26 g, 0.68 mmol) and zinc dust (0,223 g, 3.41 mmol) in MeOH : THF (1:1,12 ml) was slowly added saturated ammonium chloride solution (1.5 ml). The reaction mixture was stirred at 25 °C for 1 hour, to which was then added saturated ammonium acetate solution (5 ml). The resulting mixture was stirred for another 30 minutes. Zn dust was removed by filtration and washed with EtOAc (20
101749
ml). The organic layer was separated, washed with brine (10 ml), dried over Na2SC>4, and concentrated to give the title compound.
Examples 56-62
Following a similar procedure to Example 55, the following compounds were synthesized from a suitable nitro-pyridine.
Ex.
Compound
NMR/MS
SM
56
Af2-(5-Cyclopropyl-l//-pyrazol-3-yl)-7V6-(4-fluorobenzyl)pyridine-2,3,6-triamine
MS: Calcd.: 338; Found: [M+FI]+ 339
Example 48
57
(2i?)-2-({5-Amino-6-[(5-cyclopropyl-l//'-
pyrazol-3-yl)amino]pyridin-2-yl}amino)-2-(4-
fluorophenyl)ethanol
MS: Calcd.: 368; Found: [M+H]+ 369
Example 49
58
2-({5-Amino-6-[(5-cyclopropyl-l//-pyrazol-3 -yl)amino]pyridin-2-yl} amino)-2-(4-fluorophenyl)propane-l ,3-diol
MS: Calcd.: 398; Found: [M+H]+ 399
Example 50
59
-Chloro-iV2-(5-cyclopropyl-1//-pyrazol-3-yl)-7V6-[(15r)-l-(4-
fluorophenyl)ethyl]pyridine-2,3,6-tri amine
MS: Calcd.: 386; Found: [M+H]+ 387
Example 51
60
S-Chlnrn-7V -f^-nvr.lnnrnnvl-l J4f-nvra7n1-'?-
yl)-A'6-(4-fluorobenzyl)pyridine-2,3,6-tri amine
MS: Calcd.: 372; Found: [M+H]+ 373
Fvnmnlp
52
61
(2R)-2-( {5-Amino-3-chloro-6- [(5-
cyclopropyl-l//-pyrazol-3-yl)amino]pyridin-
2-yl}amino)-2-(4-fluorophenyl)ethanol
MS: Calcd.: 402; Found: [M+H]"1' 403
Example 53
62
(2i?)-2-({5-Amino-3-chloro-6-[(5-methyl-l//-pyrazol-3-yl)amino]pyridin-2-yl} amino)-2-(4-fluorophenyl)ethanol
MS: Calcd.: 376; Found: [M+Flf 377
Example 54
Example 63
A^-f5-Cyclopropvl-l//-pvrazol-3-yl)-iV-(4-fluorobenzvl)pvridine-2,6-diamine 10 To a flask was added Pd(OAc)2 (22.4 mg, 0.1 mmol), (biphenyl-2-
ylmethylene)bis(dimethylphosphine) (60 mg, 0.2 mmol) and sodium tert-butoxide (240 mg, 2.5 mmol). The flask was sealed and refilled with N2. To the mixture was added a solution of
101749
6-bromo-AL(4-fluorobenzyl)pyridin-2-amine (Method 19; 281 mg, 1.0 mmol) and 5-cyclopropyl-l//-pyrazol-3-amine (123 mg, 1.0 mmol) in toluene (5 ml). The reaction mixture was heated at 110°C overnight. The solvent was removed and EtOAc was added and the mixture was washed with brine and was concentrated. Semi-prep HPLC (Gilson) purification 5 gave the title compound (6.4 mg, 2%). 'H NMR (CDCI3) § 0.65 (m, 2H), 0.95 (m, 2H), 1.80 (m, IH), 4.43 (m, 2H), 4.91 (brs, IH), 5.60 (br s, IH), 5.80 (m, IH), 6.18(m, IH), 6.73 (m, IH), 7.00 (m, 2H), 7.25 (m, 3H).
Example 64
(5y5-Chloro-6-(5-cyclopropyl-l./7-pyrazol-3-vlamino)-2-(T-f5-fluoropvridin-2-v I )ethy lamino)ni cotinonitrile
A solution of 2,5-dichloro-6-(5-cyclopropyl-l//-pyrazol-3-ylamino)nicotinonitrile (Method 43, 0.60 g, 2.04 mmol), DIEA (0.34 g, 2.65 mmol), and (£)-l-(5-fluoropyridin-2-yl)ethanamine (Method 33; 0.90 g. 6.12 mmol) in tt-BuOH was heated to 120 °C for 9 hours. 15 The reaction was then cooled to room temperature, diluted with water (20 ml), and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over NaaSO/t, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.42 g, 52%). *H NMR (400 MHz, CD3OD) 5 8.42 (d, J = 2.7 Hz, IH), 7.61 (s, IH), 7.51-7.49 (m, IH), 7.38-7.32 (m, IH), 6.06 (br s, IH), 5.28-5.22 20 (m, IH), 1.94-1.88 (m, IH), 1.58 (d, J= 6.9 Hz, 3H), 1.01 (br s, 2H), 0.76-0.75 (m, 2H). MS: Calcd.: 397; Found: [M+H]+ 398.
Example 65
(y)-Ar2-(5-CyclopropyI-li/-pyrazol-3-ylV3-fluoro-A/6-(l-(4-fluorophenyl)&thvl)-5-25 nitropyridine-2,6-diamine
To a solution of (5)-5,6-difluoro-7V-(l-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine (Method 23, 0.60g, 2.0mmol) in THF (10m3) at room temperature was added 5-cycIopropyl-l/Y-pyrazol-3-amine (0.50g, 4.0mmol), and DIEA (0.26g, 2.0mmol). The reaction was then heated to 55 °C for 24 hours, cooled to room temperature, and quenched with water. The 30 reaction was then extracted with DCM (2 x 75 ml), and the combined organic fractions were dried over Na2S04, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.53 g. 66%). 'H NMR (400 MHz, CD3OD) 8 8.00 (d, J= 11.1Hz, IH), 7.38-7.35 (m, 2H), 7.07-7.02 (m, 2H), 6.17
101749
(s, IH), 5.41-5.39 (m, IH), 1.93-1.87 (m, IH), 1.61 (d,J= 7.0Hz, 3H), 1.02-1.00 (m, 2H), 0.69-0.66 (m, 2H). MS: Calcd.: 400; Found: [M+H]+ 401.
Example 66
(5r)-3-Fluoro-./V6-fl-f4-fluorophenvl)ethyl)-./V2-(5-isopropoxy-l//-pvrazoI-3-vl)-5-nitropyridine-2,6-diamine
To a solution of (5)-5,6-difluoro-Ar-(l-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine (Method 23; 0.60 g, 2.0 mmol) in THF (10 ml) at room temperature was added 5-isopropoxy-l//-pyrazol-3-amine (0.50 g, 3.0 mmol), and DIEA (0.29 g, 2.2 mmol). The reaction was then 10 heated to 55 °C for 24 hours, cooled to room temperature, and quenched with water. The reaction was then extracted with DCM (2 x 75 ml), and the combined organic fractions were dried over Na2S04, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.34 g, 40%). ]H NMR (400 MHz, CD3OD) 8 8.00 (d, J= 10.9 Hz, IH), 7.45-7.35 (m, 2H), 7.07-7.03 (m, 2H), 5.88-15 5.71 (m, IH), 5.48-5.30 (m, IH), 4.58-4.29 (m, IH), 1.68-1.56 (m, 3H), 1.34-1.28 (m, 6H). MS: Calcd.: 418; Found: [M+H]+ 419.
Example 67
(/?")-2-(6-f5-Cvclopropvl-liJ-pyrazol-3-vlamino')-5-fluoro-3-nitropyridin-2-vlamino)-2-(4-20 fl uoropheny Pethanol
To a solution of (iS)-2-(5,6-difluoro-3-nitropyridin-2-ylamino)-2-(4-fluorophenyl) ethanol (Method 25, 0.40 g, 1.3 mmol) in THF (10 ml) at room temperature was added 5-cyclopropyI-l//-pyrazol-3-amine (0.31 g, 2.6 mmol), and DIEA (0.18 g, 1.4 mmol). The reaction was then heated to 55 °C for 12 hours, cooled to room temperature, and quenched 25 with water. The reaction was then extracted with DCM (2 x 75 ml), and the combined organic fractions were dried over Na2S04, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.45 g, 85%). 'HNMR (400 MHz, CDC13) 5 10.84 (s, IH), 8.02 (d,J = 10.7 Hz, IH), 7.35-7.31 (m, 2H), 7.10-7.06 (m, 2H), 6.21-6.19 (m, IH), 5.80 (br s, IH), 4.07 (dd, J= 11.3, 3.9 Hz, 30 IH), 3.99 (dd, J= 11.3, 6.4 Hz, IH), 1.88-1.86 (m, IH), 1.62 (brs, IH), 0.98-0.95 (m, 2H), 0.70-0.68 (m, 2H). MS: Calcd.: 416; Found: [M+H]+ 417.
101749
Example 68
fi?)-2-f5-Fhioro-6-f5-methyl-li?-pyrazol-3-ylamino)-3-nitropyridm-2-yIamino)-2-(4-fluorophenvPethanoI
To a solution of (5)-2-(5,6-difluoro-3-nitropyridin-2-ylamino)-2-(4-fluorophenyl) 5 ethanol (Method 25; 0.60 g, 1.9 mmol) in THF (10 ml) at room temperature was added 5-methyl-l//-pyrazol-3-amine (0.37 g, 3.8 mmol), and DIEA (0.27 g, 2.1 mmol). The reaction was heated to 55 °C for 12 hours, cooled to room temperature, and quenched with water. The reaction was then extracted with DCM (2 x 75 ml), and the combined organic fractions were dried over Na2S04, filtered, and then concentrated. The resulting oil was purified by column 10 chromatography (DCM-MeOH = 100 :1) to give the title compound (0.51 g, 68%). !H NMR (400 MHz, CDC13)8 10.85 (brs, IH), 8.02 (d, ./= 10.5 Hz, IH), 7.34-7.31 (m, 2H), 7.10-7.06 (m, 2H), 6.26-6.25 (m, IH), 5.86 (br s, IH), 5.30-5.27 (m, IH), 4.07 (dd, J= 11.3 and 3.9 Hz, IH), 3.97 (dd, J= 11.1, 6.2 Hz, 1H),2.27 (s, 3H), 1.61 (br s, IH). MS: Calcd.: 390; Found: [M+H]+ 391.
Example 69
(6f)-3-Chioro-A/2-(l-(4-fluorophenvl)ethvl)-A^-(5-isopropoxy-l//-pvrazol-3-vl)-5-nitropyridine-2,6-diamine
A mixture of 5,6-dichloro-7V-(5-isopropoxy-l//-pyrazol-3-yl)-3-nitropyridin-2-amine 20 (Method 26, 0.25 g, 0.75 mmol), (S)-l-(4-fluoro-phenyl)-ethylamine (0.13 g, 0.90 mmol) and DIEA (0.16 ml, 0.94 mmol) in rc-BuOH (3 ml) was heated in a sealed tube at 145 °C for 4 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane-EtOAc = 1 : 1) to give the title compound as a yellow solid (0.32 g, 98%). !HNMR (400 MHz) 5 12.16 & 11.72 (s, IH), 10.64&10.58 (s, IH), 8.30 (m, 25 2H), 7.37 & 7.31 (m, 2H), 7.16 & 7.08 (m, 2H), 5.81 & 5.71 (s, IH), 5.48 & 5.33 (m, IH), 4.60 & 4.21 (m, IH), 1.61 &1.57 (d, J= 6.8 Hz, 3H), 1.25 (m, 6H). MS: Calcd.: 434; Found: [M+H]+ 435.
Example 70
(^r)-3-Chloro-A/6-(l-(4-fluorophenvl)ethvi)-JV"2-(5-isopropoxy-l//-pyrazol-3-yl)-5-nitropyridine-2,6-diamine
A mixture of 3,6-dichloro-jV-(5-isopropoxy-l//-pyrazol-3-yl)-5-nitropyridin-2-amine (Method 27, 0.25 g, 0.75 mmol), (5)-l-(4-fluoro-phenyl)-ethylamine (0.13 g, 0.90 mmol) and
101749
DIEA (0.16 ml, 0.94 mmol) in «-BuOH (3 ml) was heated in a sealed tube at 145 °C for 2 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane-EtOAc = 1 : 1) to give the title compound as a yellow solid (0.32 g, 98%). *H NMR (400 MHz) 5 12.22 & 11.40 (s, IH), 9.74 & 9.37 (s, IH), 8.93 (d, J = 5 7.6 Hz, IH), 8.33 & 8.27 (s, IH), 7.34 & 7.27 (m, 2H), 7.12 & 7.05 (m, 2H), 5.75 & 5.62 (s, IH), 5.35 & 5.25 (m, IH), 4.66 & 4.03 (m, IH), 1.55 (d, J= 6.4 Hz, 3H), 1.29 (d,J= 6.0 Hz, 6H). MS: Calcd.: 434; Found: [M+H]+ 435.
Example 71
(STi-N6-(l-(4-Fluorophenvl)ethyl')-Ar2-('5-isopropoxv-l//-pvrazol-3-yl)-3-nitropvridine-2.6-diamine
A mixture of 6-chloro-/V-(5-isopropoxy-177-pyrazol-3-yl)-3-nitropyridin-2-amine (Method 28, 0.33 g, 1.1 mmol), (5)-l-(4-fluoro-phenyl)-ethylamine (0.16 g, 1.2 mmol) and DIEA (0.21 ml, 1.2 mmol) in «-BuOH (3 ml) was heated in a sealed tube at 165 °C for 4 15 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane-EtOAc = 1 : 1) to give the title compound as a yellow solid (0.43 g, 97%). *HNMR (400 MHz) 5 12.09, 12.05 & 11.64 (s, IH), 10.94, 10.87 & 10.72 (s, IH), 8.98, 8.76 & 8.70 (d, ,7=7.6 Hz, IH), 8.16 & 8.11 (d, ,7=9.6 Hz, IH), 7.40-7.33 (m, 2H), 7.22-7.10 (m, 2H), 6.25 & 6.04 (d,.7= 9.6 Hz, IH), 6.23 & 5.86 (d,./= 13,6 Hz, IH), 20 5.31,5.21 & 4.89 (m, IH), 4.71, 4.59 & 4.27 (m, IH), 1.52 (m, 3H), 1.26 (m, 6H). MS:
Calcd.: 400; Found: [M+H]+ 401.
Example 72
fy)-A/-(('6-f5-Cyclopropvl-177-pyrazoI-3-vlamino')-5-fluoi'o-2-(l-f4-fluorophenvnethylamino') 25 pvridin-3-yl)methyl)-2-morpholinoacetamide
A solution of (5)-3-(aminomethyl)-A'6-(5-cyclopropyl-17/-pyrazol-3-yl)-5-fluoro-7V2-(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3, 0.16 g, 0.42 mmol), 2-morpholinoacetic acid (0.06 g, 0.42 mmol), HBTU (0.16 g, 0.42 mmol) and DIEA (0.16 g, 1.2 mmol) in DCM (3 ml) was stirred at room temperature for I hour. The reaction was then 30 quenched with a saturated aqueous solution of NaHCOs, and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na2S04, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.02 g, 10%). !H NMR (400 MHz, CD:,OD) 5 7.35 (br s, 2H), 7.17 (br s, IH),
101749
7.01-6.97 (m. 2H), 6.06 (br s, IH), 5.16-4.99 (m, IH), 4.30 (br s, 2H), 3.68 (br s, 4H), 3.06 (br s, 2H), 2.48 (brs, 4H), 1.87-1.82 (m, IH), 1.51 (d, J =6.4 Hz, 3H), 0.91 (br s, 2H), 0.64 (brs, 2H). MS: Calcd.: 511; Found: [M+H]+ 512.
Example 73
(5)-6-(5-Cyclopropyl-17/-pvrazol-3-vlaminoV5-fluoro-2-( 1 -(4-fluorophenyl')ethvlamino) nicotinaldehyde
(S)-6-(5-Cyclopropyl-l/7-pyrazol-3-yIamino)-5-fluoro-2-(l -(4-fluorophenyl) ethylamino)nicotinonitrile (Example 1, 0.4 g, 1.1 mmol) was dissolved in the mixture 10 pyridine-acetic acid-water (1 : 1 : 1, 18 ml total volume) at room temperature, to which was added Raney nickel (0.09 g, 1.1 mmol). The reaction was purged with nitrogen, evacuated, and then placed under hydrogen filled balloon for 18 hours. The reaction mixture was flushed with nitrogen, and filtered to remove the catalyst, which was washed with MeOH (30 ml). The filtrate was then extracted with DCM (5 x 50 ml), washed with aq. NaHC03, and purified 15 by reverse phase column chromatography (5-30% ACN) to give the title compound (0.18 g, 45%). 'HNMR (400 MHz, CD3OD) 6 9.40 (s, IH), 7.45 (d,J= 10.4 Hz, IH), 7.34-7.31 (m, 2H), 7.05-7.01 (m, 2H), 6.11 (s, IH), 5.26 (s, IH), 1.92-1.86 (m, IH), 1.55 (d, J = 7.0 Hz, 3H), 1.00-0.98 (m, 2H), 0.71-0.64 (m, 2H). MS: Calcd.: 383; Found: [M+H]+ 384.
Example 74
(»SV(6-(5-Cyclopropvl-l/7-pvrazol-3-vlamino>5-fluoro-2-n-f4-fluorophenyl)ethvlamino) pyridin-3-vDmethanol
To a solution of (5)-6-(5-cyclopropyl-l//-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluorophenyl)ethylamino)nicotinaldehyde (Example 73; 0.10 g, 0.26 mmol) in MeOH (5 ml) 25 at 0 °C was added NaBFU (0.012 g, 0.33 mmol). The reaction was stirred for 10 minutes, and then quenched with water and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na?S04, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.088 g, 88%). 'H NMR (400 MHz, CD3OD) 5 7.42-7.39 (m, 2H), 7.16-7.01 (m, IH), 7.01 30 (br s, 2H), 6.06-5.41 (m, IH), 5.19-5.02 (m, IH), 4.52 (br s, 2H), 1.88-1.81 (m, 1FI), 1.53 (d, J = 6.6 Hz, 3H), 0.97-0.91 (m, 2H), 0.65 (br s, 2H). MS: Calcd.: 385; Found: [M+H]+ 386.
101749
Example 75
(S)-N2-(5-Cvclopropvi-l//-pyrazol-3-yl)-3-fluoro-/V6-(T-(4-fIuorophenyl)ethyl)-5-(morpholinomethyl)pyridine-2,6-diamine
To a solution of (5,)'6-(5-cyclopropyl-7//-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-5 fluorophenyl)ethylamino)nicotinaldehyde (Example 73, 0.12 g, 0.31 mmol) in DCE (5 ml) was added morpholine (0.1 g, 1.14 mmol) and NaBH(OAc)3 (0.30 g, 1.5 mmol). The reaction was then stirred for 2 days, quenched with aq. Na2C03 (10 ml), and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na2S04, filtered, and then concentrated. The resulting oil was purified by reverse-phase column chromatography (5-35% 10 ACN) to give the title compound (0.09 g, 67%). 'H NMR (400 MHz, CD3OD) 5 7.41 (br s, 2H), 7.06-7.02 (m, 3H), 6.13 & 5.44 (s, IH), 5.12 & 4.97 (s, IH), 3.63 (br s, 4H), 3.42 (br s, 2H), 2.41 (br s, 4H), 1.87-1.82 (m, IH), 1.54 (d, .7=6.5 Hz, 3H), 0.96-0.90 (m, 2H), 0.65-0.64 (m, 2H). MS: Calcd.: 454; Found: [M+H]+ 455.
Example 76
(i?)-2-(4-Fluorophenyl)-2-('6-(5-methyl-17/-pvrazol-3-ylamino)-3-nitropvridin-2-ylamino")ethanol
A mixture of (J?)-2-(6-chloro-3-nitropyridin-2-ylamino)-2-(4-fluorophenyl) ethanol (Method 29, 0-36 g, 1.2 mmol), 5-methyl-1 //-pyrazol-3-amine (0.14 g, 1.4 mmol), and DIEA 20 (0.25 ml, 1.4 mmol) in rc-BuOH (5 ml) was heated in a sealed tube at 90 °C for 6 days. The solvent was removed under reduced pressure and the residue was purified by column chromatography (EtOAc) to give the title compound as a yellow solid (0.31 g, 73%). 'H NMR (400 MHz) 5 12.06 (s, IH), 10.40 (br, IH), 9.58 (br, IH), 8.11 (d, J= 9.2 Hz, lH),7.40(m, 2H), 7.16 (m, 2H), 6.20 (br, IH), 6.02 (s, IH), 5.29 (br, IH), 5.24 (t,J= 4.4 Hz, IH), 3.85 (m, 25 IH), 3.74 (m, IH), 2.20 (s, 3H). MS: Calcd.: 372; Found: [M+H]+ 373.
Example 77
(5r)-A^-(l-(4-Fluorophenvl)ethvl)-A^-(5-isopropoxy-l//-pyrazol-3-vn-3-nitropyridine-2,6-diamine
A mixture of (5')-6-chloro-AL(l-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine
(Method 30, 1.08 g, 3.7 mmol), 5-isopropoxy-l//-pyrazol-3-amine (0.57 g, 4.0 mmol), and DIEA (0.80 ml, 4.6 mmol) in ;?-BuOH (10 ml) was heated in a sealed tube at 115 °C for 72 hours. The solvent was removed under reduced pressure and the residue was purified by
101749
chromatography (hexane-EtOAc = 3 : 1) to give the title compound as a yellow solid (0.32 g, 22%). MS: Calcd.: 400; Found: [M+H]+ 401.
Example 78
(j?)-2-(4-Fluorophenyl)-2-(6-(5-isot>ropoxv-l//-pyrazol-3-vlaminoV5-nitropyridin-2-ylamino)ethanol
A mixture of 6-chloro-A^-(5-isopropoxy-l//-pyrazol-3-yl)-3-nitropyridin-2-amine (Method 28; 0.25 g, 0.84 mmol), (7?)-2-amino-2-(4-fluorophenyl)ethanol (0.15 g, 0.97 mmol) and DIEA (0.16 ml, 0.92 mmol) in /j-BuOH (3 ml) was heated in a sealed tube at 165 °C for 4 10 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane-EtOAc =1 : 2) to give the title compound as a yellow solid (0.30 g, 87%). "H NMR (400 MHz) 5 12.12, 12.10 & 11.61 (s, IH), 10.94, 10.89 & 10.74 (s, IH), 9.05, 8.82 & 8.73 (d, J=7.2Hz, IH), 8.13 & 8.11 (d, J-9.2 Hz, IH), 7.45-7.32 (m, 2H), 7.20-7.10 (m, 2H), 6.32 & 6.07 (d,J= 9.2 Hz, IH), 5.90, 5.83 & 5.79 (s, IH), 5.23, 5.12 15 & 4.78 (m,2H), 4.71, 4.64 & 4.37 (m, IH), 3.69 (m. 2H), 1.34 & 1.29 (d, J= 6.0 Hz, 6H). MS: Calcd.: 416; Found: [M+H]+ 417.
Example 79
(.Sr)-Af-((6-('5-CycIopropvl-l//-pvrazol-3-vlamino)-5-fluoro-2-n-('4-fluorophenyI)ethy1amino) 20 pvridin-3-vl)methy1)isoxazole-5-carboxamide
To a solution of (S)-3-(aminomethyl)-7V6-(5-cyclopropyl-l//-pyrazoI-3-yl)-5-f]uoro-Ar"-(l-(4-fluorophenyI)ethyl)pyridine-2,6-diajmine (Example 3, 0.08 g, 0.21 mmol) in DCM-THF mixture (1 : 1,4 ml) at 0 °C was added 1.0 eq. of isoxazole-5-carboxylic acid loaded TFP resin. The resulting mixture was stirred vigorously for 1 hour at 0 °C, and then filtered. 25 The remaining resin was then washed with DCM-THF (1 : 1, 2 x 10 ml portions) for 30 min, and then filtered. The combined filtrates were concentrated, and the resulting oil was purified by column chromatography to give the title compound (3.4 mg, 4%). MS: Calcd.: 479; Found: [M+H]+ 480.
Example 80-103
The following compounds were prepared by the procedure similar to that of Example 79 using (5)-3-(aminomethyl)-A/6-(5-cyclopropyl-li/-pyrazoI-3-yl)-5-fluoro-A^2-(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3) and a TFP resin loaded reagent.
101749
Ex.
Compound
NMR and/or LC/MS
TFP loaded resin
80
(S)-N-((6-(5-Cyclopropyl-lH-pyrazol-3-ylamino)-5-fluoro-2-(1 - (4-fluorophenyl)
ethylamino )pyridin-3-yl)methyl)benzamide
MS: Calcd.: 488; Found: [M+Hf 489.
benzoic acid
81
(5)-7/-((6-(5-Cyclopropyl-l H-pyrazol-3-ylamino)-5-fluoro-2-(1 -(4-fluorophenyl) ethylamino)pyridin-3 -y 1 )methyl)nicotinamide
MS: Calcd.: 489; Found: [M+H]+ 490.
pyridine-3-carboxylic acid
82
(S)-iV-((6-(5-Cyclopropyl-li/-pyrazol-3 -ylamino)-5 -fluoro-2-(1 -(4-fluorophenyl) ethylamino)pyridin-3 -yl)methyl)isonicotinamide
MS: Calcd.: 489; Found: [M+H]+490.
pyridine -4 -c arboxy lie acid
83
(>S)-./V-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-
-fZL-f1nnrrmVt^n,ulNl
^ 1 11UV1 J. J
ethylamino)pyridin-3 -
yl)methyl)-5-methylisoxazole-
4-carboxamide
MS: Calcd.: 493; Found: [M+H]+ 494.
-methyIisoxazole-4-carboxylic acid
84
(iS)-Af-((6-(5-Cyclopropyl-l //-pyrazol-3-yIamino)-5-fluoro-2-(1 -(4-fluorophenyl) ethylamino)pyridin-3 -yl)methyl)thiophene-2-carboxamide
MS: Calcd.: 494; Found: [M+H]+ 495.
thiophene-2-carboxylic acid
101749
Ex.
Compound
NMR and/or LC/MS
TFP loaded resin
85
(S)-A/-((6-(5-Cyclopropyl-l//'-
pyrazol-3-ylamino)-5-fluoro-2-
(1 -(4-fluorophenyl)
ethylamino)pyridin-3-
yl)methyl)-2-(4-
(dimethylamino)phenyl)aceta mide
MS: Calcd.: 545; Found: [M+H]+ 546.
4-
(dimethylamino)phen yl acetic acid
86
(5)-JV-((6-(5-Cyclopropyl-17/-
pyrazol-3-ylamino)-5-fluoro-2-
(1 -(4-fluorophenyl)
ethy lamino)py ri din- 3 -
yl)methyl)-2-(yV-(isopropyl)-//-
methylsulfonamido)acetamide
MS: Calcd.: 561; Found: [M+H]+ 562.
(isopropylmethanesul fonylamino)acetic acid
87
(£)-/V-((6-(5-Cyclopropyl-l//-pyrazol-3-ylamino)-5-fluoro-2-(1 -(4-fluorophenyl) ethylamino)pyridin-3-
_yi ^iiiciiiji j" i -^nicui^iauiiuiij i j piperidine-4-carboxamide
MS: Calcd.: 573; Found: [M+H]+ 574.
1 -methanesulfonyl piperidine-4-carboxylic acid
88
(<$)■-N-( (6-(5'-Cycl opropy 1-1H-pyrazol-3-ylamino)-5-fluoro-2-(1 -(4-fluorophenyl) ethylamino)pyridin-3 -yl)methyl)-6-(dimethylamino) nicotinamide
MS: Calcd.: 532; Found: [M+H]+ 533.
6-dimethylamino nicotinic acid
89
(S)-N-((6-(5 -Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1 - (4-fluorophenyl) ethylamino)pyridin-3 -yl)methyl)-6-morpholino nicotinamide
MS: Calcd.: 574; Found: [M+H]+575.
(6-morpholin-4-yl)nicotinic acid
101749
Ex.
Compound
NMR and/or LC/MS
TFP loaded resin
90
(5)-JV-((6-(5-Cyclopropyl -1H-pyrazol-3-ylamino)-5-fluoro-2-(1 -(4-fluorophenyl) ethylamino)pyridin-3 -yl) methyl)-2-(pyridin-3 -yl) acetamide
MS: Calcd.: 503; Found: [M+H]+ 504.
(3-pyridyl)acetic acid
91
(S)-W-((6-(5-CycIopropyl-ltf-
pyrazol-3-ylamino)-5-fluoro-2-
(1 -(4-fluorophenyl)
ethy lamino)pyridin-3 -
yl)methyl)tetrahydro-2H-
thiopyran-4-carboxamide
MS: Calcd.: 512; Found: [M+H]+513.
tetrahydrothiopyran-4-carboxyIic acid
92
(5)-Ar-((6-(5-Cyclopropyl-1H-pyrazoI-3-ylamino)-5-fluoro-2-(1 -(4-fluorophenyl)
ethy lamino)pyridin- 3 -yl)methyl)-2-(thiophen-2-
J J yv+vvvv+l*j,iv*v
MS: Calcd.: 508; Found: [M+H]+ 509.
2-thiophene acetic acid
93
(S)-N- ((6-(5-Cy cl oprop yl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1 -(4-fluorophenyl) ethylamino)pyridin-3 -yl)methyl)-2-(thiophen-3 -yl)acetamide
MS: Calcd.: 508; Found: [M+H]+ 509.
3-thiophene acetic acid
94
(5)-iV-((6-(5-Cyclopropyl-li/-
pyrazol-3-ylamino)-5-fluoro-2-
(1 -(4-fluorophenyl)
ethylamino)pyridin-3-
yl)methyl)-3-
phenylpropanamide
MS: Calcd.: 516; Found: [M+H]+517.
hydrocinnamic acid
101749
Ex.
Compound
NMR and/or LC/MS
TFP loaded resin
95
(S)-iV-(2-((6-(5-Cyclopropyl-
MS: Calcd.: 559;
N-methylhippuric
l//-pyrazol-3-ylamino)-5-
Found: [M+H]+ 560.
acid
fl uoro-2 -(1 - (4-fluorophenyl)
ethy lam i no)pyridin-3 -
yl)methylamino)-2-oxoethyl)-
yV-methylbenzamide
96
(S)-7V-((6-(5-Cyclopropyl-l//-
MS: Calcd.: 623;
(methanesul fonylphe
pyrazol-3-ylamino)-5-fluoro-2-
Found: [M+H]+ 624.
nethylamino)acetic
(1-(4-fluorophenyl)
acid
ethylamino)pyridin-3 -
y 1 )methy l)-2-(JV-phenethy 1 -N -
methy isulfonamido) acetamide
97
(5)-A^-((6-(5-Cyclopropyl-\H-
MS: Calcd.: 531;
4-
pyrazol-3 -ylamino)-5-fluoro-2-
Found: [M+H]+ 532.
(dimethylamino)benz
(1 -(4-fluorophenyl)
oic acid
ethylamino)pyridin-3-
yl)methyl)-4-(dimethylamino)
henzamide
98
(5)-iV-((6-(5-Cyclopropyl-l//-
lH NMR (400 MHz,
benzenesulfonyl
pyrazoI-3-ylamino)-5-fluoro-2-
CD3OD) 8 7.90-7.88
chloride
(1 -(4-fluorophenyl)
(m, 2H), 7.65-7.55 (m,
ethylamino)pyridin-3-
3H), 7.44-7.41 (m, 2H),
yl)methyl)benzenesulfonamide
7.03-6.99 (m, 3H), 5.75 (brs, IH), 5.10-5.08 (m, IH), 3.88 (dd, J = 35.2, 14.2 Hz, 2I-I), 1.88-1.84 (m, IH), 1.55 (d, ./= 6.8 Hz, 3H), 0.95-0.93 (m, 2H), 0.67-0.64 (m, 2H). MS: Calcd.: 524; Found: [M+I-If 525.
101749
Ex.
Compound
NMR and/or LC/MS
TFP loaded resin
99
(5)-Ar-((6-(5-Cyclopropyl-l H-pyrazol-3 -ylamino)-5 -fluoro-2 -(1 -(4-fluorophenyl) ethylamino)pyridin-3-yl)methyl)
cy clopropanec arboxamide
MS: Calcd.: 452; Found: [M+H]+ 453.
cyclopropane carboxylic acid
100
(S)-iV-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1 -(4-fluorophenyl) ethylamino)pyridin-3 -yl)methyl)- li/-pyrrole-2-carboxamide
MS: Calcd.: 477; Found: [M+H]+ 478.
pyrrole-2-carboxylic acid
101
7V-((6-(5-Cyclopropyl-1H-pyrazo 1-3 -y I amino) - 5 - fl uo ro- 2 -((S)-1 -(4-fluorophenyl) ethylamino)pyridin-3 -yl)methyl)tetrahydrofuran-2-
WUi yVAL+llHUV
MS: Calcd.: 482; Found: [M+H]+483.
tetrahydrofuran-3 -carboxylic acid
102
(5)-7vr-((6-(5-Cyclopropyl-1H-pyrazol-3 -ylamino)- 5 -fl uoro-2-(1 -(4-fluorophenyl) ethylamino)pyridin-3-yl)methyl)furan-2-carboxamide
MS: Calcd.: 478; Found: [M+H]+ 479.
2-furoic acid
101749
Ex.
Compound
NMR and/or LC/MS
TFP loaded resin
103
(S)-jV-((6-(5-Cyclopropyl-li/-
'HNMR (400 MHz,
cyclopropylsulfonyl
pyrazol-3-yIamino)-5-fluoro-2-
CD3OD) § 7.41 (br s.
chloride
(1 -(4-fluorophenyl)
2H), 7.15 (brs, IH),
ethyl ami no)pyridin-3-
7.01-6.97 (m, 2H), 6.07
yl)methyl)
& 5.42 (s, IH), 5.17 &
cyclopropanesulfonamide
.03 (s, IH), 4.14 (brs,
2H), 2.58 (brs, IH),
1.88-1.84 (m, IH), 1.52
(d, J= 6.8 Hz, 3H),
1.10-0.92 (m, 6H), 0.66
(br s, 2H). MS: Calcd.:
488; Found: [M+FI]+
489.
Example 104
(■SV2-Amino-Af-((6-f5-cvclopropvl-l//-pvrazol-3-ylamino')-5-fluoro-2-f(>?>)-l-(4-fluorophenvl)ethvlamino)pyridin-3-vl)methyl)-3-methylbutanamide
^ A Prtlntirtn 1 ^ n r n /mm rl A ^ /n r/>1 v-\ i..-. r1 1 t7 ii i M'n I ^ w1\ C fl A T^"
u rs. ouiuuuti yj i \lj j--ytixxxxixvxi.A'^uiy x j~i \ Laujji i~ 111 ~\jy i a.t-.KJ i~-J - y 1 j -juluiu-j v -
(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.10 g, 0.26 mmol), (S)-2-(tert-butoxycarbonylamino)-3-methylbutanoic acid (0.06 g, 0.26 mmol), and HBTU (0.10 g, 0.26 mmol) in DCM (3 ml) was stirred at room temperature for 1 hour. The reaction was then quenched with a saturated aqueous solution of NaHCOs, and extracted with DCM (2x50 ml). 10 The combined organic fractions were dried over Ka?SOi, filtered, and then concentrated. The resulting oil was then passed through a silica plug. The resulting foam was placed in dioxane (4 ml) and 4 M HC1 in dioxane (1ml) was then added, and the reaction was stirred for 3 hours. The reaction was then concentrated to give a solid which was dissolved in a minimal amount of MeOH (0.5ml) with stirring, followed by fast addition of ether (50 ml). The resulting solid 15 was filtered, washed with ether, and dried to give the title compound (0.033 g, 26%). lH NMR (400 MHz, CD3OD) 8 7.58 (d, J= 10.7 Hz, IH), 7.49-7.46 (m, 2H), 7.07-7.02 (m, 2H), 5.80 (s, IH), 5.09-5.04 (m, IH). 4.58 (dd, J - 15.4, 6.8Hz, 1H),4.26 (dd, J= 15.4, 5.2 Hz, IH), 3.71 (d, 6.0 Hz, IH), 2.23-2.18 (m, IH), 2.01-1.97 (m, IH), 1.63 (d,J=6.8Hz, 3H), 1.19-1.13 (m, 2H), 1.05-1.03 (m, 6H), 0.85-0.81 (m, 2H). MS: Calcd.: 483; Found: [M+H]+484.
101749
Example 105
(£iT)-Ar2-f5-Cyclopropyl-l//-T3vrazol-3-viy5-ffcYclopropylimino)methvO-3-fluoro-J?V6-fl-f4-fIuorophenyl)ethvl)pyridine-2.6-diamine
To a solution of (5)-6-(5-cyclopropyl-l//-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-5 fluorophenyl)ethylamino)nicotinaldehyde (Example 73, 0.10 g, 0.26 mmol) in THF (5 ml) was added cyclopropanamine (0.03 g, 0.52 mmol) and NaBH(OAc)3 (0.55 g, 0.26 mmol). The reaction was stirred for 3 hours, quenched with aqueous Na2C03 (10 ml), and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na2S04, filtered, and then concentrated. The resulting oil was purified by reverse phase column chromatography (5-35% 10 ACN) to give the title compound (0.068 g, 62%). 'H NMR (400 MHz) 5 11.92 (s, IH), 9.62 (s, IH), 8.93 (s, IH), 8.35 (s, IH), 7.39 (d, ,/ = 7.4 Hz, IH), 7.31-7.27 (m, 2H), 7.16-7.11 (m, 2H), 6.10 (s, IH), 5.13-5.10 (m, IH), 2.96-2.94 (m, IH), 1.89-1.80 (m, IH), 1.42 (d,J = 6.9 Hz, 3H), 0.98-0.88 (m, 2H), 0.76-0.63 (m, 2H). MS: Calcd.: 422; Found: [M+H]+ 423.
Example 106
fS)-N2-f5-Cvclopropvl-lH-pyrazol-3-vl)-3-fluoro-N6-n-f4-fluorophenvDethvl)pyridine-2,6-diamine
A mixture of A^-(5-cyclopropyl-l//-pyrazol-3-yl)-3,6-difluoropyridin-2-amine (Method 31, 0.10 g, 0.42 mmol) and (5^-1 -(4-fluorophenyl)ethanamine (0.3 g, 2.2 mmol) 20 were heated to 185 °C under microwave conditions (30 min x 3 cycles). The resulting dark oil was purified by column chromatography (DCM-MeOH = 80 : 1) to give the title compound (0.04 g, 26%). 'H NMR (400 MHz, CD3OD) 5 7.08-6.99 (m, 3H), 6.67-6.62 (m, 2H), 6.22 (dd, J = 8.9,2.3 Hz,- IH), 5.04 (s, IH), 4.64-4.59 (m, IH), 1.16-1.12 (m, 4H), 0.30-0.14 (m, 3H), 0.04-0.02 (m, IH). MS: Calcd.: 355; Found: [M+H]+ 356.
Example 107
(jSVAr2-(5-CvciopropvI-lf/-pvrazol-3-yl)-3-fluoro-V5-n-f4-fluorophenyl)ethyl)-5-((methylamino)methvDpyridine-2,6-diamine
To a solution of (5)-6-(5-cyclopropyl-l//-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-30 fluorophenyl)ethylamino)nicotinaldehyde (Example 73, 0.10 g, 0.26 mmol) in THF (5 ml) was added methylamine (2.0 M in THF, 0.52 mmol) and NaBH(OAc)3 (0.82 g, 0.39 mmol). The reaction was stirred for 3 hours, quenched with water, and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na2S04, filtered, and then concentrated.
101749
The resulting crude imine was dissolved in MeOH (5 ml) and NaBH4 (0.06 g, 0.4 mmol) was added. The reaction was stirred for 10 min, quenched with aq. Na2C03 (10 ml), and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na2S04, filtered, and then concentrated. The resulting oil was purified by reverse phase column chromatography (5-5 35% ACN) to give the title compound (0.05 g, 48%). 'H NMR (400 MHz, CD3OD) 5 7.41 -7.38 (m, 2H), 7.10 (d,J = 9.2 Hz, IH), 7.02-6.98 (m, 2H), 6.00-5.52 (br s, IH), 5.05(s, IH), 3.63 (s, 2H), 2.37 (s, 3H), 1.87-1.82 (m, IH), 1.51 (d,J= 6.9 Hz, 3H), 0.93-0.91 (m, 2H), 0.67-0.63 (m, 2H). MS: Calcd.: 398; Found: [M+H]+ 399.
Example 108
fj?)-6-('5-Cvclopropvl-l//-pvrazol-3-ylamino)-5-fluoro-2-(l-('4-fluorophenvl)ethvlamino') nicotinonitrile
A solution of 2-chloro-6-(5-cyclopropyl-l/-/-pyrazol-3-ylamino)-5-fluoro nicotinonitrile (Method 1, 0.3 g, 1.0 mmol) and (i?)-l-(4-fhiorophenyl)ethanamine (0.3 g, 2.1 15 mmol) was added to w-BuOH (2 ml) and DIEA (0.18 g, 1.4 mmol) in a sealed tube. The reaction was heated to 140 °C for 48 hours, then cooled to room temperature and concentrated. The resulting residue was purified by column chromatography (DCM-MeOH = 80 : 1) to give the title compound (0.11 g, 26%). 'H NMR (400 MHz, CDC13) 5 8.44 (br s, IH), 7.37-7.33 (m, 2H), 7.27 (d, J= 9.6 Hz, IH), 7.07-7.03 (m, 2H), 6.11 (s, IH), 5.24-5.20 20 (m,2H), 1.87-1.83 (m, IH), 1.60 (d, J= 6.2 Hz, 3H), 1.01-0.98 (m, 2H), 0.79-0.65 (m, 2H). MS: Calcd.: 380; Found: [M+H]+ 381.
Example 109
fyi-yV-((6-(5-Cvclopropvl-l/:/-pyrazol-3-ylamino)-5-fluoro-2-(l-f4-fluorophenvl)ethvlamino) 25 pyridin-3 -yl)methyl)-l ,1.1 -trifluoromethanesulfonamide
To a solution of (iS)-3-(aminomethyl)-A^-(5-cyclopropyl-l//-pyrazol-3-yl)-5-fluoro-jV2-(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3, 0.10 g, 0.26 mmol) in THF (5 ml) at room temperature was added 1.1 equivalent of trifluoromethylsulfonyl chloride loaded TFP resin, and DMAP (0.031 g, 0.26 mmol). The reaction was then stirred at room 30 temperature for 15 hours and filtered. The remaining resin was then washed with THF (2x10 ml for 20 min), and then combined organic fractions were concentrated. The resulting oil was purified by reverse-phase column chromatography (5-50%) ACN) to give the title compound (0.02 g, 15%). 'HNMR (400 MFIz, CD3OD) 5 7.40-7.37 (m, 2H), 7.17 (d, ./ = 10.9 Hz, IH),
101749
7.02-6.97 (m, 2H), 5.90-5.60 (br s, IH), 5.14-5.12 (m, IH), 4.28-4.25 (m, 2H), 1.88-1.84 (m, IH), 1.54 (d,J = 7.0 Hz, 3H), 0.95-0.93 (m, 2H), 0.67-0.64 (m, 2H). MS: Calcd.: 516; Found: [M+H]+ 517.
Example 110
f5r)-6-(5-Cvclopropyl-l//-pyrazol-3-vlamino)-5-fluoro-2-('l-(5-fluoropvridin-2-vl')ethvlamino') nicotinonitrile
A suspension of 6-(5-cyclopropyl-l//-pyrazol-3-yIamino)-2,5-difluoronicotinonitrile (Method 32, 5.75 g, 22.0 mmol), in m-BuOH (28.75 ml) was prepared at room temperature in 10 a 48 ml sealed tube. DIEA (4.98 ml, 28.6 mmol) was then added, followed by the addition of (5)-l-(5-fluoropyridin-2-yi)ethanamine (Method 33; 4.0 g, 28.6 mmol). The tube was then sealed, and the suspension was heated to 130 °C over 45 minutes. The reaction was then allowed to stir at 130 °C for 18 hours. The reaction was then cooled to room temperature and concentrated by rotary evaporation at 60 °C to remove «-BuOH. The remaining oil was then 15 taken up in DCM (100 ml) and washed with water (2 x 100 ml). The combined aqueous fractions were then extracted with DCM (100 ml), and the combined organic fractions were dried over NajSO^ filtered and concentrated. The resulting oil was then purified by column chromatography (DCM, then DCM-MeOFI = 100 : 1) to give the title compound (5.2 g, 62%). ]H NMR (400 MHz, CD3OD) 5 8.43 (d, J= 2.5 Hz, IH), 7.60-7.34 (m, 3H), 6.09-5.63 (m, 20 IH), 5.24 (q, /= 7.0 Hz, IH), 1.91 (septet, IH), 1.58 (d, 6.6 Hz, 3H), 1.08-0.90 (m, 2H), 0.79-0.70 (m, 2H). MS: Calcd.: 381; Found: [M+H]+ 382.
Example 111
-CvcIopropyl-1 //-pyrazol-3-yl)-3 -fluoro-A^-C 1 -(4-fluorophenyl )ethyl)-5 -25 isopropylpyridine-2,6-diamine
To a solution of (&)-6-(5-cyclopropyl-l//-pyrazol-3-ylamino)-5-fluoro-2-(i-(4-fluorophenyl)ethylamino)nicotinaldehyde (Example 73, 0.15 g, 0.39 mmol) in THF (6 ml) at 0 °C was added methyl magnesiumbromide (1.4 M THF, 0.50 mmol). The reaction was then stirred for 4 hours at room temperature, quenched with water, and extracted with DCM (2 x 30 20 ml). The combined organic fractions were dried over Na2SC>4, filtered, and then concentrated. The resulting oil was purified by reverse phase column chromatography (5-50% ACN) to give the title compound (0.10 g, 64%). !HNMR (400 MFIz, CD3OD) 5 7.40-7.37 (m, 2H), 7.12 (d, J~ 11.9 Hz, IH), 7.02-6.97 (m, 2H), 5.70 (s, IH), 5.17-5.12 (m, IH), 2.99-
101749
2.96 (m, IH), 1.87-1.82(m, IH), 1.54 (d,J= 7.0 Hz, 3H), 1.23-1.21 (m, 6H), 0.94-0.90 (m, 2I-I), 0.66-0.63 (m, 2H). MS: Calcd.: 397; Found: [M+H]+ 398.
Example 112
fiSy6-f5-Cyclopropyl-l//-pyra2ol-3-vlamino)-5-fluoro-2-n-(4-fluorophenyl)ethylamino)-4-(isopropylamino)nicotinonitrile
To a solution of (S)-6-(5-cyclopropyl-l//-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluorophenyl)ethyIamino)-4-iodonicotinonitriIe (Example 134, 0.07 g, 0.14 mmol) and DIEA (0.023 g, 0.18 mol) in «-BuOH (1.5 ml) was added isopropylamine (0.16 g, 2.7 mmol). The 10 reaction was then heated to 185 °C under microwave conditions (1 hour x 4 cycles). The reaction was then cooled to room temperature, DCM (10 ml) was added, and washed with 10% aqueous Na2S203. The organic layer was then dried over Na2SC>4, filtered, and then concentrated. The resulting oil was purified by reverse-phase column chromatography (5-50% ACN) to give the title compound (0.031 g, 51%). ]H NMR (400 MHz, CD3OD) 8 7.36-7.33 15 (m,2H), 7.04-7.00 (m, 2H), 5.99-5.59 (brs, IH), 5.14 (s, IH), 4.29-4.23 (m, IH), 1.87-1.83 (m, 1H), 1.52 (d, J= 7.0 Hz, 3H), 1.25 (d, J= 6.2 Hz, 6H), 0.95-0.94 (m, 2H), 0.65-0.63 (m, 2H), MS: Calcd.: 437; Found: [M+H]+ 438.
Example 113
CSV 6-('5-Cvclopropyl-1 i7-pyrazol-3-vlamino)-5-fluoro-2-( 1 -(4-fiuorophenvl)ethylamino )-4-fmethylamino)nicotinonitrile
To a solution of (5)-6-(5-cyclopropyl-l//-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluorophenyl)ethylamino)-4-iodonicotinonitrile (Example 134. 0.10 g, 0.19 mmol) and DIEA (0.03 g, 0.25 mol) in 77-BuOH (1.5 ml) was added methylamine (2.0 M in THF, 1.9 mmol). 25 The reaction was then heated to 185 °C under microwave conditions (1 hour x 2 cycles). The reaction was then cooled to room temperature, DCM (10 ml) was added, and washed with 10% aqueous Na2S203. The organic layer was then dried over Na2S04, filtered, and then concentrated. The resulting oil was purified by reverse-phase column chromatography (5-50% ACN) to give the title compound (0.04 g, 49%). 'H NMR (400 MHz, CD3OD) 5 7.35 (br s, 30 2H), 7.04-7.00 (m, 2H); 5.95 (brs, IH), 5.14 (brs, IH), 3.15 (d, J= 2.7 Hz, 3H), 1.87-1.82 (m, 1H), 1.52 (d, J = 6.8 Hz, 3H), 0.95-0.94 (m, 2H), 0.65-0.63 (m, 2H). MS: Calcd.: 409; Found: [M+H]+ 410.
101749
Example 114
(5>5-Fhioro-2-n-f4-fluorophenvI)ethvlamino)-6-(5-methyl-l.Z7-pvrazol-3-ylamino) nicotinonitrile
A suspension of 2,5-difhioro-6-(5-methyI-l/f-pyrazol-3-ylamino)nicotinonitrile 5 (Method 41, 0.20 g, 0.85 mmol). DIEA (0.14 g, 1.1 mmol), and (5)-1-(4-fluorophenyl) ethanamine (0.23 g, 1.7 mmol) in rc-BuOH (2 ml) was heated to 130 °C for 18 hours. The reaction was then cooled to room temperature, diluted with water (20 ml), and extracted with DCM (2 x 50 ml). The combined organic fractions were dried oyer Na2SC>4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 10 : 1) to give the title compound (0.27 g, 91%). ]H NMR (400 MHz, CD3OD) 5 7.38-7.32 (m, 3H), 7.03-6.99 (m, 2H), 5.99 (br s, IH), 5.15-5.14 (m, IH), 2.24 (s, 3H), 1.53 (d, ./= 6.8 Hz, 3H). MS: Calcd.: 354; Found: [M+H]+ 355.
Example 115
f^-5-Fluoro-2-U-f5-fluoropyridin-2-vl)ethylamino)-6-(5-methyl-li:/-pvrazol-3-vlamino) nicotinonitrile
A suspension of 2,5-difluoro-6-(5-methyl-l//-pyrazol-3-ylamino)nicotinonitrile (Method 41, 0.24 g, 1.02 mmol), DIEA (0.17 g, 1.3 mmol), and (S)-l-(5-fluoropyridin-2-yl)ethanamine (Method 33, 0.21 g, 1.5 mmol) in «-BuOH (2 ml) was heated to 130 °C for 18 20 hours. The reaction was cooled to room temperature, diluted with water (20ml), and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na2S04, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.20 g, 55%). ]H NMR (400 MHz, CD3OD) 5 8.42 (s, IH), 7.51-7.38 (m, 3FI), 6.01 (s, IH), 5.21-5.19 (m, IH), 2.27 (s, 3H), 1.58 (d, J= 6.7 Hz, 25 3H). MS: Calcd.: 355; Found: [M+H]+ 356.
Example 116
(y)-6-(5-Cvclopropvl-l//-pvrazol-3-vlamino)-5-fluoro-2-(l-f5-fluoropvridin-2-vl)ethylamino) nicotinamide
A solution of (S)-6-(5-cyclopropyl-l//-pyrazol-3-ylamino)-5-fluoro-2-(l-(5-
fluoropyridin-2-yl)ethylamino)nicotinonitrile (Example 110, 0.24 g, 0.62 mmol) in MeOH (20 ml) was prepared at room temperature. An aqueous solution (0.7 ml) of KOH (0.17 g, 3.15 mmol) was then added dropwise, followed by the addition of 0.05 ml of 30%) H2O2. The
101749
reaction was then heated to 65 °C for 3 hours, cooled to room temperature, and concentrated. The resulting residue was dissolved in EtOAc (50 ml), and washed with water (50 ml). The organic fraction was then dried over Na2S04, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 30 : 1) to give the title compound 5 (0.13 g, 52%). 'H NMR (400 MHz, CD3OD) 8 8.42 (s, IH), 7.70 (d, J= 12.1 Hz, IH), 7.48-7.38 (m,2H), 6.02 (s, IH), 5.25-5.02 (m, IH), 1.91-1.86 (m, IH), 1.57 (d, J= 7.0 Hz, 3H), 0.97 (br s, 2H), 0.73 (br s, 2H). MS: Calcd.: 399; Found: [M+H]+ 400.
Example 117
(1S>A^(6-(5-Cvclopropyl-li7-pyrazol-3-ylamino)-5-fluoro-2-ffff)-l-(4-fluorophenvO ethyIamino)pyridin-3-yl)methyl)-5-oxopyrrolidine-2-carboxamide
To a DCM (10ml) solution of (6)-3-(aminomethyl)-A^-(5-cyclopropyl-l//-pyrazol-3-yl)-5-fluoro-iV2-(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3, 0.45 g, 1.17 mmol) and HBTU (0.44 g, 1.17 mmol) cooled at 0 °C was added a solution of (S)-5-15 oxopyrrolidine-2-carboxylic acid (0.15 g, 1.17 mmol) in DMF (5 ml), followed by the addition of DIEA (0.14 g, 1.17 mmol). The reaction was then stirred at room temperature for 1 hour and quenched with 20 ml of aqueous NaHC03, and extracted with DCM (2 x 30 ml). The combined organic fractions were dried over NaiSO,], filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 20 : 1) to give the title 20 compound (0.30 g, 51%). 'HNMR (400 MHz, CD3OD) 8 7.35-7.32 (m, 2H), 7.10 (d, J= 10.9 Hz, IH), 7.00-6.96 (m, 2H), 5.80-5.65 (br s, IH), 5.06-5.05 (m, IH), 4.30-4.15 (m, 3H), 2.45-2.24 (m, 3H), 2.05-2.00 (m, IH), 1.85-1.80 (m, IH), 1.48 (d,.7=6.8 Hz, 3H), 0.91-0.89 (m, ■ 2H), 0.63-0.62 (m, 2H). MS: Calcd.: 495; Found: [M+FI]+ 496.
Example 118
(7?)-iV-((6-(5-CvcIopropvl-l//-pyrazol-3-ylamino)-5-fluoro-2-f(S)-l-(4-fluorophenyl) ethvlamino)pyridin-3-yl)methvl)-5-oxopyn'olidine-2-carboxamide
To a DCM (10 ml) solution of (5}-3-(aminomethyI)-A/6-(5-cyclopropyl-17/-pyrazol-3-yl)-5-fluoro-/V -(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.45 g, 1.17 30 mmol) and HBTU (0.44 g, 1.1 7mmol) cooled at 0 °C was added a solution of (R)-5-oxopyrrolidine-2-carboxyIic acid (0.15 g, 1.17 mmol) in DMF (5 ml), followed by the addition of DIEA (0.14 g, 1.17 mmol). The reaction was then stirred at room temperature for 1 hour and quenched with 20 ml aqueous NaHC03, and extracted with DCM (2 x 30 ml). The
101749
combined organic fractions were dried over Na2SC>4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 20 : 1) to give the title compound (0.25 g, 43%). 'H NMR (400 MHz, CD3OD) 5 7.37-7.34 (m, 2H), 7.14 (d, J= 10.9 Hz, IH), 7.02-6.97 (m, 2H), 5.80-5.65 (br s, IH), 5.07 (brs, IH), 4.33-4.16 (m, 3H), 2.46-5 2.22 (m,3H), 2.05-1.98 (m, IH), 1.88-1.81 (m, IH), 1.51 (d, J= 6.8 Hz, 3H), 0.93-0.92 (m, 2H), 0.66-0.62 (m, 2H). MS: Calcd.: 495; Found: [M+H]+496.
Example 119
(iSV5-Fluoro-2-(l-(5-fluoropvridin-2-vl)ethvlamino)-6-(5-isopropoxy-lZ/-pyrazol-3-ylamino) 10 nicotinonitrile
A solution of 2,5-difluoro-6-(5-isopropoxy-l/f-pyrazol-3-ylamino)nicotinonitrile (Method 42, 0.30 g, 1.07 mmol), DIEA (0.16 g, 1.29 mmol), and (5)-l-(5-fluoropyridin-2-yl)ethanamine (Method 33; 0.22 g, 1.6 mmol) in «-BuOH (3 ml) was heated to 130 °C for 18 hours. The reaction was then cooled to room temperature, diluted with water (20 ml), and 15 extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na2S04, filtered, and then concentrated. The resulting oil was purified by column chromatography (hexanes-EtOAc = 3 : 1) to give the title compound (0.25 g, 58%). JH NMR (400 MHz, CD3OD) 5 8.40 (s, IH), 7.56-7.55 (m, 2H), 7.45 (d, J= 10.5 Hz, IH), 5.42 (s, IH), 5.25-5.22 (m, IH), 4.63 (br s, IH), 1.60 (d, .7 =7.0 Hz, 3H), 1.34 (d,J= 6.1 Hz, 6H). MS: Calcd.: 399; 20 Found: [M+H]+ 400.
Example 120
6-[(5-Cvclopropyl-l/-/-pvrazol-3-yl)amino1-2-{r(iy)-l-(3,5-difluoropvridin-2-y 1 )ethyl ] amino ) -5 -fl uor onicotinonitril e 25 Following a similar procedure to the synthesis of Example 1, the title compound was synthesized from 6-[(5-cyclopropyl-l//-pyrazol-3-yl)amino]-2,5-difluoronicotinonitrile (Method 32) and (S)-l-(3,5-difluoropyridin-2-yl)ethanamine (Method 50). 'H NMR (400 MHz) 8 0.68 (m, 2 H), 0.95 (m, 2 H), 1.45 (d, J = 6 Hz, 3 H), 1.87 (m, 1 H), 5.48 (m, 1 H), 6.19 (s, 1 H), 6.69 (m, 1 H), 7.63 (d, 1 H), 7.98 (m, 1 H), 8.51 (s, 1 H), 9.58 (s, 1 H), 12.15 (s, 30 1 H). MS: Calcd.: 399; Found: [M+H]+ 400.
101749
Example 121
/Sr)-5-Chloro-6-(5-cvclopropvi-l//-pyrazol-3-ylamino)-2-(T-(5-fluoropvrimidin-2-vOethylamino)nicotinonitrile
A mixture of 2,5-dichloro-6-(5-cyclopropyl-l/7-pyrazol-3-ylamino)nicotinonitrile 5 (Method 43, 0.17 g, 0.58 mmol), (S)-l-(5-fluoropyrimidin-2-yl)ethanamine HCl salt (Method 55, 0.186 g, 0.87 mmol), and DIEA (0.60 ml, 3.5 mmol) in «-BuOH (3 ml) was heated in a sealed tube at 130 °C for 44 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane-EtOAc =1 : 1) to give the title compound as a white solid (0.095 g, 41%). 'H NMR (400 MHz) 5 12.16 (s, IH), 8.88 (s, 2H), 10 8.52 (s, IH), 7.84 (s, 1H),7.05 (d, .7=7.2 Hz, IH), 5.98 (s, IH), 5.28 (m, IH), 1.84 (m, IH), 1.57 (d, 7 =7.2 Hz, 3H), 0.96 (m, 2H), 0.71 (m, 2H). MS: Calcd.: 398; Found: [M+H]+ 399.
Example 122
Ar-(5-rfli?)-l-f(3-Cyano-6-r(5-cyclopropyl-17/-pyrazol-3-yl)aminol-5-fluoropyridin-2-15 vl}amino)ethyl1-2-fluorophenyi}methanesulfonamide and Example 123
jV-{5-[(15f)-l-({3-Cyano-6-r(5-cyclopropyl-lj1/-pyrazol-3-yl)amino'l-5-fluoropvridin-2-yUamino)ethvIl-2-fluorophenyllmethanesulfonamide
To a 10-ml microwave vessel was added, 2-chloro-6-[(5-cyclopropyl-l//-pyrazoI-3-20 yl)amino]-5-fluoronicotinonitrile (Method 1, 600 mg, 2.3 mmol), A^5-(l-aminoethyl)-2-fluorophenyljmethanesulfonamide (Method 61, 500 mg, 2.3 mmol), DIEA (0.5 ml, 2.76 mmol), and n-butanol (5 ml). The vessel was sealed and subjected to microwave heating at 150 °C for 5 hours (CEM Discover System). The resulting mixture was then purified by silica gel chromatography using 5% MeOFI/DCM, The racemic product obtained was then chirally 25 purified by HPLC on Chiralcel OJ column (500 x 50mm, 20 microns) using 50:25:25:0.1 % of hexane/MeOH/EtOH/diethylamine at 118 ml/min. The chiral purification gave 220 mg of N-{5-[(lJ?)-I-({3-cyano-6-[(5-cyclopropyl-l//-pyrazol-3-yl)amino]-5-fluoropyridin-2-yl}amino)ethyl]-2-fluorophenyl}methanesulfonamide 'H NMR: 5 11.77 - 12.26 (br s, IH), 9.51 (s, IH), 9.34 - 9.48 (brs, IH), 7.62 (d, 0.55 Hz, IH), 7.39 (d, J-8.29 Hz, 1H),7.02-30 7.23 (m, 3H), 6.00 (s, IH), 5.07 - 5.24 (m, IH), 2.95 (s, 3H), 1.81 - 1.95 (m, IH), 1.49 (d, J= 7.54 Hz, 3H), 0.88 - 0.97 (m, 2H), 0.57 - 0.68 (m, 2H). MS: Calcd.: 473; Found: [M+H]+ 474 and 223 mg of yV-{5-[(15)-l-({3-cyano-6-[(5-cyclopropyl-l//-pyrazoI-3-yl)amino]-5-fluoropyridin-2-yl}amiiio)ethyl]-2-f!uorophenyl}methanesulfonamidel; 'HNMR: 11.73 -
101749
12.38 (brs, 1H),9.42 (s, IH), 8.41 -9.12 (brs, IH), 7.61 (d, J=1 1.30 Hz, IH), 7.37 (d, J=7.54 Hz, IH), 6.96 - 7.24 (m, 3H), 6.02 (s, IH), 5.05 - 5.26 (m, IH), 2.90 (s, 3H), 1.79 - 1.96 (m, IH), 1.49 (d,.7=6.78 Hz, 3H), 0.89 - 0.98 (m, 2H), 0.59 - 0.67 (m, 2H). MS: Calcd.: 473; Found: [M+H]+ 474.
Example 124
-Chloro-2-U(l.SVl-(5-fluoropvridin-2-vDethvnamino}-6-r(5-methvl-l//-t)vrazol-3-
yl)amino"|nicotinonitrile
To a 10-ml microwave vessel was added, 2,5-dichloro-6-[(5-methyl-l//-pyrazol-3-10 yl)amino]nicotinonitrile (Method 60, 8 mmol), [(l<S)-l-(5-fluoropyridin-2-yI)ethyl]amine (Method 33, 8 mmol, 97wt% solution in dioxane), DIEA (0.3 ml, 1.66 mmol), and n-butanol (4 ml). The vessel was then sealed and subjected to microwave heating at 150 °C for 3 hours. After 3 hours, more 2-pyridyl amine (100 mg, 0.69 mmol) was added. The resulting mixture was purified by silica gel chromatography (Biotage Horizon System) using an isocratic 15 system of 15:0.5:0.5% of DCM/EtOAc/MeOH to give 312 mg of the title compound. :H NMR: 12.04 (br s, IH), 8.41 - 8.63 (m, 2H), 7.84 (s, IH), 7.56 - 7.71 (m, IH), 7.40 (dd, .7=8.67,4.14 Hz, IH), 7.28 (s, IH), 5.86 (s, IH), 5.06 - 5.25 (m, lH),2.17(s, 3H), 1.51 (d, 7=7.54 Hz, 3H). MS: Caicd.: 371/373; Found: [M+H]+ 372/374.
Example 125
AL(5-ri-('l3-Cvano-6-f(5-cvciopropvl-I7/-pvrazol-3-vI)ammo1-5-fluoropvridin-2-yl) amino)ethyll -2 -fluorophenyl I acetami de
To a 10-ml microwave reaction vessel was added, 6-[(5-cyclopropyl-lT/-pyrazol-3-yl)amino]-2,5-difluoronicotinonitrile (Method 32, 300 mg, 1.13 mmol), A/-[5-(l-aminoethyl)-25 2-fluorophenyl]acetamide (Method 66, 331 mg, 1.7 mmol), and DIEA (0.8 ml, 4.6 mmol) in n-butanol (4 ml). The resulting suspension was set to microwave heating (CEM Discover System) at 150 °C for 3 hours. The reaction was concentrated in vacuo and purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 25-35% EtOAc (20% v/v MeOH) in hexanes to give 180 mg (36% isolated yield) of the title compound. *H 30 NMR: 9.66 (br s, 1 H) 9.43 (s, 1 H) 7.81 (d, J=6.03 Hz, 2 H) 7.60 (d, J=11.30 Hz, 1 H) 6.92 -7.21 (m, 3 H) 5.98 (s, 1 H) 5.13 (t, 7=7.16 Hz, 1 H) 2.05 (s, 3 H) 1.76 - 1.92 (m, 1 FI) 1.46 (d, .7=6.78 Hz, 3 H) 0.82 - 0.95 (m, 7=8.29 Hz, 2 H) 0.54 - 0.66 (m, 2 H). MS: Calcd.: 437;
Found: [M+H]+438.
101749
Example 126
AM5-ri-({3-Cvano-6-r(5-cvclopropvl-l//-pvrazol-3-vl)amino1-5-fluoropyridin-2-yl} amino)ethyl"l-2-fluorophenyl} cyclopropanecarboxamide
To a 10-ml microwave reaction vessel was added 6-[(5-cyclopropyl-l//-pyrazol-3-5 yl)amino]-2,5-difluoronicotinonitrile (Method 32, 431 mg, 1.65 mmol), A^-[5-(l-aminoethyl)-2-fluorophenyl]cyclopropanecarboxamide (Method 69, 550 mg, 2.5 mmol), and DIEA (1.15 ml, 6.6 mmol) in n-butanol (5 ml). The resulting suspension was set to microwave heating (CEM Discover System) at 150 °C for 3 hours. The reaction was concentrated in vacuo and purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 10 25-35% EtOAc (20% v/v MeOH) in hexanes to give 267 mg (35% isolated yield) of the title compound. 'HNMR: 11.99 (s, 1 H) 9.91 (s, 1 H) 9.42 (s, 1 H) 7.88 (d, .7=6.03 Hz, 1 H) 7.59 (d, .7=10.55 Hz, 1 H) 6.95 - 7.20 (m, 3 H) 5.99 (s, 1 H) 5.02 - 5.21 (m, 1 H) 1.89 - 2.03 (m, 1 H) 1.76 - 1.89 (m, 1 H) 1.45 (d, J=7.54 Hz, 3 H) 0.87 (t, J=8.67 1-Iz, 2 H) 0.75 (d, .7=6.03 Hz, 4 H) 0.54 - 0.66 (m, 2 H). MS: Calcd.: 463; Found: [M+H]+ 464.
Example 127
6- rf5-Cyclopropyi- l//-pvrazol-3-yDaminol-5-fluoro-2- ((Y15")-! -(6-fluoropvridin-3 -yQethvll amino I nicotinonitrile and Example 128
6-rf5-Cvclopropyl-l//-pyrazol-3-yl)amino"|-5-fluoro-2-(r(l^)-l-f6-fluoropvridin-3-vDethyll amino} nicotinonitrile
To a 10-ml microwave reaction vessel was added 6-[(5-cyclopropyl-17/-pyrazol-3-yI)amino]-2,5-difluoronicotinonitrile (Method 32, 1 g, 4 mmol), l-(6-fluoropyridin-3-yl)ethanamine (Method 76, 560 mg, 4 mmol), and DIEA (0.84, 4.8 mmol) in n-butanol (5 ml). 25 The resulting suspension was set to microwave heating (CEM Discover System) at 150 °C for 3 hours. The reaction was then concentrated in vacuo and purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 1-4% MeOH in DCM to give 380 mg (25% isolated yield) of 6-[(5-cyclopropyI-l//-pyrazol-3-yl)amino]-5-fluoro-2-{[l-(6-fluoropyridin-3-yl)ethyI]amino}nicotinonitrile. The racemic product obtained was then 30 chirally purified by HPLC on Chiralpak AS column (500 x 50mm, 20 microns) using
80:10:10:0.1% of hexane-MeOH-EtOFI-diethylamine at 118 ml/min. The chiral purification gave 145 mg of 6-[(5-cyclopropyl-17/-pyrazol-3-yl)amino]-5-f]uoro-2-{[(lS)-l-(6-fluoropyridin-3-yl)ethyl]amino}nicotinonitriIe: 'H NMR: 9.43 (s, 1 FI) 8.08 (s, 1 H) 7.84 -
101749
8.00 (m, 1 H) 7.61 (d, J=\ 1.30 Hz, 1 H) 7.18 (d, .7=7.54 Hz, 1 H) 7.04 - 7.13 (m, 1 H) 5.94 (s,
1 H) 5.15 (t, 7=7.54 Hz, I H) 1.81 - 1.97 (m, 1 H) 1.51 (d,7=7.54 Hz, 3 H) 0.92 (d,7=6.03 Hz, 2 H) 0.64 (s, 2 H). MS: Calcd.: 381; Found: [M+H]+ 382; and 137 mg of 6-[(5-cyclopropyl-l//-pyrazol-3-yl)amino]-5-fluoro-2-{[(li?)-l-(6-fluoropyridin-3-
yl)ethyl]amino}nicotinonitrile: lH NMR: 9.42 (s, 1 H) 8.08 (s, 1 H) 7.93 (t, ,7=8.29 Hz, 1 H) 7.61 (d, .7=10.55 Hz, 1 H) 7.18 (d, .7=8.29 Hz, 1 H) 7.08 (dd, ,7=8.29, 3.01 Hz, 1 H) 5.94 (s, 1 H) 5.15 (t, ,7=7.54 Hz, 1 H) 1.81 - 1.96 (m, 1 H) 1.51 (d, .7=7.54 Hz, 3 FI) 0.91 (d, 7=8.29 Hz,
2 H) 0.64 (s, 2 H). MS: Calcd.: 381; Found: [M+H]+ 382.
Example 129
-Fhioro-2-{ n-(5-fiuoropvrimidin-2-yl)ethvf| amino}-6-[Y5-methyl-17/-pyrazol-3-vDaminol nicotinonitrile
A mixture of l-(5-f!uoropyrimidin-2-yl)ethanamine (Method 72, 0.05 g, 0.35mmol), 2,5-difluoro-6-[(5-methyl-I7/-pyrazol-3-yl)amino]nicotinonitrile (Method 41, 0.06 g, 0.25 15 mmol), and DIEA (0.12 ml, 0.7 mmol) in w-BuOH (3 ml) was charged into a microwave reaction vessel The vessel was sealed and heated in microwave reactor at 160 °C for 6 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography (DCM - EtOAc = 1 : 1) to give the title compound as a yellow solid (0.016 g, 15%). LC-MS, 357 (M+l). 'i-l NMR (400 MHz, MeOD) 5 8.70 (s, 2H), 7.45 (d, IH), 6.40 (br, 20 IH), 5.45 (q IH), 2.35 (s, 3H), 1.65 (d, 3H).
Example 130
-Chloro-2-(n-(5-fluoropvrimidin-2-yl)ethvl1amino}-6-r(5-methvl-17/'-pvrazol-3-yDamino]nicotinonitrile
A mixture of l-(5-fluoropyrimidin-2-yI)ethanamine (Method 72, 0.05 g, 0.35 mmol),
2,5-dichloro-6-[(5-methyM/7-pyrazol-3-yl)amino]nicotinonitriIe (Method 60, 0.06 g, 0.25 mmol), and DIEA (0.12 ml, 0.7 mmol) in «-BuOH (10 ml) was charged into a microwave reaction vessel. The vessel was sealed and heated in microwave reactor at 160 °C for 6 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel 30 chromatography (DCM - EtOAc = 1 : 1) to give the title compound as a yellow solid (0.017 g, 15%). LC-MS, 373 (M+l). lH NMR (400 MHz, MeOD) 8 8.75 (s, 2H), 7.45 (s, 1FI), 6.40 (s, IH), 5.45 (br 1FI), 2.35 (s, 3H), 1.60 (d, 3H).
101749
Example 131
AL{5-rn5yi-f(3-Cvano-5-fluoro-6-[Y5-methyl-l//-pyrazol-3-yI)amino1pyridin-2-vl}amino)ethyl~[-2-fluorophenyIlmethanesulfonamide and Example 132
AL{5-rni?)-l-f{3-Cvano-5-fluoro-6-[f5-methvI-l//-pvrazol-3-yDamino1pyridin-2-yl)amino')ethyl1-2-fluorophenvl}methanesuifonamide
A mixture of A''-f 5 -(1 -aminocthyl)-2-fluorophcnyl |rnethanesul fbnamide (Method 61, 0.2 g, 0.86 mmol), 2,5-difluoro-6-[(5-methyl-l/-/-pyrazol-3-yl)amino]nicotinonitrile (Method 41, 0.2 g, 0.8 mmol), and DIEA (0.3 ml, 2.1 mmol) in «-BuOH (4 ml) was charged into a 10 microwave reaction vessel. The vessel was sealed and heated in microwave reactor at 160 °C for 6 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography (DCM - EtOAc =1 : 1) to give the title compound as a yellow solid (0.16 g, 35%). The resulting racemic compound was separated by a Chiralpak AS-H SFC HPLC column (25 % MeOH) to two enantiomers (The retention time of the first elute 15 Example 131 (S-isomer) was 7 min, and the retention time of the second elute Example 132 (R-isomer) was 8.5 min). LC-MS, 448 (M+l). fH NMR (400 MHz, MeOD) 8 7.45 (d, 1H), 7.40 (d, IH), 7.20 (s, IH), 7.10 (t, IH), 6.00 (s, IH), 5.20 (br IH), 2.90 (s, 3H), 2.20 (s, 3H), 1.60 (d,3H).
Example 133
-Fluoro-2-1 [ 1 -f 5-fluoropvrimidin-2-vDethyl]aminol -6- IY5-isopropoxy-1 //-pyrazol-3-yDaminolnicotinonitrile
A mixture of l-(5-fluoropyrimidin-2-yl)ethanamine (Method 72, 0.05 g, 0.35mmol), 2,5-difluoro-6-[(5-methyl-l//-pyrazol-3-yl)amino]nicotinonitrile (Method 41, 0.05 g, 0.25 25 mmol), and DIEA (0.12 ml, 0.7 mmol) in «-BuOH (4 ml) was charged into a microwave reaction vessel. The vessel was sealed and heated in microwave reactor at 160 °C for 6 hrs. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography (DCM - EtOAc =1 : 1) to give the title compound as a yellow solid (0.006 g, 5%). LC-MS, 401 (M+l). 'H NMR (400 MHz, MeOD) 5 8.70 (s, 2H), 7.50 (d, IH), 5.50 (s, 30 IH), 5.45 (br, 1H), 4.60 (in, IH), 1.60 (d, 3H), 1.25 (d, 6H).
101749
Example 134
(■SV6-(5-Cyclopropvl-l./y-pvrazol-3-Ylamino)-5-fluoro-2-(l-(4-fIuorophenvI)ethYlamino)-4-iodonicotinonitrile
A solution of 2-chloro-6-(5-cyclopropyM#-pyrazol-3-ylamino)-5-fIuoro-4-5 iodonicotinonitrile (Method 39, 0.28 g, 0.69 mmol), (S)-l-(4-fluorophenyl)ethanamine (0.19 g, 1.3 mmol), and DIEA (0.11 g, 0.90 mmol) in /7-BuOH (1 ml) was heated to 140 °C for 18 hours. The reaction was diluted with water (10 ml), extracted with DCM (2 x 20 ml) and the combined organic fractions were dried over Na2S04, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title 10 compound (0.07 g, 20%). MS: Calcd.: 506; Found: [M+H]+ 507.
Preparation of starting materials
Method 1
2-Chloro-6-(5-cyclopropyl-l/7-pvrazol-3-vlaminoV5-fluoronicotinonitrile
A solution of 5-cyclopropyl-l#-pyrazol-3-amine (1.9g, 16.0 mmol) in CH3CN (20 ml) was added dropwise to a solution of 2,6-dichIoro-5-fluoronicotinonitrile (3.0g, 16.0 mmol) and triethylamine (2.1g, 20.0 mmol) in CH3CN (80 ml) at 25 °C. The resulting solution was then heated to 82 °C for 18 hrs, and then cooled to 25 °C, at which point the product 20 precipitated from solution. The resulting solid was filtered, and washed with CH3CN (100 ml) to give the title compound (3.2g, 73%). MS: Calcd.: 277; Found: [M+H]+ 278.
Method 2
2-Chloro-5-fluoro-6-(5-isopropoxy-l//-pyrazol-3-ylamino)nicotinonitrile 25 A solution of 5-isopropoxy-17/-pyrazol-3-amine (0.96g, 6.8 mmol), 2,6-dichloro-5-
fluoronicotinonitrile (1.3g, 6.8 mmol), and triethylamine (0.9g, 8.8 mmol) in THF (30 ml) was heated to 60 °C for 4 days, and then cooled to 25 °C, at which point the product precipitated. The resulting solid was filtered and washed with hexanes (100 ml) to give the title compound (1.0g, 50%). MS: Calcd.: 295; Found: [M+H]+ 296.
101749
Method 3
3.5.6-Trichloro-Af-C5-cycIopropyl-l//-pyrazol-3-yi)pyridin-2-amine
A solution of 2,3,5,6-tetrachloropyridine (0.20g, 0.9 mmol), 5-cyclopropyl-li/-pyrazol-3-amine (0.20g, 1.8 mmol), and triethylamine (0.1 Og, 1.4 mmol) inNMP (2 ml) was heated in a microwave at 200 °C for 30 min. The reaction was cooled to 25 °C, quenched with water (10 ml), and extracted with MTBE (4 x 30 ml). The combined organic fractions were then dried, filtered, and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 50 : 1) to give the title compound (0.035g, 12%). MS: Calcd.: 303; Found: [M+H]+ 303.
Method 4
(2-Chloro-pyridin-4-yl)-(5-cvclopropyl-li/-pvrazoIe-3-yl)-amine
A mixture of 4-iodo-2-chloropyridine (0.26 g, 1.1 mmol), 3-amino-5-cyclopropy 1-pyrazole-1 -carboxylic acid tert-butyl ester (0.20 g, 0.89 mmol), Pd2dba3 (0.016 g, 2 mol%), 15 Xantphos (0.031 g, 6 mol%), and CS2CO3 (0.41 g, 1.3 mmol) in degassed toluene (4 ml) was purged with N2 and heated to 100 °C in a sealed tube for 2 days. The mixture was diluted with THF and filtered to remove CS2CO3. The filtrate was concentrated under reduced pressure and purified by column chromatography (hexane - EtOAc = 3 : 1) to give the title compound (0.10 e. 48%). MS: Calcd.: 234: Found: FM+H1+ 235.
Method 5
(y)-6-Chloro-Af-(l-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine
To a mixture of 2,6-dichloro-3-nitropyridine (2.26 g, 10.8-mmol) and potassium carbonate (1.29 g, 9.34 mmol) in anhydrous CH3CN (20 ml), was added (5)-l -(4-fluoro-25 phenyl)-ethylamine (1.00 g, 7.19 mmol) dropwise at 0 °C. The reaction mixture was stirred at 25 °C for 17 hrs. The solid was removed by filtration and the resulted cake was washed with EtOAc (20 ml). The combined filtrate was concentrated and purified by column chromatography (hexane - EtOAc = 10 : 1) to give the title compound as a yellow solid (1.74 g, 82%). 'H NMR (400 MHz) 5 8.65 (d, J= 7.6 Hz, IH), 8.43 (d, J - 8.4 Hz, IH), 7.51 (m, 30 2H), 7.16 (m,2H), 6.81 (d, J=8.8Hz, IH), 5.37 (m, IH), 1.59 (d, J= 6.8 Hz, 3H).
101749
Methods 6-9
Following a similar procedure to Method 5, the following compounds were synthesized from a 2,6-dichloro-3-nitropyridine by reacting it with an amine.
Method
Product
NMR/MS
Amine
6
6-Chloro-N-(4-
fluorobenzyl)-3-
nitropyridin-2-amine
(400 MHz, CDCI3) 8.58 (br s, IH), 8.37 (d, J = 8.4 Hz, IH), 7.36 (m, 2H), 7.04 (m, 2H), 6.67 (d, J = 8.4 Hz, IH), 4.78 (d, J = 5.6 Hz, 2H)
(4-fluoro-phenyl) methanamine
7
(2R)-2-[(6-Chloro-3-nitropyridin-2-yl)amino]-2-(4-fluorophenyl)ethanol
(400 MHz) 8.96 (d, J = 7.6 Hz, IH), 8.46 (d, J = 8.4 Hz, IH), 7.45 (m, 2H), 7.15 (m, 2H), 6.81 (d, J = 8.8 Hz, IH), 5.27 (m, 2H), 3.80 (m, 2H)
(R)-2-amino-2-(4-
fluorophenyl)
ethanol
8
2-[(6-Chloro-3-nitropyridin-2-yl)amino]-2-(4-fluoroph eny 1 )prop ane -1,3-diol
(400 MHz) 9.13 (s, IH), 8.44 (d, J = 8.4 Hz, IH), 7.39 (m, 2H), 7.06 (m, 2H), 6.73 (d, J = 8.8 Hz, IH), 5.16 (t, J = 5.6 Hz, 2H), 4.07 (m 2H), 3.96 (m, 2H). MS: Calcd.: 341; Found: [M+H]+ 342
Method 10
9
fi-rinlnrn-N.rnR^-l-(4-fluorophenyl)
ethyl ]-3-ni tropyridin-2-amine
MS- Palrrl • 90^- FminH- n\/M-TTI+ 9Q£
i- ^ 1 V+A V Vi » « frr ^ b' j J. V U11W ■ |^-L T 1 1 _l_ J. J i—t y V
V.V x y . xxwiv/ivy phenyl) ethanamine
Method 10
2-Aroino-2-(4-fluorophenyl)propane-lJ-diol
A suspension of 2-(4-fluorophenyl)-2-nitroproane-l,3-diol (Method 11; 4.5 g, 20.9 mmol) and Raney nickel (0.45 g, 5.23 mmol) in MeOH (50 ml) was degassed and stirred under H2 (48 psi) for 2 hours. The catalyst was removed by filtration. The filtrate was 10 concentrated and recrystallized from hexane : EtOAc (1 : 1) to give the title compound (2.35 g, 61%) as a white solid. NMR (400 MHz) 7.55 (m, 2H), 7.07 (m, 2H), 4.65 (t, J= 5.2 Hz, 2H), 3.49 (m, 4H), 1.76 (s, 2H).
101749
Method 11
2-(4-Fluorophenyl)-2-nitroproane-1.3-dioI
To a solution of l-fluoro-4-(nitromethyl)benzene (Method 12; 10.0 g, 80% pure; 52 mmol) and TEA (15.1 ml, 108.3 mmol) in dioxane (50 ml) was added formaldehyde (8.6 ml, 5 116 mmol) dropwise at 0 °C. After addition, the reaction was slowly warmed up to 25 °C overnight. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane : EtOAc = 10 : 1) to give the title compound as a white solid (4.5 g, 41%). NMR (400 MHz) 7.41 (m, 2H), 7.22 (m, 2H), 5.39 (t, J= 5.2 FIz, 2H), 4.22 (m, 4H).
Method 12
1 - F i uo ro -4-(ni trornelh yl )ben y.en e
A mixture of 1 -(bromomethyl)-4-fluorobenzene (11.52 g, 61 mmol) and AgNOj (11.3 g, 73 mmol) in benzene (200 ml) was stirred vigorously at 25 °C for 25 hrs. The solid was 15 removed by filtration and washed with ether (500 ml). The combined organic was concentrated to give the title compound (10.0 g, 80% pure; 85%) which was used without further purification. NMR (400 MHz, CDCla) 7.44 (m, 2H), 7.18 (m, 2H), 5.42 (s, 2H).
Method 13
(ySr)-5,6-Chloro-Air-n-('4-fluorophenyl)ethvl)-3-nitropvridin-2-amine
To a mixture of 2,3,6-trichloro-5-nitropyridine (1.00 g, 4.40 mmol) and potassium carbonate (0.79 g, 5.7 mmol) in anhydrous acetonitrile (10 ml) was added (S)-l-(4-fluoro-phenyl)-ethylamine (0.64 g, 4.62 mmol) dropwise at 0 °C. After addition, the reaction mixture was stirred at 25 °C for 17 hours. The solid was removed by filtration and washed with 25 EtOAc (20 ml). After evaporation of the solvent, the resulted residue was purified by column chromatography (hexane : EtOAc =10:1) to give the title compound as a yellow solid (0.61 g, 79% pure, 33%). NMR (400 MHz, CDCI3) 8.46 .(br s, 2H), 7.36 (m, 2H), 7.03 (m, 2H), 5.40 (m, IH), 1.63 (d, 6.8 Hz, 3H).
Methods 14-15
Following a similar procedure to Method 13, the following compounds were synthesized from a 2,3,6-trichloro-5-nitropyridine by reacting it with an amine.
101749
Method
Product
NMR/MS
Amine
14
(2R)-2-[(5,6-Dichloro-3-
nitropyridin-2-yl)amino]-2-
(4-fluorophenyl)ethanol
(400 MHz) 8.91 (d, J = 7.2 Hz, IH), 8.66 (s, IH), 7.45 (m, 2H), 7.15 (m, 2H), 5.25 (m, 2H), 3.80 (m, 2H)
(R)-2-amino-2-
(4-fluoro phenyl)ethanol
3,6-Dichloro-./V-(5 -cyclopropyl- l/Z-pyrazol-3-yl)-5-nitropyridin-2-amine
(400 MHz) 12.37 (s, IH), 9.83 (s, IH), 8.54 (s, 1H), 6.27 (s, IH), 1.94 (m, IH), 0.95 (m, 2H), 0.70 (m, 2H). MS: Calcd.: 313; Found: [M+H]+ 314
-cyclopropy 1-
lH-pyrazol-3-
amine
Method 16
6- Chi oro-N-( 5-cycIopropyl-l H-p yrazo 1-3 -yl) -3 -nitropyridin-2-amine
To a solution of 2,6-dichloro-3-nitropyridine (0.67 g, 3.2 mmol) and DIEA (0.46 ml, 5 2.65 mmol) in EtOH (20 ml) was added 5-cyclopropyl-l/7-pyrazol-3-amine (0.26 g, 2.12 mmol) solution in EtOH (5 ml) dropwise at 0 °C. After addition, the reaction mixture was stirred at 25 °C for 24 hrs. The solvent was removed under reduced pressure and the resulted residue was purified by column chromatography (hexane - EtOAc = 5 : 1) to give the title compound as a yellow solid (0.58 g, 98%). !H NMR (400 MHz) 512,36 (s, IH), 10.20 (s, IH), 10 8.54 (d, ,7 =8.4 Hz, IH), 7.01 (d, 7=8.4 Hz, IH), 6.39 (d, J= 1.6 Hz, 1H), 1.94 (m, 1H), 0.96 (m, 2H), 0.71 (m, 2H). MS: Calcd.: 279; Found: [M+H]+ 280.
Method 17
.6-Ch3oro-7V-(5-cyclopropvl-l//-pvrazol-3-yl)-3-nitropyridine-2-amine 15 To a solution of 2,3,6-trichloro-5-nitropyridine (1.62 g, 7.10 mmol) and DIEA (1.24
ml, 7.1 mmol) in THF (25 ml) was added dropwise a solution of 5-cyclopropyl-l//-pyrazol-3-amine (0,70 g, 5.68 mmol) in THF (5 ml) at 0 °C. After addition, the reaction mixture was stirred at 25 °C for 24 hours. The solvent was removed under reduced pressure and the resulted residue was purified by column chromatography (hexane : EtOAc = 1.5 : 1) to give 20 the title compound as a yellow solid (0.83 g, 47%). NMR (400 MFIz) 12.39 (s, IH), 10.12 (s, IH), 8.77 (d, ,7= 1.2 Hz, IH), 6.35 (s, IH), 1.95 (m, IH), 0.96 (m, 2H), 0.71 (m, 2H). MS: Calcd.: 313; Found: [M+H]+ 314.
101749
Method 18
Following a similar procedure to Method 17, the following compound was synthesized from a 2,3,6-trichloro-5-nitropyridine by reacting it with the appropriate amine.
Meth
Product
NMR/MS
Amine 1
18
(J?)-2-(3,6-Dichloro-5-nitropyridin-2-ylamino)-2-(4-fluorophenyl)ethanol
(400 MHz) 8.46 (s, IH), 8.22 (d, J= 8.0 Hz, IH), 7.45 (m, 2H), 7.16 (m, 2H), 5.22 (m, IH), 5.05 (t,J= 6.0 Hz, IH), 3.87 (m, IH), 3.72 (m, IH)
(R)-2-amino-2-(4-fluoro phenyl) ethanol
Method 19
6-Bromo-vV-(4-fluorobenzv0pvridin-2-amine
To a suspension of 6-bromopyridin-2-amine (500 mg, 2.89 mmol), sodium tert-butoxide (695 mg, 7.24 mmol) in anhydrous toluene (20 ml) was added 4-fluorobenzylchloride (415 mg, 2.90 mmol) at room temperature. The reaction mixture was 10 heated at 100 °C overnight. EtOAc was added and the mixture was washed with brine and was concentrated. Flash chromatography (10-14% EtOAc in hexanes) gave the title compound (506 mg, 63%). ]H NMR (CDC13) 5 4.40 (m, 2H), 4.95 (br s, IH), 6.20 (m, IH), 6.73 (m, IH), 7.00 (m, 2H), 7.25 (m, 3H).
Method 20
6-Chloro-iV-[(l^-l-(4-fluorophenvl')ethvl1pvridin-2-amine
To a 25 ml round bottom flask was added Pd(OAc)2 (45 mg, 0.2 mmol), (biphenyl-2-ylmethylene)bis(dimethylphosphine) (120 mg, 0.4 mmol) and sodium tert-butoxide (480 mg, 5.0 mmol). The flask was sealed and refilled with N2. To the mixture was added a solution of 20 2,6-dichloropyridine (300 mg, 2.0 mmol) and [(15)-l-(4-fluorophenyl)ethyl]amine (306 mg, 2.2 mmol) in toluene (4 ml). The reaction mixture was heated at 85 °C overnight. The solvent was removed and EtOAc was added and the mixture was washed with brine and was concentrated. Flash chromatography (10-40% EtOAc in hexanes) gave the title compound (339 mg, 68%). "H NMR (CDC13) 5 1.55 (m, 3H), 4.66 (m, IH), 5.07 (brs, 1H),6.01 (m, IH), 25 6.54 (m, IH), 7.00 (m, 2H), 7.25 (m, 3H).
101749
Method 21
tert-Butyl 5-cyclopropyl-34f6-{rn<SVl-(4-fIuorophenvl)ethyllamino)pvridin-2-vl)amiiio1-1//-pyrazole-1 -carboxylate
To a 25 ml round bottom flask was added Pd2(dba)3 (84 mg, 0.092 mmol), (biphenyl-5 2-ylmethylene)bis(dimethylphosphine) (55 mg, 0.184 mmol) and sodium tert-butoxide (132 mg, 1.38 mmol). The flask was sealed and refilled with N2. To the mixture was added a solution of 6-chloro-/V-[(lS)-l-(4-fluorophenyl)ethyl]pyridin-2-amine (Method 20; 230 mg, 0.92 mmol) and /er/-butyl 3-amino-5-cyclopropyl-l//-pyrazole-l-carboxylate (223 mg, 1.0 mmol) in toluene (4 ml). The reaction mixture was heated at 110 °C overnight. Solvent was 10 removed and EtOAc was added and the mixture was washed with brine and was concentrated. Flash chromatography (15-40% EtOAc in hexanes) gave the title compound (146 mg, 36%).
NMR(CDC13) 5 0.80- 1.00 (m, 4H), 1.60 (m, 3H), 1.65 (s, 9H), 1.95 (m, IH), 4.71 (m, 1H), 4.75 (m, IH), 5.75 (m, IH), 6.09 (m, IH), 6.21 (s, IH), 7.00 (m, 2H), 7.23 (m, 2H), 7.30 (m, IH), 9.40 (s, IH).
Method 22
/er/-Butyl (2-{r(6-r(5-cyclopropyl-1 i/-pyrazol-3-yl)aminol-5-fluoro-2-(("f\S)-l-(4-fluorophenvl )ethy 11 amino} pyridin- 3 -y 1 )methy 11 amino j -2 -oxoethyl) carbamate
A round bottom flask was charged with (^^-(aminomethylYA^-tS-cyclopropyl- \H-20 pyrazol-3-yl)-5-f]uoro-A^-(l-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.07g, 0.18 mmoi), 2-(/e/t-butoxycarbonyl)acetic acid loaded TFP resin (1.15 mmol/g loading, 0.18 mmol), and a THF - DCM solution (1 : 1,4 ml) at 0 °C. The resulting solution was shaken vigorously at 0 °C for 2 hrs and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and 25 concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH3CN in H20 over 400 ml) to give the title compound (0.035g, 35%). MS: Calcd.: 541; Found: [M+H]+ 542.
Method 23
(1Sr)-5.6-Difluoro-A/-(l-('4-fluorophenyl)ethyl)-3-nitropyridin-2-amine
A solution of 2,3,6-trifluoro-5-nitropyridine (Method 24, 2.0g, 11.2 mmol) in THF (50ml) was cooled to 0 °C. (S)-\ -(4-FluorophenyI)ethanamine (1.56g, 11.2mmoI) was added and the reaction was stirred at 0 °C for 30 minutes. The reaction was quenched with water (50
101749
ml) and then extracted with DCM (2 x 75 ml). The combined organic fractions were dried over Na2SC>4, filtered, and then concentrated. The resulting oil was purified by column chromatography (hexane-DCM =1 : 1) to give the title compound (2.3 g, 70%).
Method 24
2J.6-Trifluoro-5-nitropyridine
To neat 2,3,6-trifluoropyridine (12.0g, 90mmol) was slowly added fuming HNO3 (142g, 2254 mmol) and H2SO4 (133g, 1353mmol) slow enough to keep the internal temperature below 40 °C. Upon completion of the addition, the resulting solution was heated 10 to 60 °C for 30minutes, and then cooled to 0 °C. Ice water (21) was added, and the reaction was extracted with hexanes (2 x 300 ml) and then DCM (1 x 300 ml). The combined organic fractions were dried over Na2SC>4, filtered, and concentrated to give the title compound (8.1 g, 50%), which was used without further purification.
Method 25
ry)-2-(5,6-Difluoro-3-nitropyridin-2-ylamino)-2-(4-fluorophenvl)ethanol
A solution of 2,3,6-trifluoro-5-nitropyridine (1.2 g, 6.7 mmol) in THF (40 ml) was cooled to 0 °C. (/?)-2-amino-2-(4-fluorophenyl)ethanol (1.0 g, 6.7 mmol) was then added and the reaction was stirred at 0 °C for 30 minutes. The reaction was quenched with water (50 ml) 20 and then extracted with DCM (2 x 75 ml). The combined organic fractions were dried over Na2SC>4, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (1.2 g, 57%). The product was carried over to the next step without characterization. .
Method 26
.6-Dichloro-7V-(5-isopropoxv-l//-pvrazol-3-vn-3-nitropyridin-2-amine
To a mixture of 2,3,6~trichloro-5-nitropyridine (2.61 g, 11.4 mmol) and DIEA (1.90 ml, 11.4 mmol) in THF (50 ml) was added the 5-isopropoxy-l//-pyrazol-3-amine (1.20 g, 8.50 mmol) at 0 °C. After addition, the reaction mixture was stirred at 25 °C for 5 days. The 30 solvent was removed under reduced pressure and the resulting residue was purified by column chromatography (hexane-EtOAc = 2.5 : 1) to give the title compound as a yellow solid (0.77 g. 27%). "H NMR (400 MHz) 6 12.26 & 11.64 (s, IH), 10.42 & 10.04 (s, IH), 8.81 & 8.77 (s,
101749
IH), 6.02 & 5.94 (s, IH), 4.70 & 4.48 (m, IH), 1.32 (d, J= 6.0 Hz, 3H), 1.27 (d, J= 6.0 Hz, IH). MS: Calcd.: 331; Found: [M+H]+ 332.
Method 27
3.6-Dichloro-Ar-(5 -isopropoxy- l#-pyrazol-3-yD-5-nitropyridin-2-amine
To a mixture of 2,3,6-trichloro-5-nitropyridine (2.61 g, 11.4 mmol) and DIEA (1.90 ml, 11.4 mmol) in THF (50 ml) was added 5-isopropoxy-l//-pyrazol-3-amine (1.20 g, 8.50 mmol) at 0 °C. After addition, the reaction mixture was stirred at 25 °C for 5 days. The solvent was removed under reduced pressure and the resulted residue was purified by column 10 chromatography (hexane-EtOAc = 1 : 1) to give the title compound as a yellow solid (0.51 g, 18%). 'H NMR (400 MHz) 6 12.22 & 11.35 (s, IH), 10.12 & 9.80 (s, IH), 8.64 & 8.54 (s, IH), 5.95 & 5.84 (s, IH), 4.70 & 4.46 (m, 1H), 1.27-1.32 (m, 6H). MS: Calcd.: 331; Found: [M+H]+ 332.
Method 28
6-Chloro-7V-('5-isopropoxv-l//-pyrazol-3-yl)-3-nitropvridin-2-amine
To a solution of 2,6-dichloro-3-nitropyridine (0.51 g, 2.7 mmol) and DIEA (0.39 ml, 2.2 mmol) in THF (10 ml) was added the 5-isopropoxy-l//-pyrazol-3-amine (0.25 g, 1.8 mmol) solution at 0 °C. After addition, the reaction mixture was stirred at 25 °C for 3 days and 20 60 °C for 24 hours. The solvent was removed under reduced pressure and the resulting residue was purified by column chromatography (hexane-EtOAc = 3 : 1) to give the title compound as a yellow solid (0.33 g, 63%). 'HNMR (400 MHz) 5 12.25 & 11.66 (s, IH), 10.46 & 10.13 (s, IH), 8.58 & 8.55 (d, ,7=8.8 Hz, 1H),7.11 & 7.02 (d, 8.8 Hz, IH), 6.08 & 5.97 (s, IH), 4.70 & 4.48 (m, IH), 1.32 & 1.27 (d, J= 6.0 Hz, 6 H). MS: Calcd.: 297; Found: [M+H]+ 298.
Method 29
(/?)-2-(6-Chloro-3-nitropyridin-2-ylamino)-2-(4-fluorophenyDethanol
To a mixture of 2,6-dichloro-3-nitropyridine (0.933 g, 4.83 mmol) and potassium carbonate (0.58 g, 4.19 mmol) in anhydrous acetonitrile (10 ml) was added (7?)-2-amino-2-(4-30 fluoro phenyl)ethanol (1.00 g, 7.19 mmol) at 0 °C. The resulting reaction mixture was stirred at 25 °C for 18 hours. The solid was removed by filtration and washed with EtOAc (20 ml). After evaporation of the solvent, the resulting residue was purified by column chromatography (hexane-EtOAc = 5 : 1) to give the title compound as a yellow solid (0.77 g,
101749
61%). lH NMR (400 MHz) 8 8.96 (d, J= 7.6 Hz, IH), 8.46 (d, J= 8.4 Hz, 1H), 7.45 (m, 2H),
7.15 (m, 2H), 6.81 (d, J = 8.8 Hz, IH), 5.27 (m, 2H), 3.80 (m, 2H).
Method 30
(^-6-Chloro-Af-d-(4-fluorophenvl)ethvn-3-nitropvridin-2-amine
To a mixture of 2,6-dichloro-3-nitropyridine (2.26 g, 10.8 mmol) and potassium carbonate (1.29 g, 9.34 mmol) in anhydrous CH3CN (20 ml), was added (5)-1-(4-fluorophenyl)'-ethylamine (1.00 g, 7.19 mmol) dropwise at 0 °C. The reaction mixture was stirred at 25 °C for 17 hours. The solid was removed by filtration and the resulted cake was washed 10 with EtOAc (20 ml). The combined filtrate was concentrated and purified by column chromatography (hexane-EtOAc = 10 : 1) to give the title compound as a yellow solid (1.74 g, 82%). ]H NMR (400 MHz) 8 8.65 (d,J = 7.6 Hz, IH), 8.43 (d, 8.4 Hz, 1H), 7.51 (m, 2H),
7.16 (m, 2H), 6.81 (d, ,7=8.8 Hz, lH),5.37(m, 1H), 1.59 (d, J= 6.8 Hz, 3H).
Method 31
Ar-(5-Cvclopropvl-l/7-pvrazo]-3-vlV3,6-difluoropvridin-2-amine
A solution of tert-butyl 5-amino-3-cyclopropyI-l//-pyrazole-l-carboxylate (1.00 g, 4.49 mmol) in THF (15ml) was cooled to -78 °C. f-BuLi (1.7 M in THF, 4.15 mmol) was added dropwise and the resulting solution was stirred for 30 min. at -78 °C. A solution of 20 2,3,6-trifluoropyridine (0.46 g, 3.4mmol) in THF (5ml) was added, and the resulting solution was stirred for 5 min at -78 °C, and then the reaction was wanned to 0 °C, and stirred at that temperature for 30 min. The reaction was quenched with aq. NH4CI and extract with EtOAc (2 x 20 ml). The organic fractions were dried over Na2S04, filtered, and concentrated. The resulting oil was then placed in ACN (15 ml) at 0 °C, and N-trimethylsilylimidazole (0.5 ml) 25 was added. The reaction was stirred for 20 min, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.10 g, 12%). MS: Calcd.: 236; Found: [M+H]+ 237.
Method 32
6-(5-Cyclopropvl-l//-pyrazoI-3-vlaminoV2.,5-difluoronicotinomtriIe
A solution of 2,5,6-trifluoronicotinonitrile (30.0 g, 189.8 mmol) in ACN (240 ml) was prepared in a 11 3-neck flask at room temperature and then cooled to -5 °C using an ice-salt bath. An addition funnel containing triethylamine (29.1 ml, 208.8 mmol) and a second
101749
addition funnel containing a solution of 5-cycIopropyl-l//-pyrazoI-3-amine (25.7 g, 208.8 mmol) in ACN (160 ml) were placed on top of the reaction flask. A total of 5 ml of triethylamine was added quickly dropwise to the reaction. The reaction was allowed to stir for 5 min, followed by the simultaneous dropwise addition of the remaining triethylamine and 5-5 cyclopropyl-177-pyrazol-3-amine solution at a rate slow enough to keep the internal temperature at or below 5 °C. Upon completion of the addition, the reaction was allowed to stir for 1 hour at 0 °C, at which point no starting material remained, and the reaction was filtered through a fritted funnel. The remaining solids were washed with 0 °C ACN (3 x 100 ml). The solid product was then dried under vacuum for 30 minutes to give the title compound 10 (25.2 g, 51%) which was used without further purification. 'H NMR (400 MHz, CD3OD) § 7.81-7.77 (m, IH), 6.33 (s, IH), 1.91 (septet, 1H), 0.99-0.98 (m, 2H), 0.76-0.73 (m, 2H). MS: Calcd.: 261; Found: [M+H]+ 262.
Method 33
(iSV 1 -f 5-Fluoropyridin-2-vl)ethanamine
To the solution of (5)-^er/-butyl-l-(5-fluoropyridin-2-yl)ethylcarbamate (Method 34, 12.8 g, 53.3 mmol) in DCM (100 ml) was added HCl/dioxane solution (107 ml, 4 N, 428 mmol). The reaction was stirred at room temperature for 3 hours. The solvent was removed and 50 ml of saturated sodium bicarbonate was added. The resulting aqueous solution was 20 extracted with ether (6 x 400 ml), dried over sodium sulfate and concentrated to give the title compound (7.30 g, 98%) as pale yellow oil. 'H NMR (400 MHz) 5 8.44 (d, ./= 2.8 FIz, IH), 7.66 (m, IH), 7.53 (m, IH), 4.01 (q, J=6.8Hz, IH), 1.94 (b, 2H), 1.26 (d, ,7=6.8 Hz, 3H). ■ MS: Calcd,: 140; Found: [M+Hf 141.
Method 34
(■SVfert-Butvl-l-(5-fluoropvridin-2-vl)ethylcarbamate
The solution of (S)-jV-(l-(5-fluoropyridin-2-yl)ethyl)acetamide (Method 35, 11.0 g, 60.37 mmol), DMAP (1.48 g, 12.07 mmol) and Boc20 (26.35 g, 120.7 mmol) in THF (100 ml) was stirred at 50 °C for 20 hours. After cooled to room temperature, lithium hydroxide 30 monohydrate (5.19 g, 123.8 mmol) and water (100 ml) were added. The reaction was stirred at room temperature for 5 hours and diluted with ether (200 ml). The organic layer was separated, washed with brine (100 ml), and dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column chromatography (Hexane-EtOAc = 5:1)
101749
to give the title compound as a pale yellow oil (13.6 g, 94%). lH NMR (400 MHz) 5 8.46 (d, J = 2.8 Hz, IH), 7.69 (m, IH), 7.35-7.41 (m, 2H), 4.67 (m, 1H), 1.37 (s, 9H), 1.32 (d,J = 7.2 Hz, 3H). MS: Calcd.: 240; Found: [M+H]+ 241.
Method 35
fiSyA^l-(5-Fluoropyridin-2-vl)ethyl)acetamide iV-(l-(5-fluoropyridin-2-yl)vinyl)acetamide (Method 36, 11.0 g, 61.1 mmol) in MeOH (120 ml) under N2 was added (+)-l ,2-bis((2S, 5S)-2,5-diethylphospholano)benzene (cyclooctadiene)rhodium(I)trifluoromethanesulfonate (0.441 g, 0.611 mmol). The solution 10 was transferred to a high pressure bomb and charged 150 psi H2. The reaction stirred at room temperature and maintained inside pressure between 120-150 psi for 7 hours. The solvent was removed and the resulted residue was purified by column chromatography (EtOAc) to give the title compound as a white solid (9.8 g, 88%). ]H NMR (400 MHz) 5 8.49 (d, J= 2.4 Hz, 1H), 8.32 (d, J= 1.6 Hz, IH), 7.66 (m, IH), 7.39 (dd, J= 4.4 and 8.8 Hz, IH), 4.95 (m, IH), 15 1.85 (s, 3H), 1.34 (d, J - 7.2 Hz, 3H). MS: Calcd.: 182; Found: [M+H]+ 183. Enantiomeric excess determined by HPLC (Chiralpak IA; 70:30 C02/Me0H), 95.3% ee.
Method 36
iV-(l-(5-Fluoropvridin-2-vl)vinvl)acetamide 20 A solution of MeMgBr (170.3 ml, 510.98 mmol) in ether was diluted with 170 ml of anhydrous THF and cooled to 0 °C. 5-FluoropicolinontriIe (Method 37, 53.6 g, 425.82 mmol) in THF (170 ml) was added dropwise. The reaction was stirred at 0 °C for 30 minutes, then diluted with DCM (170 ml). Acetic anhydride (48.3 ml, 510.98 mmol) in DCM (100 ml) was added dropwise at 0 °C. After addition, the reaction was wanned to room temperature and 25 stirred at room temperature for 8 hours. Saturated sodium bicarbonate solution (50 ml) was added and extracted with EtOAc (2 x 200 ml). The combined organic was dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column chromatography (hexane-EtOAc = 2.5 : 1) to give the title compound as a white solid (26.6 g, 35%). 'PI NMR (400 MHz) 5 9.37 (s, IH), 8.57 (d, J= 2.8 Hz, IH), 7.81 (m, 2H), 6.01 (s, 30 IH), 5.52 (s, IH), 2.08 (s, 3H). MS: Calcd.: 180; Found: [M+H]+ 181.
101749
Method 37
-Fiuoropicolinontrile
2-Bromo-5-fluoropyridine (93.0 g, 528 mmol), Zn dust (8.29 g, 127 mmol), zinc cyanide (40.3 g, 343 mmol), diphenylphosphinoferrocene (11.7 g, 21.1 mmol) and Pd2dba3 5 (9.68 g, 10.6 mmol) in anhydrous DMA (300 ml) was heated at 95 °C for 3 hours. After cooled to room temperature, brine (100 ml) and ether (500 ml) was added. The solid formed was removed by filtration and washed with ether (300 ml). The organic layer was separated, washed with brine (200 ml) and dried over sodium sulfate, and concentrated. After removal of solvent, the resulted residue was purified by column chromatography (hexane-DCM = 1:1) to 10 give the title compound as a white solid (49 g, 72%). *H NMR (400 MHz) 5 8.82 (d, J — 2.8 Hz, 1H), 8.21 (dd, J= 4.4 and 8.8 Hz, IH), 8.05 (dd, J= 2.8 and 8.8 Hz, IH).
Method 38
6 -F luoro-iV-methox v-T^-methylnicoti namide 15 To a solution of 6-fluoronicotinic acid (10 g, 70.9 mmol) in DCM (200 ml), was added jV,0-Dimethylhydroxylamine hydrochloride (7.3 g, 74.8 mmol), jV-(3-Dimethylaminopropyl)-yV'-ethylcarbodiimide hydrochloride (15 g, 78.5 mmol), and triethylamine (22 ml, 156 mmol). The reaction mixture was allowed to stir at room temperature for 16 hours. The reaction was partitioned with water, layers were cut, and organic layer was dried over NaiS04, filtered, and 20 concentrated in vacuo. The crude residue obtained was purified by a silica gel filtration using EtOAc-DCM (4:1) to give 7.2 g (55% isolated yield) of the title compound. lI-I NMR: 8.48 (s, 1 H) 8.21 (t, ,7=8.29 Hz, 1 H) 7.27 (dd, J-8.29, 3.01 Hz, 1 H) 3.54 (s, 3 H) 3.27 (s, 3 H).
Method 39
2-Chloro-6-f5-cvclopropyl-l//-pyrazol-3-vlamino)-5-fluoro-4-iodonicotinonitrile
The crude 2,6-dichloro-5-fluoro-4-iodonicotinonitriIe (8.0 g, 25.2 mmol), Et3N (3.3 g, 32.8 mmol) and 5-cyclopropyl-l/7-pyrazol-3-amine (3.1 g, 25.2 mmol) were placed in ACN (50 ml) and the resulting solution was heated to 80 °C for 24 hours. The reaction was cooled to room temperature, filtered, and the resulting solid was washed with cold ACN, dried, and 30 collected to give the title compound (3.0 g, 29%). MS: Calcd.: 403; Found: [M+H]+ 404.
101749
Method 40
2,6-Dichloro-5-fliioro-4-iodonicotinonitrile
To a solution of diisopropylamine (15.9 g, 157 mmol) in THF (400 ml) at -78 °C was added ft-butyllithium (2.5 M hexanes, 154 mmol), and the solution was stirred at -78 °C for 30 5 minutes. The lithium diisopropylamide solution was then added slowly dropwise to a -78 °C solution of 2,6-dichloro-5-fluoronicotinonitrile (10.0 g, 52.3 mmol) and iodine (26.5 g, 104 mmol) in THF (175 ml). Upon completion of the addition, the reaction was allowed to warm slowly to room temperature, and stirred at room temperature for 12 hours. An aqueous 10% Na2S2C>3 solution (500 ml) was added and the reaction was extracted with EtOAc (3 x 300 10 ml). The combined organic fractions were dried over Na2S04, filtered, and then concentrated to give the title compound (14.5 g, 87%) as a brown solid that was used without further purification.
Method 41
2,5-Difhioro-6-(5-methvl-l#-pyrazol-3-ylamino)nicotinonitrile
To a solution of 2,5,6-trifluoronicotinonitrile (1.0 g, 6.3 mmol) and triethylamine (0.83 g, 8.2 mmol) in ACN (30 ml) at 0°C was added 5-methyI-l//-pyrazol-3-amine (0.67 g, 6.9 mmol). The reaction was stirred at 0 °C for 1 hour, at which point the reaction was filtered. The resulting solid was washed with cold ACN, dried and collected to give the title compound 20 (0.44 g, 29%). MS: Calcd.: 235; Found: [M+H]+ 236.
Method 42
2,5-Difluoro-6-(5-isopropoxy-l J/-pvrazol-3-ylamino)nicotinonitrile
To a solution of 2,5,6-trifluoronicotinonitrile (3.0 g, 19.0 mmol) and triethylamine (2.5 25 g, 24.7 mmol) in ACN (30 ml) at 0 °C was added 5-isopropoxy-l/7-pyrazol-3-amine (2.95 g, 20,9 mmol) in ACN (15 ml). The reaction was stirred at 0 °C for 1 hour, at which point the reaction was diluted with water (50 ml) and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na2S04, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 :1) to give the title compound 30 (0.48 g, 9%). MS: Calcd.: 279; Found: [M+H]+ 280.
101749
Method 42 (alternative procedure)
2.5-Difluoro-6-(5-isopropoxy-li1/-pvrazol-3-vlamino)nicotinonitrile tert-Butyl 5-(5-cyano-3,6-difluoropyridin-2-ylamino)-3-isopropoxy-lH-pyrazoIe-l-carhoxylate (Method 79, 10.6g, 27.9mmol), was placed in DCM (500ml) at room 5 temperature. A 4.0 M solution of HCl (16,3g, 447mmol) in dioxane was added dropwise, and upon completion of the addition the reaction was allowed to stir for an additional 30 minutes. The reaction was concentrated to dryness, and dissolved in DCM (300ml) with a minimal amount of MeOH (5ml) to aid solubility. A saturated aqueous solution of Na2C03 (300ml) was added, and the reaction was stirred vigorously for 30 minutes. The layers were allowed to 10 separate, and the organic fraction was dried (Na2S04), filtered, and concentrated. The resulting residue was slurried with cold DCM (approx. 50ml), filtered, and the remaining solid was washed with DCM and dried to give the title compound (5.5g, 70%). MS: Calcd.: 279; Found: [M+H]+ 280.
Method 43
2.5-Dichloro-6-(5-cvclopropyl-liZ-pyrazol-3-ylamino)nicotinonitrile
To a solution of 2,5,6-trichloronicotinonitrile (Method 44, 1.0 g, 4.8 mmol) and DIEA (0.81 g, 6.2 mmol) in «-BuOH (5 ml) was added 5-cyclopropyl-l/7-pyrazol-3-amine (2.3 g, 19.3 mmol). The reaction was heated to 60 °C for 2 hours, at which point the reaction was 20 cooled to room temperature and concentrated. The resulting residue was diluted with 10 ml ACN, and stored at 0 °C for 1 hour. The solids that formed were then filtered, washed with cold ACN, dried and collected to give the title compound (0.62 g, 43%). MS: Calcd.: 294; Found: [M+H]+ 295.
Method 44
2,5.6-Trichloronicotinonitrile
A suspension of 2,5,6-trichIoronicotinamide (Method 45, 2.3 g, 10.2 mmol) in POCl3 (20 ml) was heated to 90 °C for 1 hour. The reaction was then cooled to room temperature, and the POCI3 was removed under vacuum. The resulting residue was taken up in DCM (50 30 ml) and ice water (50 ml) was then added, followed by the careful addition of an aqueous solution of Na2C03 until pH 8 was achieved. The organic fraction was then dried over Na2S04, filtered, and concentrated to give the title compound (2.1 g, 80%) which was used without further purification. ]FINMR (400 MHz, CD3OD) 6 8.54 (s. IH).
101749
Method 44 (alternative procedure)
2,5,6-Trichloronicotinonitrile
To a solution of 2.4,5,6-tetrachloronicotinonitrile (7.6 g, 31.4 mmol) in MeOH/THF (230ml/230 mi) was added zinc dust (4,0 g, 62.8 mmol) slowly at 0°C and the saturated 5 NH4CI solution (105 ml) and the mixture was stirred for 30 minutes. TLC indicated that the reaction is complete. Saturated NH4OAC solution (180 ml) was added to the mixture and the mixture was allowed to stir at room temperature for 30 minutes. The mixture was filtered and was washed with EtOAc (500 ml). The filtrate was washed with brine and dried and concentrated to give a solid. ISCO column purification gave the title compound (4.63 g, 10 71%). lH NMR (CDCI3): 5 8.97 (s, 1 H).
Method 45
2.5.6-Trichloronicotinamide
A solution of 2,5,6-trichloronicotinoyl chloride (Method 46, 2.5 g, 10.2 mmol) in 15 dioxane (20 ml) was added dropwise to 10 ml ammonium hydroxide (28% NH3 in water) at 0 °C. Upon completion of the addition, the reaction was allowed to stir for an additional 10 minutes, and then extracted with DCM (3 x 50 ml). The combined organic fractions were dried over Na2S04, filtered, and concentrated to give the title compound (2.3 g, 100%), which was used without further purification.
Method 46
2.5,6-Trichloronicotinovl chloride
To a suspension of 2,5,6-trichloronicotinic acid (Method 47, 2.3 g, 10.2 mmol) in DCM (25 ml) at room temperature was added oxalyl chloride (3.0 g, 24.4 mmol) and 3 drops 25 of dry DMF. After 30 minutes, the resulting clear solution was concentrated to dryness to give the title compound (2.5 g, 100%), which was immediately used without further purification.
Method 47
2,5,6-Trichloronicotinic acid 30 A suspension of 2,3,6-trichloro-5-methylpyridine (Method 48, 11.8 g, 60.0 mmol) in water (400 ml) was heated to 100 °C. Portionwise, KMn04 (28.5 g, 180.2 mmol) was then added over 12 hours. The reaction was then allowed to stir for 2 days at 100 °C, over which time an additional 10 g of KM11O4 was added portionwise. When no starting material
101749
remained, the hot reaction was filtered, washed with hot water (2 x 75 ml), and the resulting filtrate was allowed to cool to room temperature. The aqueous filtrate was then extracted with EtOAc (3 x 100 ml), and then concentrated to a 50 ml volume. This aqueous solution was then cooled to 0 °C and adjusted to pH 1-2 with 6.0 M HCl. The resulting solid was then 5 collected by filtration, washed with cold water, and dried to give the title compound (2.5 g, 18%) that was used without further purification.
Method 48
2.3.6-Trichloro-5-methvIpyridine 10 A well powdered mixture of 3-methylpiperidine-2,6-dione (Method 49, 15.0 g, 118
mmol) and PCI5 (155.0 g, 743 mmol) was slowly heated to 150 °C and kept at that temperature for 2 hours. The resulting solution was then cooled to room temperature, and slowly poured onto ice. The resulting precipitate was filtered, washed with cold water, and dried. The resulting precipitate was then recrystallized from a mixture of EtOH-petroleum 15 ether (1 : 8) to give the title compound (11.8 g, 51 %).
Method 49
3-MethvIpiperidine-2.6-dione
A solution of H2SO4 (80ml), acetic acid (500ml) and 2-methylpentanedinitrile (128.0 20 g, 1184 mmol) was stirred at room temperature. An aqueous solution of acetic acid (100 ml in 32 ml water) was then added dropwise. Upon completion of the addition, the reaction was heated to 130 °C for 1 hour. The reaction was then allowed to cool to room temperature and filtered to remove solids, which were washed with acetic acid (100 ml). The filtrate was then concentrated until a residue resulted. This residue was poured into water (0.75 1), and adjusted 25 to pli 5 with Na2C03. The resulting solid was collected by filtration and washed with cold water to give the title compound (101 g, 67%) which was used without further purification.
Method 50
(S)-1 -(3.5-Difluoropyridin-2-vl)ethanamine 30 To a solution of (S)-/er/-butyl-l-(3,5-difluoropyridin-2-yl)ethylcarbamate (Method 51,
2.05 g, 7.94 mmol) in DCM (15 ml) was added HCl/dioxane (15.9 ml, 4 N, 63.5 mmol). The reaction was stirred at room temperature for 3 hours. The solvent was removed and 10 nil of saturated sodium bicarbonate was added. The resulting aqueous solution was extracted with
101749
- Ill -
ether (5 x 100 ml), dried over sodium sulfate and concentrated to give the title compound (1.1 g, 88%) as a pale yellow oil. 'H NMR (400 MHz) 8 8.46 (d, J= 2.0 Hz, IH), 7.85 (m, 1H), 4.23 (q, J — 6.8 Hz, 1H), 1.90 (b, 2H), 1.27 (d, J= 6.8 Hz, 3H). MS: Calcd.: 158; Found: [M+H]+ 159.
Method 51
(SVfe?t-Butyl-l-(3,5-difluoropyridin-2-v0ethvlcarbamate
A solution of (S)-jV-(l-(3,5-difluoropyridin-2-yl)ethyl)acetamide (Method 52, 2.0 g, 9.99 mmol), DMAP (0.244 g, 2.00 mmol), and B0C2O (6.54 g, 30.0 mmol) in THF (20 ml) 10 was stirred at 50 °C for 40 hours. After cooling to room temperature, lithium hydroxide monohydrate (0.671 g, 16.0 mmol) and water (20 ml) were added. The reaction was stirred at room temperature for 18 hours. To which was added ether (100 ml). The organic layer was separated, washed with brine (50 ml) and dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column chromatography (hexane-EtOAc = 5:1) to give 15 the title compound as a colourless oil (2.05 g, 79%). 'H NMR (400 MHz) 5 8.45 (s, 1H)S 7.87 (m, IH), 7.24 (d, J= 7.6 Hz IH), 4.92 (m, IH), 1.34 (s, 9H), 1.32 (d,J=7.2 Hz, 3H). MS: Calcd.: 258; Found: [M+H]+ 259. Enantiomeric excess was determined by HPLC (Chiralpak ADH; 98:2 C02/Me0H), 93.6 % ee.
Method 52
("S)-iV-(T-(3,5-Difluoropyridin-2-yl)ethyl)acetamide
To a solution of A/-(l-(3,5-difluoropyridin-2-yl)vinyl)acetamide (Method 53, 2.2 g, 11.1 mmol) in MeOH (20 ml) under N2 was added (+)-l,2-bis((2S, 5S)-2,5-dimethyl phospholano)benzene (cyclooctadiene)rhodium(I)trifluoromethanesulfonate (0.074 g, 0.111 25 mmol). The solution was transferred to a high-pressure bomb and charged 150 psi H2. The reaction stirred at room temperature and maintained inside pressure between 120-150 psi for 24 hours. The solvent was removed and the resulted residue was purified by column chromatography (EtOAc) to give the title compound as a white solid (2.0 g, 90%). 'H NMR (400 MHz) 8 8.47 (d,J=2.4 Hz, IH), 8.34 (d, J= 7.2 Hz, IH), 7.89 (m, IH), 5.21 (m, IH), 30 1.81 (s, 3H), 1.34 (d, J= 6.8 Hz, 3H). MS: Calcd.: 200; Found: [M+H]+201.
101749
Method 53
N-( 1 -(3.5-Difluoropvridin-2-yl)vinyl)acetamide
To a mixture of (Z)-l-(3,5-difluoropyridin-2-yl)ethanone oxime (Method 54, 12.5 g, 72.6 mmol), acetic anhydride (54.8 ml, 581 mmol), and iron powder (32.4 g, 581 mmol) in 5 DMF (100 ml) was added TMSC1 (0.01 ml, 0.073 mmol). The reaction mixture was stirred at room temperature for 18 hours, then diluted with ether (300 ml) and filtered through a short pad of celite. The filtrate was concentrated and the residue was partitioned between 200 ml of EtOAc and 50 ml of saturated sodium bicarbonate. The organic layer was separated and dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column 10 chromatography (hexane-EtOAc = 2:1) to give the title compound as a white solid (2.70 g, 19%). 'H NMR (400 MHz) 5 9.55 (s, 1H), 8.51 (d, J= 2.0 Hz, IH), 7.97 (m, IH), 5.87 (s, 1H), 5.14 (s, 1H), 1.99 (s, 3H). MS: Calcd.: 198; Found: [M+H]+ 199.
Method 54
(Z)-l-(3,5-Difluoropvridin-2-yl)ethanone oxime
To a solution of 3,5-difluoropicolinonitrile (10.0 g, 71.4 mmol) in THF (200 ml) was added methylmagnesium bromide (61.2 ml, 85.7 mmol) in THF solution at 0 °C. The reaction was stirred at room temperature for 1.5 hours. Saturated sodium bicarbonate solution (50 ml) was added, extracted with ether (100 ml), and dried over sodium sulfate. The solvent was removed. The residue (11.2 g, 71.28 mmol), hydroxylamine hydrochloride (9.907 g, 142.6 mmol) and sodium acetate (11.70 g, 142.6 mmol) in EtOH (100 ml) and water (50 ml) was heated at reflux for 3 hours. The solvent was removed and diluted with 50 ml of saturated sodium bicarbonate and extracted with EtOAc (2 x 200 ml). After dried over sodium sulfate, the solvent was removed and the title compound was used directly in next step without purification.
Method 55
(iSr)-l-('5-Fluoropyrimidin-2-yl)ethanamine
To a solution of (iS)-ter/-butyl-l-(5-fluoropyrimidin-2-yl)ethylcarbaniate (Method 56, 30 0.21 g, 0.87 mmol) in DCM (5 ml) was added HCl (1.3 ml, 5.2 mmol) in dioxane. The reaction was stirred at room temperature for 3 hours. The solvent was removed give (,S)-l-(5-fluoropyrimidin-2-yl)ethanamine as FIC1 salt as white solid (quantitative). MS: Calcd.: 141; Found: [M+H]+ 142.
101749
Method 56
(iSyfert-Butvl-l-(5-fluoropvrimidin-2-vl)ethyIcarbamate
(5)-jV-(l-(5-f]uoropyrimidin-2-yl)ethyl)acetamide (Method 57, 0.20 g, 1.09 mmol), DMAP (0.027 g, 0.22 mmol) and B0C2O (0.60 g, 2.73 mmol) in THF (10 ml) was stirred at 50 5 °C for 40 hours. After cooled to room temperature, lithium hydroxide monohydrate (0.094 g, 2.24 mmol) and water (10 ml) was added. The reaction was stirred at room temperature for 9 hours. Ether (30 ml) was added, organic layer was separated, washed with, brine (20 ml) and dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column chromatography (Hex-EtOAc=5:l) to give the title compound as a pale yellow oil 10 (0.21 g, 80%). !H NMR (400 MFIz) 8.84 (s, 2H), 7.24 (d,J= 7.6 Hz, IH), 4.74 (m, IH), 1.35 (s, 12H). MS: Calcd.: 241; Found: [M+H]+ 242.
Method 57
(^)-Af-n-('5-Fluoropvrimidin-2-yl)ethyl)acetamide 15 iV-(l-(5-Fluoropyrimidin-2-yl)vinyl)acetamide (Method 58, 0.10 g, 0.55 mmol) in
MeOH (5 ml) under N2 was added (+)-l,2-bis((2S, 55)-2,5-diethylphospholano)benzene (cyclooctadiene)rhodium(I)trifluoromethanesulfonate (0.04 g, 0.0055 mmol). The solution was transferred to a high pressure bomb and charged 150 psi H2. The reaction stirred at room temperature for 4 hours. The solvent was removed and the resulted residue was purified by 20 column chromatography (EtOAc) to give the title compound as a white solid (0.096 g, 95%). fH NMR (400 MHz) 8.84 (d, J= 0.8 Hz, 2H), 8.34 (d, J= 7.6 Hz, IH), 5.00 (m, IH), 1.84 (s, 3H), 1.37 (d, 6.8 Hz, 3H). MS: Calcd.: 183; Found: [M+FI]+ 184. Enantiomeric excess - determined by HPLC (Chiralpak IA; 95:5 C02/Me0H), >99% ee.
Method 58
AMl-f5-Fluoropyrimidin-2-vj)vinvl)acetamide
-Fluoropyrimidine-2-carbonitrile (Method 59, 1.0 g, 8.1 mmol) in THF (10 ml) was added a solution of MeMgBr (3.3 ml, 9.75 mmol) in ether drop wise at 0 °C. After addition, the reaction was wanned to room temperature, stirred at room temperature for 1 hour and then 30 diluted with DCM (10 ml). Acetic anhydride (1.23 ml, 13.0 mmol) was added in one portion. The reaction was stirred at room temperature for 1 hour and 40 °C for 1 hour. Saturated sodium bicarbonate solution (10 ml) was added and extracted with EtOAc (2x20 ml). The combined organic was dried over sodium sulfate. After removal of solvent, the resulted
101749
residue was purified by column chromatography (hexane-EtOAc ~ 2.5 : 1) to give the title compound as a white solid (0.38 g, 26%). lH NMR (400 MHz) 9.34 (s, IH), 8.95 (s, 2H), 6.25 (s, IH), 6.03 (s, 1H), 2.11 (s, 3H). MS: Calcd.: 181; Found: [M+H]+ 182.
Method 59
-Fluoropyrimidine-2-carbonitrile
A 10 ml microwave vial was charged with 2-chloro-5-fluoropyrimidine (2.0 g, 15.09 mmol), Pd2(dba)3 (0.549 g, 0.6 mmol), DPPF (0.67 g, 1.21 mmol), zinc cyanide (1.15 g, 9.81 mmol), and zinc dust (0.237 mg, 3.62 mmol). The flask was evacuated and backfilled with N2, 10 and anhydrous dimethylacetamide. The vial was mounted onto a Personal Chemistry microwave reactor and heated at 100 °C for 10 hours. The reaction mixture was diluted with EtOAc and then washed with brine three times. The organic layer was obtained and evaporated to dryness. The dried residue was purified by silica gel chromatography (By ISCO Combiflash with gradient EtOAc and hexanes) to afford the title compound as a creamy solid 15 (1.50 g, 80%). GC-MS: 123 (M); *H NMR (CDC13) 8 8.80 (s, 2H).
Method 60
2.5-Dichloro-6-r(5-methyl-l/f-pvrazol-3-vl)amino]nicotinonitrile
To a25-ml, round-bottom flask, was added 2,5,6-trichloronicotinonitri.le (Method 44, 20 1 g, 4.8 mmol), 5-methyl-l//-pyrazol-3-amine (466 mg, 4.8 mmol), DIEA (1.1 ml, 6.3 mmol), and EtOH (5 ml) and set to heat at 55 °C for 16 hours. The resulting mixture was then purified by silica gel chromatography (Biotage Horizon System) using 25-75% EtOAc/hexanes to give ■ 770 mg-of the title compound. 'HNMR: 12.36 (s, IH) 9.68 (s, IH) 8.39 (s, IH) 6.32 (s, IH) 2.29 (s, 3H). MS: Calcd.: 268; Found: [M+H]+ 267/269.
Method 61
N-\5-( 1 -Aminoethvl)-2-fluorophenyllmethanesulfonamide
N- {2-Fluoro-5 -[(1 Z)-yV-hydroxyethanimidoyl]phenyl} methanesulfonamide (Method 62, 200 mg, 812 pmol) was dissolved in 15 ml THF, to which was added Raney nickel 2800 30 slurry in water (200 ul). The mixture was charged with nitrogen and stirred over 1 atm of hydrogen. After 1 hour, MeOH (4 ml) was added and the reaction mixture was stirred overnight. The following morning the solution was filtered through celite, and the cake washed with MeOH, and the organic layer was concentrated to a yellow solid which was
101749
dried under high vacuum (181 mg, 96%). !H NMR: 1.26 (d, 3 H, CH3), 2.92 (s, 3 H, SOiMe), 3.33 (HOD), 4.04 (q, 1 H, CH), 5.70 (br, 2 H, NH2); 7.06-7.16 (m, 2 H, Ar), 7.35 (m, 1 H, Ar). LC/MS: 0.79 min, 231.08 (M-H)".
Method 62
A^-{2-Fluoro-5-[(lZ)-A^-hvdroxyethanimidoyllphenvl}methanesulfonamide
In a 100 ml Round bottom flask was added. N-(5-acetyl-2-fluorophenyl)methanesulfonamide (Method 63, 1.41 g, 6.10 mmol), hydroxylamine hydrochloride (847 mg, 12.2 mmol), sodium acetate (1.25 g, 15.24 mmol) and 30 ml water. 10 The mixture was heated to 50°C and then 10 ml EtOH was added to dissolve the contents. The mixture was continued heating at 50 °C for 1 hour, then fitted with a reflux condenser and refluxed at 80 °C for 2 hours, (note: the solution turns homogeneous at 80°C). The solution was cooled to room temperature (note: crystals develop), rotovapped to remove traces of EtOH, cooled on an ice bath and filtered off-white crystals. The crystalline product 15 was washed with ice cold water and air dried to obtain the white crystalline product (1.47 g, 98%.) TLC (1:1 Hexanes:EtOAc): Rf0.50. 'H NMR: 2.12 (s, 3 H, Me), 3.02 (s, 3 H, S02Me), 3.32 (HOD), 7.29 (m, 1 H, Ar), 7.48 (m, 1 H, Ar), 7.68 (m, 1 H, Ar), 9.67 (s, 1 H, NH), 11.31 (s, 1 H, OH). LC/MS: 1.70 min, 247.04 (M+l)+.
Method 63
N-(5-Acetvl-2-fluorophenyl)methanesulfonamide
3-Amino-4-fluoroacetophenone (Method 64, 1.00 g, 6.53 mmol) and pyridine (503 pi, 6.53 mmol) were stirred in 10 ml DCM over a blanket of nitrogen at 0°C. Methanesulfonylchloride (505 pi, 6.53 mmol) was added dropwise and the reaction was 25 stirred at 0°C for 5 minutes and warmed to room temperature and stirred for 3 hours.
Quenched with 30 ml IN HCl, and extracted with 30 ml DCM. Washed organic layer with Brine, dried over Na2SG4 and concentrated to orange oil, and dried under high vacuum. Yellow solid/crystals develop which were triturated with hexanes, redissolved in DCM and evaporated and dried under high vacuum to obtain an off-white/yellow solid (1.42 g, 94%.) 30 TLC (1:1 Hexanes:EtOAc): Rf 0.46. SH NMR (CDCI3): 5 2.60 (s, 3 H, COMe), 3.08 (s, 3 H, S02Me), 6.56 (br, 1 H, NH), 7.23 (dd, 1 H, Ar), 7.81 (m, 1 H, Ar), 8.16 (m, 1 H, Ar). LC/MS: 1.66 min, 230.08 (M-l)~
101749
Method 64
3-Amino-4-fluoroacetophenone
In a 250 ml round bottom flask was added 3-nitro-4-FIuoroacetophenone (5.00 g, 27.3 mmol) and HCl (12M, 13ml.) The solution was cooled to 0°C on an ice bath, and SnClh (15.5 5 g, 81.9 mmol) dissolved in 20 ml of water, was added dropwise over a 15 minute period. (Note: The reference material indicates the reaction is exothermic after 1 equivalent addition of Tin Chloride.) After complete addition the reaction mixture was stirred at 0°C for 10 min, warmed to room temp, brought to reflux for 15 minutes, cooled back to room temp and stirred for 2 hours. The mixture was poured over ice (150 g) and adjusted to pH 12 with 50% NaOH 10 at 0°C. The resulting yellow emulsion was extracted with ether (2x150 ml), washed with brine (1x30 ml), dried over sodium sulfate and concentrated to a yellow solid. The solid was triturated with hexanes and dried to obtain a yellow solid (3.61 g, 86%). TLC (1:1 Flexanes:EtOAc): Rf 0.63. !H NMR (CDC13): 5 7.44 (m, 1 H, Ar), 7.34 (m, 1 H, Ar), 7.04 (m, 1 H, Ar), 4.32 (br, 2 H, NH), 2.54 (s, 3 H, Me). LC/MS 1.67 min, 154.07 (M+l)+
Method 65
l-(6-Fluoropyridin-3-yl)ethanone
To a cold solution (-78 °C) of 6-fluoro-ALmethoxy-ALmethylnicotinamide (Method 38,
7 9 ft mmnl^ in TT-TT^ (\ 'Jfl m 1 "l wac maanAOinm KmmiHp i-nl
' s iiiinvi y 111 j.xj.x 1- —' v AAiiy*, n niv *.a a j j. iiiuc.iivji laj.j. a l/a vjnina\- \j uj,A} ^ illlllVlj
3M solution in ether) dropwise. The cooling bath was removed and reaction mixture was allowed to warm to room temperature and stir for 2 hours. The reaction was quenched with 3N HCl solution, layers were cut, and organic layer was dried over Na2S04, filtered, and concentrated in vacuo to afford 3.8 g (70% yield) of the title compound. ]H NMR (CDCI3) 5 8.80 (s, 1 H) 8.29 - 8.43 (m, 1 H) 6.98 - 7.06 (m, 1 H) 2.62 (s, 3 H).
Method 66
N- F5-( 1 -Aminoethyl)-2-fluorophenyl"| acetamide
To a round, bottom flask was added A^-{2-fluoro-5-[(lZ)-iV-hydroxyethanimidoyl] phenyl}acetamide (Method 67, 715 mg, 3.4 mmol) and AcOH (0.5 ml) in EtOH (20 ml), followed by the addition of Palladium on carbon (146 mg, 10wt%) under N2 atmosphere. Once the catalyst was added, the system was evacuated and purged with hydrogen (atmospheric pressure). This process was performed several times to ensure complete saturation of hydrogen to the system. The reaction was then allowed to stir for 16 hours at
101749
room temperature. The heterogeneous mixture was then filtered over a pad of Celite and the filtrate was concentrated in vacuo to give quantitative yield of the title compound. !H NMR: 9.67 (s, 1 H) 7.80 (d, 7= 7.54 Hz, 1 H) 7.07 - 7.19 (m, 2 H) 4.00 (q, J= 6.28 Hz, 1 H) 2.06 (s, 3 H) 1.15 - 1.30 (m, 3 H).
Method 67
-/V-{2-Fluoro-5-rnZ)-7V-hvdroxvethanimidoynphenyl}acetamide
To a round, bottom flask was added N-(5-ace ty 1 -2-.11 uoropheny 1)acetamide (Method 68, 1.17 g, 6 mmol), hydroxyl amine hydrochloride salt (834 mg, 12 mmol), and NaOAc (1.2 10 g, 15 mmol) in water:EtOH solution (20 ml, 3:1). The resulting mixture was then set to heat at 50 °C for 1 hour. The reaction was allowed to cool to room temperature and partitioned with EtOAc. The layers were cut and the organic layer was then dried over Na2S04, filtered and concentrated in vacuo. The crude residue obtained was then purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 5-50% EtOAc in DCM 15 to give 815 mg of the title compound (60% overall yield, 2 steps). 'H NMR: 11.22 (s, 1 H) 9.75 (s, 1 H) 8.22 (dd, .7=7.54, 1.88 Hz, 1 H) 7.30 - 7.46 (m, 1 H) 7.24 (dd, 7=10.93, 8.67 Hz, 1 H) 1.98 - 2.18 (m, 6 H).
Method 68
JV-(5-Acetyl-2-fluorophenyl)acetamide
To a round, bottom flask was added 3-amino-4-fluoroacetophenone (Method 64, 1 g, 6.54 mmol) in DMF (15 ml), followed by the addition of acetyl chloride (0.56 ml, 7.84 mmol) and DIEA (2.3 ml, 13.08 mmol). The solution was set to stir at room temperature. The reaction appeared complete by TLC after 30 min. The reaction was then quenched with water 25 and partitioned with EtOAc. The layers were cut, followed by an additional wash of the aqueous with EtOAc. The combined organic layers were dried over Na2S04, filtered and concentrated in vacuo. The crude residue obtained (1.17 g), was used directly in the next step. ]H NMR (CDCI3) 5 8.94 (d5 J=7.54 Hz, 1 H) 7.71 (d, 1 H) 7.43 (s, 1 H) 7.15 (s, 1 H) 2.56 -2.60 (m, 3 H) 2.21 - 2.28 (m, 3 H).
101749
Method 69
A^5-(l-Aminoethvl)-2-fluorophenyncyclopropanecarboxamide
To a round, bottom flask was added JV-{2-fluoro-5-[(lZ)-Ar-hydroxyethanimidoyl]phenyl}cyclopropanecarboxamide (Method 70, 458 mg, 1.94 mmol) 5 and HOAc (1 ml) in EtOH (25 ml), followed by the addition of Palladium on carbon (100 mg, 10wt%) under N2 atmosphere. Once the catalyst was added, the system was evacuated and purged with hydrogen (atmospheric pressure). This process was performed several times to ensure complete saturation of hydrogen to the system. The reaction was then allowed to stir for 16 hours at room temperature. The heterogenous mixture was then filtered over a pad of 10 celite and the filtrate was concentrated in vacuo to give quantitative yield of the title compound. *HNMR: 9.99 (s, 1 H) 7.85 (d, J=8.29 Hz, 1 H) 7.17 (s, .7=8.29 Hz, 2 H) 4.03 (d, J=6.03 Hz, 1 H) 1.90 - 2.04 (m, 1 H) 1.26 (d, J=6.78 Hz, 3 H) 0.78 (d, .7=6.03 Hz, 4 H)
Method 70
AM2-Fhaoro-5-[YlZ)-A^-hvdroxyethanimidovllphenyl}cyclopropanecarboxamide To a round, bottom flask was added A-(5-acetyl-2-fluorophenyl)cyclopropanecarboxamide (Method 71, 458 mg, 2.07 mmol), hydroxyl amine hydrochloride salt (288 mg, 4.14 mmol), and NaOAc (424 mg, 5.17 mmol) in water-EtOH solution (7 ml, 3:1). The reaction mixture was set to heat at 50 °C for 1 hour. As the reaction 20 reached desired temperature, no dissolution was observed, thus more EtOH (7 ml) was added for dissolution to occur. The reaction was complete after 1 hour and concentrated in vacuo. The title compound (458 mg, 94% yield) was used directly in next step. fH NMR: 11.32 (s, 1 H) 10.10 (s, 1 H) 8.19 (d, .7=6.03 Hz, 1 H) 7.30 - 7.44 (m, 1 H) 7.23 (s, 1 H) 2.09 (s, 3 H) 2.01 (s, 1 H) 0.79 (s, 4 H).
Method 71
A^-(5-Acetyl-2-fluoi'ophenyl)cyclopropanecarboxamide
To a round, bottom flask was added 3-amino-4-fluoroacetophenone (Method 64, 1 g, 6.54 mmol), cyclopropyl carboxylic acid (0.62 ml, 7.84 mmol), HATu (2.5 g (6.57 mmol), 30 and DIEA (2.3 ml, 13.08 mmol) in DMF (15 ml). The reaction mixture was allowed to stir at room temperature for 16 hours. The reaction mixture was quenched with water and partitioned with EtOAc. The layers were cut, followed by an additional wash of the aqueous with EtOAc. The combined organic layers were dried over NajSO^ filtered and concentrated
101749
in vacuo. The crude residue obtained was then purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 5-15% EtOAc in DCM to give 458 mg of the title compound (32% isolated yield). lH NMR: 10.16 (s, 1 H) 8.53 (dd, .7=7.91, 2.26 Hz, 1 H) 7.67 - 7.82 (m, 1 H) 7.40 (dd, 7=10.55, 8.67 Hz, 1 H) 2.54 (s, 3 H) 1.95 - 2.09 (m, 1 H) 0.78 - 0.88 5 (m, 4 H).
Method 72
1-(5-Fluoropyrimidin-2-vQethanamine
A round-bottom flask containing 2-(l-azidoethyl)-5-fluoropyrimidine (Method 73, 10 0.60 g, 3.59 mmol) was charged with 10% Pd/C (0.191 g) and was evacuated and backfilled with H2 via a filled balloon. MeOH (10 ml) was added, and the mixture was allowed to stir at room temperature for 3 hours. The mixture was filtered through a plug of diatomaceous earth, which was subsequently washed well with MeOH. The filtrates were concentrated to give the title compound as a pale yellow oil (0.50 g, 99%). ]H NMR (CDCI3) 5 8.60 (s, 2H), 4.65 (br s 15 2H), 4.10 (m, IH), 1.20 (d, 3H).
Method 73
2-( 1 -Azidoethyl)-5-fluoropvrimidine
A round-bottom flask containing l-(5-fluoropyrimidin-2-yl)ethanol (Method 74, 0.79 20 g, 5.55 mmol) was charged with triethylamine (0.67 g, 6.66 mmol) and anhydrous DCM (10 ml). The solution was cooled to 0 °C, and methanesulfonyl chloride (0.70 g, 4.1 mmol) was added dropwise. The resulting mixture was allowed to stir at room temperature for 2 hours, at which point the volatile components were removed using a rotary evaporator. The residue was dissolved in DMF (15 ml) and treated with sodium azide (0.72 g, 11.1 mmol). The resulting 25 mixture was stirred at room temperature for 60 hours. It was then partitioned between EtOAc and brine. The organic layer was obtained, dried (Na2S04), and evaporated to dryness. The crude material was purified by silica gel chromatography (by 1SCO Combiflash with gradient EtOAc and hexanes) to afford the title compound as a colourless oil (0.60 g, 65% yield over two steps). GC-MS, 167 (M), 138 (M-N2), 125 (M-N3); 'HNMR (CDC13) 8 8.60 (s, 2H), 4.60 30 (m, IH), 1.65 (d, 3H).
101749
Method 74
l-(5-Fluoropyrimidin-2-vl)ethanol l-(5-Fluoropyrimidin-2-yl)ethanone (Method 75, 0.77 g) was dissolved in MeOH (15 ml), and the solution was cooled to 0 °C. NaBH4 (0.210 g, 5.55 mmol) was added. The 5 mixture was stirred at room temperature for 1 hour and then partitioned between EtOAc and H2O. The organic extract was washed with brine, dried (Na?S04.), filtered, and concentrated to give the title compound as a yellowish oil (0.79 g, 99%). 'H NMR (CDCI3) 6 8.65 (s, 2H), 5.20 (m, IH), 4.00 (br s, 1H), 1.80 (d, 3H).
Method 75
l-(5-Fluoropvrimidin-2-vOethanone
A round-bottom-flask containing 5-fluoropyrimidine-2-carbonitrile (Method 59, 1.50 g, 12.19 mmol) was charged with anhydrous THF (30 ml) under N2. The solution was cooled to 0 °C, and a solution of MeMgBr (4.90 ml of a 3.0 M solution in ether, 14.62 mmol) was 15 added dropwise. After 2 hours at 0 °C, the reaction mixture was quenched with ice water and extracted with EtOAc. The organic extract was washed with brine, dried over Na2S04, and evaporated to dryness to give the title compound as an oil (0.778 g, yield 46%). GC-MS, 140 (M); ]H NMR (CDC13) 5 8.65 (s, 2H), 2.65 (s, 2H).
Method 76
l-('6-Fluoropyridin-3-yl)ethanamine
To a slurry of Raney Nickel in EtOH solution (75 ml), under inert atmosphere, was added l-(6-fluoropyridin-3-yl)ethanone oxime (Method 77, 2.3 g, 14.9 mmol). The system was purged with hydrogen and evacuated several times to ensure complete saturation with 25 hydrogen. The reaction, after 2 hours stirring at room temperature, was filtered over celite and filtrate collected was concentrated in vacuo to give 2 g (95% isolated yield) of the title compound. !H NMR: 8.16 (s, 1 H) 7.97 (t, ,7=8.29 Hz, 1 H) 7.09 (dd, J=8.29, 3.01 Hz, 1 H) 4.03 (q, ,7=6.78 Hz, 1 H) 1.23 (d, 7=6.03 Hz, 3 H).
Method 77
1 -(6-Fluoropyridin-3-yl)ethanone oxime
To a 200-ml, round bottom flask was added, l-(6-fiuoropyridin-3-yi)ethanone (Method 65, 2.5 g, 17.9 mmol), hydroxylamine hydrochloride (2.5 g, 35.8 mmol), and NaOAc
101749
(3.7 g, 44.8 mmol) in a solution of water-EtOH (65 ml, 3.3:1). The resulting mixture was heated to 50 °C for 1 hour. The reaction was then allowed to cool to room temperature, partitioned with EtOAc, layers were cut, and organic layer was dried over Na2S04, filtered, and concentrated in vacuo to afford the title compound in quantitative yield. 'H NMR: 11.49 5 (s, 1 H) 8.47 (s, 1 H) 8.17 - 8.27 (m, 1 H) 7.21 (dd, J=8.29, 3.01 Hz, 1 H) 2.17 (s, 3 H).
Method 78
tert-Butyl 5-amino-3-isopropoxv-lH-pyrazole-l-carboxylate
A solution of 5-isopropoxy-lH-pyrazol-3-amine (3.5g, 24.8mmol) in DCM (100ml) 10 was prepared at room temperature. A 4.5M aqueous KOH solution (11.1 g, 198mmol) was added dropwise, followed by the addition of di-tert-butyl dicarbonate (5.68g, 26mmol) in DCM (20ml). The resulting reaction was then stirred vigorously for 30 hours, at which point water (200ml) was added and the layers were allowed to separate. The organic fraction was separated, dried (Na2S04), filtered, and then concentrated. The resulting oil was purified by 15 column chromatography (100:1 DCM:MeOH) to give the title compound (5.4g, 90%). MS: Calcd.: 241; Found: [M+H]+ 242.
Method 79
tert-Butyl 5-f5-cvano-3.6-difluoropvridin-2-ylamino>-3-isoproTX)xy-lH-pvrazole-l-20 carboxylate
A solution of tert-butyl 5-amino-3-isopropoxy-lH-pyrazole-l-carboxylate (Method 78, 4.0g, 16.4mmol) in THF (45ml) was cooled to -78°C. A 1.0M THF solution of LiHMDS (2.61 g, 15.6mmol) was added dropwise and the reaction was stirred at -78°C for 30 minutes. A -78°C solution of 2,5,6-trifluoronicotinonitrile (1.3g, 8.2mmoI) in THF (20ml) was added 25 dropwise via cannula to the above anion solution. Upon completion of the addition, the resulting reaction was allowed to stir for 10 minutes at -78°C, and was then quenched with water (100ml). The reaction was allowed to warm to room temperature, extracted with DCM (3 x 100ml), dried (Na2S04), filtered, and then concentrated to give the title compound (95% conversion by LCMS) which was used without further purification. MS: Calcd.: 379; Found: 30 [M+H]+ 380.
101749
Utility
The compounds of the present invention have utility for the treatment of cancer by inhibiting the tyrosine kinases, particularly the Trks and more particularly Trk A and B. Methods of treatment target tyrosine kinase activity, particularly the Trk activity and more 5 particularly Trk A and B activity, which is involved in a variety of cancer related processes. Thus, inhibitors of tyrosine kinase, particularly the Trks and more particularly Trk A and B, are expected to be active against neoplastic disease such as carcinoma of the breast, ovary, lung, colon, prostate or other tissues, as well as leukemias and lymphomas, tumours of the central and peripheral nervous system, and other tumour types such as melanoma, 10 fibrosarcoma and osteosarcoma. Tyrosine kinase inhibitors, particularly the Trk inhibitors and more particularly Trk A and B inhibitors are also expected to be useful for the treatment other proliferative diseases including but not limited to autoimmune, inflammatory, neurological, and cardiovascular diseases.
In addition, the compounds of the invention are expected to be of value in the 15 treatment or prophylaxis of cancers selected with up regulated of constitutively activated Trk kinases, including but not limited to, oncogenic rearrangements leading to ETV6-TrkC fusions, TRP-TrkA fusions proteins, AML-ETO (t8;21), autocrine or paracrine signalling leading to elevated serum levels of NGF, BDNF, neurotropins or tumours with constitutively active Trk associated with disease aggressiveness, tumour growth and proliferation or survival 20 signalling.
Compounds of the present invention have been shown to inhibit tyrosine kinases, particularly the Trks and more particularly Trk A and B, as determined by the Trk A Assay described herein. ...
Compounds provided by this invention should also be useful as standards and reagents 25 in determining the ability of a potential pharmaceutical to inhibit tyrosine kinases, particularly the Trks and more particularly Trk A and B. These would be provided in commercial kits comprising a compound of this invention Trk A Assay Format
Trk A kinase activity was measured for its ability to phosphorylate synthetic tyrosine 30 residues within a generic polypeptide substrate using an Amplified Luminescent Proximity Assay (Alphascreen) technology (PerkinElmer, 549 Albany Street, Boston, MA).
To measure Trk A kinase activity, the intracellular domain of a HIS-tagged human Trk A kinase (amino acids 442-796 of Trk A, Swiss-Prot Primary Accession Number P04629)
Claims (29)
1. A compound of formula (I): 5 (I) wherein: R1 and R2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^alkyl, C2-6alkenyl, C2-6alkynyl, C^alkoxy, Ci^alkanoyl, Ci^alkanoyloxy, iV-(Ci-6alkyl)amino, 10 JVjjV-tCi-ealkyl^amino, Ci^alkanoylamino, jV-(Ci.6alkyl)carbamoyl, A^Af-(C].(;alkyl)2carbamoyl, Ci^alkylS(0)a wherein a is 0 to 2, Ci^alkoxycarbonyl, A/_/T\ ,-Qllrvf ^ctiltVhiamrwl Al ..Qll/vlcnlrvhrHriwlcirrii-rir* navKn r» \ / r* 1 rl 1 2 or heterocyclyl; wherein R and R independently of each other may be optionally substituted on carbon by one or more R6; and wherein if said heterocyclyl contains an -NH- moiety that 15 nitrogen may be optionally substituted by a group selected from R7; one of X1, X2, X3 and X4 is =N-, the other three are independently selected from CR8-, =CR9- and =CR10-; R3 is hydrogen or optionally substituted Chalky!; wherein said optional substituents are selected from one or more R11; 20 R4 and R34 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^alkyl, C2-6alkenyI, C2-6alkynyl, Cf-ealkoxy, Ci-galkanoyl, Ci^alkanoyloxy, A^-(C].f,alkyl)amino, N,N-(C]-6alkyl)2amino, C i^alkanoyl amino, N-(Ci .galkyljcarbamoyl, iV,jV-(C].6alkyl)2carbamoyl, Ci-6alkylS(0)a wherein a is 0 to 2, C]^alkoxycarbonyl, 25 AL(Ci-6alkyl)sulphamoyl, A^jV-(Ci-6alkyl)2sulphamoyl, Ci^alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R4 and Rj4 may be independently optionally substituted on carbon by 101749 - 125 - one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13; A is a direct bond or Ci^alkylene; wherein said C^alkylene may be optionally substituted by one or more R!4; 5 Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from Rlr'; R""' is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Cj^alkyl, C'j.f.alkenyl. C2-6alkynyl, Ci-6alkoxy, Cj-salkanoyl, Cj^aikanoyloxy, ^-(Ci^alky^amino, A^A^Ci-ealkyl^amino, 10 Ci-galkanoylamino, jV-(Ci.6alkyl)carbamoyl, A^ A'-tCi-ealkyl^carbamoyl, C]-6alkylS(0)a wherein a is 0 to 2, Cj.salkoxycarbonyl, A^Ci^alkyl) sulphamoyl, 37 3 8 A7,A-(C)-(,alkyl )?sulphamoy 1. Ci-ealkylsulphonylamino, carbocyclyl-R - or heterocyclyl-R -; wherein R5 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group 17 15 selected from R ; n is 0, 1, 2 or 3; wherein the values of R5 may be the same or different; R8, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, C^alkoxy, Cj.fjalkanoyl, Ci^alkanoyloxy, A^Ci-ealky^amino, 20 A^AZ-fCi-fialkyl^amino, Cj^alkanoylamino, A^Ci-ealky^carbamoyl, Af,A^-(Ci-6alkyl)2carbamoyl, Ci_6alkylS(0)a wherein a is 0 to 2, Ci^alkoxycarbonyl, A^-(C|.6alkyl)sulphainoyl, Ar,A^-(Ci-6alkyl)2Sulphamoyl, Ci.galkylsulphonylamino, carbocyclyl-R2:>- or heterocyclyl-R26-; wherein R8, R9 and R10 independently of each other 18 may be optionally substituted on carbon by one or more R ; and wherein if said heterocyclyl 25 contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R'9; R6, Rn, R12, Ru, R16 and R18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci_,jalkyl, C2-6alkenyl, C2-6alkynyl, C].6alkoxy, C]_6alkanoyl, Ci.galkanoyloxy, A^Ci-galkyOamino, 30 A^A^Ci-talkyl^amino, Ci^alkanoylamino, Ar-(Ci.6alkyI)carbamoyl, A^A^Ci-calkyl^carbamoyl, C|.6alkylS(0)a wherein a is 0 to 2, Ci^alkoxycarbonyl, N-(C i .f,alkyl)sulphamoy 1, N,N-(C i .f,alkyl)2Sulphamoyl, C ] .salkylsulphonylamino, carbocyclyl-R27- or heterocyclyl-R28-; wherein R6, Rn, R12, R14, R16 and R,s independently of 101749 -126 - each other may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group 9 I selected from R ; R7, R13, Rl3, R17, R19 and R21 are independently selected from C]_6alkyl, Cuealkanoyl, 5 Ci-ealkylsulphonyl, C \ .^alk o x y carbon yl. carbamoyl, A,r-(C ] _6al k y 1 jcarbam oy 1, /V, ;V-((] [-^alkyOcarbarnoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R7, R13, R15, R17, R19 and R2i independently of each other may be optionally substituted on carbon by one or more R22; 20 22 RiU and R are independently selected from halo, nitro, cyano, hydroxy, 10 trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-galkyl, C2-6alkenyl, C2-6alkynyl, Cj-ealkoxy, Ci-6aIkanoyl, C]-6alkanoyloxy, A^Ci^alkyl)amino, iV,A'T-(Ci_6alkyl)2amino, Ci^alkanoylamino, Ar-(Ci-salky 1)carbamoyl, A/",7V-(Ci-6alkyl)2carbamoyl, Ci-<;alkylS(0)a wherein a is 0 to 2, Ci^alkoxycarbonyl, A^-fC i .6alkyl)sulphamoy 1, A', 7V-( C i _6al ky 1)2 su 1 pham oy I, C [ -salky 1 sulphony lamino, 15 Ci_(;alkylsuiphonyl-Af-(Ci-6alkyl)amino, carbocyclyl-R''3- or heterocyclyl-R36-; wherein R20 22 and R independently of each other may be optionally substituted on carbon by one or more R23; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R24; R2', R26, R27, R28, R35, R36, R37 and R38 are independently selected from a direct 20 bond, -0-, -N(R29)-, -C(O)-, -N(R30)C(O)-, -C(0)N(R31)-, -S(0)s-, -NH=CH-, -S02N(R32)- or -N(R33)S02-; wherein R29, R30, R31, R32 and R33 are independently selected from hydrogen or Cj-galkyl and s is 0-2; R23 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, 25 acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, A^-methyl-A'-ethylamino, acetylamino, TV-methyl carbamoyl, A/-ethyIcarbamoyl, A^A^-dimethylcarbamoyl, A^jV-diethylcarbamoyl, A^-methyl-A^-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, A^-methylsulphamoyl, 7V-ethylsulphamoyl, A^ A^-dimetliylsuIphamoyl, A^.A^-diethylsulphamoyl, 30 Af-methyl-A^-ethylsulphamoyl or phenyl; and R24 is selected from Ci.6alkyl, C].6alkanoyL Ci^alkylsulphonyl, Cuealkoxycarbonyl, carbamoyl, Af-(Ci_6alkyI)carbamoyl, A^A^Ci-ealky^carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; 101749 - 127- or a pharmaceutically acceptable salt thereof.
2. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 wherein R1 is Ci-galkyl, Ci^alkoxy and cyclopropyl. 5
3. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed ■j in either claim 1 or claim 2 wherein R is hydrogen.
4. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed 10 in any one of claims 1-3 wherein X3 or X4 is =N-, X1 and X2 and the other of XJ and X4are independently selected from =CR8-, =CR9- and =CR10-.
5. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 -4 wherein R3 is hydrogen. 15
6. A compound of formula (1), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 -5 wherein R4 and R34 are independently selected from hydrogen or C]-6alkyl; wherein R4 and R34 may be independently optionally substituted on carbon by one or more R12; wherein R12 is selected from hydroxy. 20
7. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 wherein A is a direct bond.
8. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed 25 in any one of claims 1-7 wherein Ring C is phenyl, pyridyl or pyrimidinyl.
9. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-8 wherein R? is selected from halo, Cj-ealkanoylamino, ^7 ^7 *» i ""i I Ci^alkylsulphonylamino or carbocyclyl-R -; wherein R is -C(0)N(RJ )-; wherein RJ is 30 hydrogen. 101749 -128 -
10. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-9 wherein n is 1 or 2; wherein the values of R3 may be the same or different. 5
11. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-10 wherein Rs, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, amino, carboxy, carbamoyl, Ci^alkyl, C].^alkanoyl. A'-(C j_6alkyl)amino or carbocyclyl-R23-; wherein R8, R9 and R10 independently of each other may be optionally | Q substituted on carbon by one or more R ; 10 R18 is selected from hydroxy, amino, N-(Cj-6alkyl)amino, Cj^alkanoylamino, Ci_6alkylsulphonylamino, carbocyclyl-R27- or heterocyclyl-R28-; wherein R1S may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21; 20 R is selected from halo, amino, Ci-ealkyl, A^A^Ci-galkyl^amino, 15 Ci.6alkylsulphonyl-7V-(C|.6alkyl)amino, carbocyclyl-R33- or heterocyclyl-R36-; wherein R20 may be optionally substituted on carbon by one or more R23; R21 is selected from Cj^alkylsulphonyl; 23 * R is dimethylamino or phenyl; and R27, R28, R35 and R36 are independently selected from a direct bond, -C(0)N(R3,)-5 20 -NH=CH- or -S02N(Rj2)-; wherein Rjl and R32 are independently selected from hydrogen or Cj-ealkyl.
12. A compound of formula (I): 25 (I) wherein: 101749 -129- R1 is methyl, /-butyl, isopropoxy or cyclopropyl; R2 is hydrogen; X3 or X4 is =N-, X1 and X2 and the other of X3 and X4are independently selected from =CR8-, =CR9- and =CR10-; 5 RJ is hydrogen; R4 and R34 are independently selected from hydrogen, methyl or hydroxymethyl; A is a direct bond; Ring C is phenyl, pyrid-2-yl, pyrid-3-yl or pyrimidin-2-yl; R3 is selected from fluoro, acetylamino, mesylamino or cyclopropylcarbony 1 amino; 10 n is 1 or 2; wherein the values of R3 may be the same or different; R8, R9 and R10 are independently selected from hydrogen, fluoro, chloro, iodo, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl, acetylaminomethyl, (2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyI, (R)-2-oxopyrrolidin-5-yi-carbonyiaminomethyl, 15 (S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, (R,S)-2-oxopyiTolidin-5-yl-carbonylaminomethyl, isoxaxol-5-yl-carbonylaminomethyI, mesylaminomethyl, morpholinomethyl, benzoylaminomethyl, pyrid-3-yl-carbonylaminomethyl, 6-dimethylaminopyrid-3-yl-carbonylaminomethyl, 6-morpholinopyrid-3-yl-carbonylaminomethyl, pyrid-4-yl-carbonylaminomethyl, 20 5-methylisoxaxol-4-yl-carbonylaminomethyl, thien-2-yl-carbonylaminomethyl, 4-dimethylaminobenzylcarbonylaminomethyl, 2-(AL(isopropyl)-AL(mesyl)amino)acetylaminomethyl, 2-(yV-(phenethyl)-/V-(mesyl)amino)acetylaminomethyI., 1 -mesylpiperidin-1 -ylcarbonylaminomethyl, 2-(pyrid-3-yl)acetylaminomethyl, 25 tetrahydro-2//-thiopyran-4-yl-carbonylaminomethyl, 2-(thien-2-yl)acetylcarbonylaminomethyl, 2-(thien-3-yl)acetylcarbonylaminomethyl, 3-phenylpropionylaminomethyl, 2-(Af-benzoyl-iV-methylamino)acetylaminomethyl, 4-dimethylaminobenzoylaminomethyl, phenylsulphonylaminomethyl, 2-amino-3-methylbutanoylaminomethyl, cyclopropylcarbonylaminomethyl, 30 pyrrol-2-yl-carbonylaminomethyl, tetrahydrofuran-2-yl-carbonylaminomethyl, furan-2-yl-carbonylaminomethyl, cyclopropylsulphonylaminomethyl, (cyclopropyliniino)methyl, methylaminomethyl, trifluoromesylaminomethyl, isopropyl, isopropylamino or methylamino; 101749 -130- or a pharmaceutically acceptable salt thereof.
13. A compound of formula (I): R NH A 5 (I) selected from: (S)-6-(5-cycIopropyl-l//-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluorophenyl)ethylamino)-4-(methylamino) ni cotinonitrile; (iS)-6-(5-cyclopropyl-l//-pyrazol-3-ylamino)-5-fluoro-2-(l-(5-fluoropyridin-2-10 yl) ethy lamino)nicotinonitril e; (5)-5-fluoro-2-(l -(5-fluoropyridin-2-yl)ethylamino)-6-(5-isopropoxy-l/7-pyrazol-3- w1 ormnA^inr'Afmnnitri !#=•* j luiiiin^yinwuuvAiiw uv; (5)-6-(5-cyclopropyl-l/7-pyrazol-3-yIamino)-5-fluoro-2-(l-(4-fluorophenyl)ethylamino)-4-(isopropylamino)nicotinonitrile; 15 (1S)-5-chloro-6-(5-cycIopropyl-l//-pyrazoI-3-ylamino)-2-( l-(5-fluoropyridin-2-yl)ethylamino)nicotinonitrile; 6-[(5-cyclopropyl-1H- pyrazol-3 -yl)amino]-2- {[(1S)-1 -(3,5-difluoropyridin-2-yl)ethyl] amino} -5 -fluoronicotinonitrile; (£r)-5-fluoro-2-(l-(4-fluorophenyl)ethylamino)-6-(5-isopropoxy-l/-/-pyrazol-3-20 ylamino)nicotinonitrile; (5)-6-(5-cyclopropyl-177-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluorophenyl)ethylamino)nicotinonitrile; (/?)-6-(5-cyclopropyl-l/^-pyrazol-3-ylamino)-5-fluoro-2-(l-(4-fluorophenyl)-2-hydroxyethylamino)nicotinonitrile; or 25 (i?)-5-fluoro-2-(l-(4-fluorophenyl)-2-hydroxyethylamino)-6-(5-isopropoxy-l//-pyrazol-3-ylamino)nicotinonitrile; 101749 - 131 - or a pharmaceutically acceptable salt thereof.
14. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in claim 1, which process comprises of: Process a) reaction of a compound of fonnuia (II): (II) wherein Pg is a nitrogen protecting group; with a compound of formula (III): L R4 r^-r.34 (III) wherein L is a displaceable group; Process b) for compounds of formula (I) wherein R4 is hydroxymethyl and Rj4 is hydrogen; reaction of a compound of formula (II) with an epoxide of formula (IV): r (IV) Process c) reacting a compound of formula (V): 101749 132- i H R X' X^ ^Xq R o 3.N^ ^R R R 34 A c -rmn (V) with hydrazine; Process d) reacting a compound of formula (VI): i H 2,X. N X X^ ^x4 NH L R1 (VI) wherein L is a displaceable group; with an amine of formula (VII): H 4 3,N^ ^R4 R R 34 A (R5)n (VII) Process e) reacting a compound of formula (VIII): 101749 -133 - C "h(R5)n (VIII) wherein L is a displaceable group; with an amine of formula (IX): H2N N NH R1 (IX) Process J) reacting an amine of formula (X): JSIH. X" X3 ^X4 ^R R with a compound of formula (XI): C -j~(R5)n (X) NH R' (XI) wherein L is a displaceable group; and thereafter if necessary: i) converting a compound of the formula (I) into another compound of the formula (I) 101749 - 134- ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt.
15. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed 5 in any one of claims 1 -13, for use as a medicament.
16. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, in the manufacture of a medicament for use in the inhibition of Trk activity. 10
17. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, in the manufacture of a medicament for use in the treatment or prophylaxis of cancer. 15
18. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 -13, in the manufacture of a medicament for use in the production of an anti-proliferative effect.
19. A pharmaceutical composition comprising a compound of formula (I), or a 20 pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, together with at least one pharmaceutically acceptable carrier, diluent or excipient.
20. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, together with 25 at least one pharmaceutically acceptable carrier, diluent or excipient for use in the inhibition of Trk activity.
21. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, together with 30 at least one pharmaceutically acceptable earner, diluent or excipient for use in the treatment or prophylaxis of cancer. 101749 -135 -
22. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the production of an anti-proliferative effect in a warm-blooded animal such as man. 5
23. A compound of fonnuia (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, for use in the inhibition of Trk activity.
24. A compound of fonnuia (I), or a pharmaceutically acceptable salt thereof, as claimed 10 in any one of claims 1 -13, for use in the treatment or prophylaxis of cancer.
25. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, for use in the production of an anti-proliferative effect. 15
26. The use according to claim 17 wherein said cancer is selected from congenital fibrosarcoma, mesoblastic nephroma, mesothelioma, acute myeloblastic leukemia, acute lymphocytic leukemia, multiple myeloma, melanoma, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer including secretory breast cancer, colorectal cancer, prostate 20 cancer including hormone refractory prostate cancer, bladder cancer, melanoma, lung cancer -non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, thyroid cancer including papillary thyroid cancer, mesothelioma and leukaemia. 25
27. A process according to claim 14 substantially as herein described with reference to any example thereof.
28. A pharmaceutical composition according to claim 19 substantially as herein described with reference to any example thereof. 30
29. A compound of fonnuia (I) or a pharmaceutically acceptable salt thereof according to claim 1 substantially as herein described with reference to any example thereof.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65005305P | 2005-02-04 | 2005-02-04 | |
| US65332905P | 2005-02-16 | 2005-02-16 | |
| US72163305P | 2005-09-29 | 2005-09-29 | |
| PCT/GB2006/000334 WO2006082392A1 (en) | 2005-02-04 | 2006-02-01 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ561145A true NZ561145A (en) | 2011-02-25 |
Family
ID=36177856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ561145A NZ561145A (en) | 2005-02-04 | 2006-02-01 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8324252B2 (en) |
| EP (2) | EP2383268B1 (en) |
| JP (1) | JP5139084B2 (en) |
| KR (1) | KR101302945B1 (en) |
| CN (1) | CN101155800B (en) |
| AR (1) | AR056184A1 (en) |
| AT (1) | ATE530545T1 (en) |
| AU (1) | AU2006210710B2 (en) |
| BR (1) | BRPI0606793A8 (en) |
| CA (1) | CA2595834C (en) |
| CY (2) | CY1115078T1 (en) |
| DK (2) | DK1846394T3 (en) |
| ES (2) | ES2555063T3 (en) |
| HK (2) | HK1114374A1 (en) |
| HR (1) | HRP20110962T1 (en) |
| HU (1) | HUE025671T2 (en) |
| IL (1) | IL184674A (en) |
| ME (1) | ME02645B (en) |
| MX (1) | MX2007009437A (en) |
| MY (1) | MY149512A (en) |
| NO (1) | NO341112B1 (en) |
| NZ (1) | NZ561145A (en) |
| PL (2) | PL2383268T3 (en) |
| PT (2) | PT1846394E (en) |
| RS (1) | RS52061B (en) |
| SA (1) | SA06270007B1 (en) |
| SI (2) | SI1846394T1 (en) |
| TW (1) | TWI370127B (en) |
| UY (1) | UY29360A1 (en) |
| WO (1) | WO2006082392A1 (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2308731T3 (en) | 2005-02-16 | 2008-12-01 | Astrazeneca Ab | CHEMICAL COMPOUNDS. |
| MX2007014328A (en) * | 2005-05-16 | 2008-02-12 | Astrazeneca Ab | Chemical compounds. |
| DK1945631T3 (en) | 2005-10-28 | 2012-10-22 | Astrazeneca Ab | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES USED AS TYROSINKINASE INHIBITORS FOR CANCER TREATMENT |
| EP2083624A4 (en) * | 2006-10-18 | 2010-06-16 | Merck Sharp & Dohme | 2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators |
| WO2008053812A1 (en) * | 2006-10-27 | 2008-05-08 | Mitsubishi Tanabe Pharma Corporation | Cyanopyridine derivative and medicinal use thereof |
| TW200826937A (en) * | 2006-11-01 | 2008-07-01 | Astrazeneca Ab | New use |
| WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
| JP5524491B2 (en) * | 2008-03-04 | 2014-06-18 | 石原産業株式会社 | Method for producing 3-amino-2-chloro-6-trifluoromethylpyridine |
| WO2010020810A1 (en) * | 2008-08-19 | 2010-02-25 | Astrazeneca Ab | 2-(imidaz0lylamin0)-pyridine derivatives and their use as jak kinase inhibitors |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| UY33213A (en) | 2010-02-18 | 2011-09-30 | Almirall Sa | PIRAZOL DERIVATIVES AS JAK INHIBITORS |
| SG186877A1 (en) * | 2010-06-30 | 2013-02-28 | Fujifilm Corp | Novel nicotinamide derivatives or salts thereof |
| UY33517A (en) | 2010-07-19 | 2012-02-29 | Astrazeneca Ab | Pharmaceutical depot for 5-fluoro-2 - [[(1S) -1- (5-fluoro-2-pyridyl) ethyl] amino] -6 - [(5-isopropoxy-1H-pyrazol-3-yl) amino] pyridin -3-carbonitrile ?. |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| SG11201403744YA (en) | 2011-12-28 | 2014-09-26 | Fujifilm Corp | Novel nicotinamide derivative or salt thereof |
| WO2013138613A1 (en) | 2012-03-16 | 2013-09-19 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
| TWI585088B (en) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | Imidazo[1,2-b]pyridazine analogues as kinase inhibitors |
| JP6479670B2 (en) * | 2012-11-05 | 2019-03-06 | エモリー ユニバーシティー | 7,8-Dihydroxyflavone and 7,8-substituted flavone derivatives, compositions and methods related thereto |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| HUE056329T2 (en) | 2014-08-11 | 2022-02-28 | Acerta Pharma Bv | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
| WO2016024228A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
| ES2805528T3 (en) | 2014-12-23 | 2021-02-12 | Sma Therapeutics Inc | 3,5-diaminopyrazole kinase inhibitors |
| WO2017157885A1 (en) | 2016-03-16 | 2017-09-21 | Bayer Cropscience Aktiengesellschaft | N-(cyanobenzyl)-6-(cyclopropyl-carbonylamino)-4-(phenyl)-pyridine-2-carboxamide derivatives and related compounds as pesticides and plant protection agents |
| EP3601267A1 (en) | 2017-03-21 | 2020-02-05 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| WO2019201848A1 (en) | 2018-04-18 | 2019-10-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| KR20210142154A (en) | 2019-03-21 | 2021-11-24 | 옹쎄오 | DBAIT molecules in combination with kinase inhibitors for the treatment of cancer |
| JP7318009B2 (en) | 2019-05-21 | 2023-07-31 | 浙江海正薬業股▲ふん▼有限公司 | Macrolide derivative, production method and use thereof |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| HUP9901155A3 (en) | 1996-02-13 | 2003-04-28 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
| DK0885198T3 (en) | 1996-03-05 | 2002-03-25 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| KR20010041015A (en) | 1998-02-17 | 2001-05-15 | 윌리엄 제이. 리플린 | Anti-viral pyrimidine derivatives |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| DE19917785A1 (en) | 1999-04-20 | 2000-10-26 | Bayer Ag | New 2,4-diamino-pyrimidine derivatives useful as microbicides in protection of plants and materials and as herbicides |
| US6399780B1 (en) | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
| KR20020027635A (en) | 1999-09-10 | 2002-04-13 | 폴락 돈나 엘. | Tyrosine kinase inhibitors |
| AU2457201A (en) | 1999-12-28 | 2001-07-09 | Bristol-Myers Squibb Company | Cytokine, especially tnf-alpha, inhibitors |
| AU3704101A (en) | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
| WO2001085699A2 (en) | 2000-05-08 | 2001-11-15 | Janssen Pharmaceutica N.V. | Prodrugs of hiv replication inhibiting pyrimidines |
| CN1431999A (en) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | Indole derivatives with vascular damagine activity |
| AU6623201A (en) | 2000-07-07 | 2002-02-05 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| KR20030014425A (en) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | Colchinol derivatives as vascular damaging agents |
| OA12368A (en) | 2000-08-31 | 2004-04-13 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors. |
| WO2002020513A1 (en) | 2000-09-01 | 2002-03-14 | Glaxo Group Limited | Oxindole derivatives |
| WO2002020479A1 (en) | 2000-09-01 | 2002-03-14 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
| EP1318997B1 (en) * | 2000-09-15 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1347971B1 (en) | 2000-12-21 | 2006-03-01 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
| US6653300B2 (en) | 2000-12-21 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US20030130264A1 (en) | 2001-02-16 | 2003-07-10 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| US7015231B2 (en) | 2001-09-27 | 2006-03-21 | Smithkline Beecham Corporation | Chemical compounds |
| SE0104140D0 (en) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
| JP2003231687A (en) | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | Pyrazolyl condensed ring compound and pharmaceutical use thereof |
| AU2003286711A1 (en) | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| BRPI0413018B8 (en) | 2003-07-30 | 2021-05-25 | Rigel Pharmaceuticals Inc | compost, and use of a compost |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| JP2007533717A (en) * | 2004-04-21 | 2007-11-22 | アストラゼネカ アクチボラグ | Compound |
| CA2580838A1 (en) | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2006067614A2 (en) | 2004-12-23 | 2006-06-29 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
| WO2006074057A2 (en) | 2004-12-30 | 2006-07-13 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| MX2007009842A (en) | 2005-02-16 | 2007-08-23 | Astrazeneca Ab | Chemical compounds. |
| ES2308731T3 (en) | 2005-02-16 | 2008-12-01 | Astrazeneca Ab | CHEMICAL COMPOUNDS. |
| CN101208093A (en) | 2005-04-27 | 2008-06-25 | 阿斯利康(瑞典)有限公司 | Use of pyrazolyl-pyrimidine derivatives in the treatment of pain |
| CA2607727A1 (en) | 2005-04-28 | 2006-11-09 | Mitsubishi Tanabe Pharma Corporation | Cyanopyridine derivative and use thereof as medicine |
| WO2006117560A1 (en) | 2005-05-05 | 2006-11-09 | Astrazeneca Ab | Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer |
| MX2007014328A (en) | 2005-05-16 | 2008-02-12 | Astrazeneca Ab | Chemical compounds. |
| DK1945631T3 (en) | 2005-10-28 | 2012-10-22 | Astrazeneca Ab | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES USED AS TYROSINKINASE INHIBITORS FOR CANCER TREATMENT |
| US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| EP2044063A1 (en) | 2006-06-30 | 2009-04-08 | Astra Zeneca AB | Pyrimidine derivatives useful in the treatment of cancer |
| TW200823196A (en) | 2006-11-01 | 2008-06-01 | Astrazeneca Ab | New use |
| TW200826937A (en) | 2006-11-01 | 2008-07-01 | Astrazeneca Ab | New use |
-
2006
- 2006-02-01 US US11/815,140 patent/US8324252B2/en not_active Expired - Fee Related
- 2006-02-01 AU AU2006210710A patent/AU2006210710B2/en not_active Ceased
- 2006-02-01 PL PL11167362T patent/PL2383268T3/en unknown
- 2006-02-01 ES ES11167362.0T patent/ES2555063T3/en active Active
- 2006-02-01 KR KR1020077020258A patent/KR101302945B1/en not_active IP Right Cessation
- 2006-02-01 PT PT06701619T patent/PT1846394E/en unknown
- 2006-02-01 EP EP11167362.0A patent/EP2383268B1/en active Active
- 2006-02-01 MX MX2007009437A patent/MX2007009437A/en active IP Right Grant
- 2006-02-01 ME MEP-2011-563A patent/ME02645B/en unknown
- 2006-02-01 RS RS20110563A patent/RS52061B/en unknown
- 2006-02-01 NZ NZ561145A patent/NZ561145A/en not_active IP Right Cessation
- 2006-02-01 CA CA2595834A patent/CA2595834C/en not_active Expired - Fee Related
- 2006-02-01 AT AT06701619T patent/ATE530545T1/en active
- 2006-02-01 SI SI200631240T patent/SI1846394T1/en unknown
- 2006-02-01 PT PT111673620T patent/PT2383268E/en unknown
- 2006-02-01 WO PCT/GB2006/000334 patent/WO2006082392A1/en active Application Filing
- 2006-02-01 JP JP2007553688A patent/JP5139084B2/en not_active Expired - Fee Related
- 2006-02-01 DK DK06701619.6T patent/DK1846394T3/en active
- 2006-02-01 EP EP06701619A patent/EP1846394B1/en active Active
- 2006-02-01 PL PL06701619T patent/PL1846394T3/en unknown
- 2006-02-01 SI SI200631992T patent/SI2383268T1/en unknown
- 2006-02-01 BR BRPI0606793A patent/BRPI0606793A8/en not_active IP Right Cessation
- 2006-02-01 DK DK11167362.0T patent/DK2383268T3/en active
- 2006-02-01 ES ES06701619T patent/ES2375735T3/en active Active
- 2006-02-01 HU HUE11167362A patent/HUE025671T2/en unknown
- 2006-02-01 CN CN2006800101082A patent/CN101155800B/en not_active Expired - Fee Related
- 2006-02-02 AR ARP060100376A patent/AR056184A1/en not_active Application Discontinuation
- 2006-02-03 TW TW095103831A patent/TWI370127B/en not_active IP Right Cessation
- 2006-02-03 MY MYPI20060475A patent/MY149512A/en unknown
- 2006-02-03 UY UY29360A patent/UY29360A1/en not_active Application Discontinuation
- 2006-02-04 SA SA06270007A patent/SA06270007B1/en unknown
-
2007
- 2007-07-17 IL IL184674A patent/IL184674A/en not_active IP Right Cessation
- 2007-07-20 NO NO20073791A patent/NO341112B1/en not_active IP Right Cessation
-
2008
- 2008-02-13 HK HK08101578.0A patent/HK1114374A1/en not_active IP Right Cessation
-
2011
- 2011-12-21 HR HR20110962T patent/HRP20110962T1/en unknown
-
2012
- 2012-01-11 CY CY20121100025T patent/CY1115078T1/en unknown
- 2012-05-02 HK HK12104298.7A patent/HK1163677A1/en not_active IP Right Cessation
- 2012-11-29 US US13/688,790 patent/US8835465B2/en not_active Expired - Fee Related
-
2015
- 2015-11-26 CY CY20151101071T patent/CY1119077T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2595834C (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| AU2006248780B2 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
| AU2006215386B2 (en) | Chemical compounds | |
| AU2006307657B2 (en) | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer | |
| AU2006215394B2 (en) | Chemical compounds | |
| EP1888561A1 (en) | Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 FEB 2016 BY COMPUTER PACKAGES INC Effective date: 20130227 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2017 BY CPA GLOBAL Effective date: 20151222 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2018 BY CPA GLOBAL Effective date: 20161217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 FEB 2019 BY CPA GLOBAL Effective date: 20171222 |
|
| LAPS | Patent lapsed |